



US 20130267696A1

(19) **United States**

(12) **Patent Application Publication**
Fortman et al.

(10) **Pub. No.: US 2013/0267696 A1**

(43) **Pub. Date: Oct. 10, 2013**

(54) **PRODUCING ALPHA-OLEFINS USING
POLYKETIDE SYNTHASES**

Publication Classification

(75) Inventors: **Jeffrey L. Fortman**, San Francisco, CA
(US); **Leonard Katz**, Oakland, CA
(US); **Eric J. Steen**, Berkeley, CA (US);
Jay D. Keasling, Berkeley, CA (US)

(51) **Int. Cl.**
C12P 5/02 (2006.01)
C12N 9/10 (2006.01)
C12P 5/00 (2006.01)

(73) Assignee: **THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA**,
Oakland, CA (US)

(52) **U.S. Cl.**
CPC **C12P 5/026** (2013.01); **C12P 5/005**
(2013.01); **C12N 9/1029** (2013.01)

(21) Appl. No.: **13/876,727**

USPC **536/23.2**; 435/166; 435/167; 435/193;
435/252.31; 435/252.33; 435/252.35;
435/254.11; 435/254.2; 435/320.1; 585/16

(22) PCT Filed: **Sep. 28, 2011**

(86) PCT No.: **PCT/US2011/053787**

(57) **ABSTRACT**

§ 371 (c)(1),
(2), (4) Date: **Jun. 24, 2013**

Related U.S. Application Data

The present invention provides for a polyketide synthase (PKS) capable of synthesizing an α -olefin, such as 1-hexene or butadiene. The present invention also provides for a host cell comprising the PKS and when cultured produces the α -olefin.

(60) Provisional application No. 61/387,435, filed on Sep. 28, 2010.




FIG. 1




FIG. 2




FIG. 3C




FIG. 3B




FIG. 3A




FIG. 5A




FIG. 5B




FIG. 6






FIG. 7B

FIG. 7A




 Specifies binding of malonyl-CoA and transfer to ACP domain

FIG. 7D




Thioester transfer of acrylate moiety to KS domain

FIG. 7C



Catalyzes reduction of the β -carbonyl group



Catalyzes condensation with release of CO₂

FIG. 7E

FIG. 7F




FIG. 7G




FIG. 8





FIG. 9



- Four genes to clone / express

FIG. 10








FIG. 11






FIG. 12E




FIG. 12F




FIG. 13






FIG. 15

X = Knockout gene
Exogenously Feed
Overexpress gene








FIG. 17




FIG. 18

PRODUCING ALPHA-OLEFINS USING POLYKETIDE SYNTHASES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application Ser. No. 61/387,435, filed Sep. 28, 2010, which is hereby incorporated by reference in its entirety.

STATEMENT OF GOVERNMENTAL SUPPORT

[0002] This invention was made with government support under Contract No. DE-AC02-05CH11231 awarded by the U.S. Department of Energy and Award No. 0540879 awarded by the National Science Foundation. The government has certain rights in the invention

FIELD OF THE INVENTION

[0003] This invention relates generally to α -olefin production using polyketide synthases and so relates to the fields of chemistry, microbiology, and molecular biology.

BACKGROUND OF THE INVENTION

[0004] Type I polyketide synthases (PKSs) are programmable, multifunctional enzymes capable of possessing all of the catalytic capacity of fatty-acid synthases (FASs). However, unlike the FAS enzyme, which iteratively extends and fully reduces the β -carbonyl generated with each extension of the hydrocarbon backbone, PKS systems utilize discrete sets of enzymatic domains for each extension and reduction of the nascent chain. These sets, commonly referred to as modules, can incorporate a variety of extenders units resulting in different side chains. They also can encode between zero and three of the reducing domains associated with FASs, respectively leading to a ketone, hydroxy, double bond, or fully saturated carbon at the beta position of the growing polyketide chain (Hopwood and Sherman. 1990. Annual Review of Genetics 24:37-66).

[0005] Due to their modularity, PKS systems have been extensively explored for production of "unnatural" natural products (Weissman and Leadlay. 2005. Nature Reviews Microbiology 3:925-936). Hundreds of these molecules have been produced, ranging from basic lactones to modified versions of drugs and drug-like compounds.

SUMMARY OF THE INVENTION

[0006] The present invention provides polyketide synthases (PKSs) capable of synthesizing α -olefins, recombinant expression vectors for producing them, recombinant host cells that express them and produce the desired alpha olefin, methods for making alpha olefins, and alpha olefins produced by the methods. The PKSs of the invention are not naturally occurring and so are referred to as "recombinant" PKS enzymes. In some embodiments of the invention, the α -olefin is not a compound synthesized by a naturally occurring PKS. In some embodiments of the invention, the PKS is a hybrid PKS comprising modules and/or portions thereof, from two, three, four or more naturally occurring PKSs. A hybrid PKS can contain naturally occurring modules from two or more naturally occurring PKSs and/or it can contain one or more modules composed of portions, including intact domains, of two or more modules from the same naturally occurring PKS or from two or more naturally occurring PKS, or both. In

some embodiments of the invention, a recombinant nucleic acid comprising a CurM module or portion thereof, which may be either naturally occurring or recombinant, is employed.

[0007] The present invention provides recombinant nucleic acids that encode PKSs of the invention. The recombinant nucleic acids include nucleic acids that include a portion or all of a PKS of the invention, nucleic acids that further include regulatory sequences, such as promoter and translation initiation and termination sequences, and can further include sequences that facilitate stable maintenance in a host cell, i.e., sequences that provide the function of an origin of replication or facilitate integration into host cell chromosomal or other DNA by homologous recombination. In some embodiments, the recombinant nucleic acid is stably integrated into a chromosome of a host cell. In some embodiments, the recombinant nucleic acid is a plasmid. Thus, the present invention also provides vectors, including expression vectors, comprising a recombinant nucleic acid of the present invention. The present invention also provides host cells comprising any of the recombinant nucleic acid and/or PKS of the present invention. In some embodiments, the host cell, when cultured under suitable conditions, is capable of producing the α -olefin. These host cells include, for example and without limitation, prokaryotes such as *E. coli* species, *Bacillus* species, *Streptomyces* species, Myxobacterial species, as well as eukaryotes including but not limited to yeast and fungal strains.

[0008] Thus, the present invention provides a wide variety of host cell comprising one or more of the recombinant nucleic acids and/or PKSs of the present invention. In some embodiments, the host cell, when cultured, is capable of producing an α -olefin that it otherwise does not produce, or produces at a lower level, in the absence of a nucleic acid of the invention.

[0009] The present invention provides methods for producing α -olefins, said methods generally comprising: providing a host cell of the present invention, and culturing said host cell in a suitable culture medium under suitable conditions such that the α -olefin is produced.

[0010] The present invention also provides compositions comprising an α -olefin from a host cell in which the α -olefin was produced, and in some embodiments may include trace residues and/or other components of the host cell. Such trace residues and/or other components may include, for example, cellular material produced by the lysis of the host cell. The present invention also provides methods of purifying α -olefins and methods for converting them to other useful products.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] The foregoing aspects and embodiments of the invention as well as others will be readily appreciated by the skilled artisan from the following detailed description of illustrative embodiments when read in conjunction with the accompanying drawings.

[0012] FIG. 1 shows an illustrative example of the modular organization of a biosynthetic pathway suitable for synthesizing 1-hexene in accordance with the invention. In this illustration, the proposed modules are sourced from the loading module of DEBS1 from the erythromycin PKS, module 5 from the nystatin PKS NysC, and CurM the terminal module of the curacin PKS. In another embodiment of the invention, the nystatin PKS module 5 is replaced with portions of mod-

ules 9 and 10 from the indanomycin PKS; this alternative embodiment has actually been used to produce 1-hexene.

[0013] FIG. 2 shows types of modules employed and corresponding precursors utilized for incorporation into polyketide chains. The loading module is designated S. While any suitable loading domain can be used (such as those loading acetate and benzoic acid), only two examples are illustrated in this figure. The remaining compounds represent the structures incorporated into the growing polyketide chain employing extender modules A-P. The dashed line indicates the C—C bond formed through Claisen condensation; atoms to the right of the bond and the C atom at the left of the dashed line represent the structures determined by the module employed. The R group represents the existing acyl chain prior to incorporation determined by the module.

[0014] FIG. 3 shows: (A) a PKS system that can be used to produce 1-hexene in accordance with the invention, (B) how additional modules can be added to yield longer, even-chain α -olefins, and (C) how changing the loading module to incorporate acetate (from malonyl-CoA) will allow access to the saturated, linear, odd-chain α -olefins in accordance with the methods of the invention.

[0015] FIG. 4 shows an embodiment of the invention that illustrates utilization of the avermectin PKS loading module. The side chains illustrated are merely examples and do not constitute the entire pool of side chains that can be incorporated using the avermectin loading module (or similar loading modules) in accordance with the methods and teaching of the invention.

[0016] FIG. 5 shows, in part (A), an example of an illustrative pathway to 3-methylenepent-4-enoic acid, an example of the carboxylated butadiene derivatives accessible using PKSs in accordance with the methods of the invention and how the distance between the diene and carboxylate moieties can be increased via the use of additional PKS modules. FIG. 5, part (B), shows the proposed mechanism of the exomethylene biosynthesis from the jamaicamide pathway (see Edwards et al. 2004. Chem. Biol. 11(6):817-33; incorporated herein by reference).

[0017] FIG. 6 shows a PKS for producing butadiene in accordance with the methods of the invention. While this invention is not to be limited in any manner by any proposed mechanism of action recited or shown herein, this figure, for simplicity, illustrates loss of the hydroxyl group as a water molecule, the enzymatic mechanism utilizes sulfate as a leaving group.

[0018] FIG. 7 shows a PKS for producing butadiene in accordance with the methods of the invention. Parts (A) and (B) show the loading of the acrylyl-CoA using the DEBS propionyl-CoA specific loading domain modified to accept acrylyl-CoA. Part (C) shows the thiotransfer of the acrylate moiety to KS domain. Part (D) shows the binding of the malonyl-CoA and transfer to ACP domain. Part (E) shows KS catalyzing the condensation of the moiety with release of CO₂. Part (F) shows KR catalyzing the reduction of the β -carbonyl group. Part (G) shows the final step and the release of the butadiene, CO₂, and water (as in FIG. 6, the loss of the hydroxyl group is illustrated with a water molecule, but the enzymatic mechanism utilizes sulfate as a leaving group).

[0019] FIG. 8 shows an enzymatic pathway accessible by the methods and materials of the invention to produce acrylyl-CoA comprising exogenously supplying propionate, and expressing PrpE and acyl-CoA dehydrogenase activities. A host cell comprising this system would be provided with

propionate, which could be exogenously fed to, if not produced endogenously by, the host cell selected for production.

[0020] FIG. 9 shows an enzymatic pathway accessible by the methods and materials of the invention to produce acrylyl-CoA comprising exogenously supplying propionate and glucose. A host cell comprising this system would be provided with propionate, either through exogenous feeding or the introduction of propionate biosynthesis pathway, as above, and a suitable organic molecule that the host cell can directly or indirectly convert into a pyruvate. For example, if the host cell is *E. coli*, the suitable organic molecule can be glucose. This pathway utilizes the central metabolic intermediate pyruvate to produce lactate via a lactate dehydrogenase. Lactate is then converted to lactoyl-CoA by a lactate CoA transferase, utilizing propionyl-CoA as a cofactor and releasing propionate. Lactoyl-CoA is then dehydrated using a lactoyl-CoA dehydratase to yield acrylyl-CoA. One embodiment of this invention includes the lactate dehydrogenase, LdhA, from *E. coli*, the lactate CoA transferase, Pct, from *Clostridium proponicum*, and the lactoyl-CoA dehydratase enzymes, EI and EII, from *C. proponicum*. The introduction of this pathway into *E. coli* or yeast for diene (such as butadiene) production represents a novel application of these enzymes. An embodiment of this invention is use of this pathway for PKS-based acrylate production.

[0021] FIG. 10 shows an enzymatic pathway accessible by the methods and materials of the invention to produce acrylyl-CoA starting from the common metabolic precursor malonyl-CoA. This pathway generates malonyl-CoA using an acetyl-CoA carboxylase, acetyl-CoA and CO₂. Malonyl-CoA is then reduced by a malonyl-CoA reductase releasing malonyl semialdehyde. Malonyl semialdehyde is converted to 3-hydroxypropionate using a substrate specific oxidoreductase. A 3-hydroxypropionate CoA ligase catalyzes the formation of 3-hydroxypropionyl-CoA. This intermediate is then dehydrated to acrylyl-CoA by the reverse reaction of 3-hydroxypropionyl-CoA hydratase. In one embodiment of the invention, these enzymes are the acetyl-CoA carboxylase complex (AccA/AccD) from *E. coli*, the malonyl-CoA reductase (The introduction of this pathway into *E. coli* or yeast for diene (e.g. butadiene) production represents a novel application of these enzymes and is a unique embodiment of this invention. An embodiment of this invention is use of this pathway for PKS-based acrylate production.

[0022] FIG. 11 shows an enzymatic pathway accessible by the methods and materials of the invention to produce isoprene via the mevalonate pathway.

[0023] FIG. 12 shows an example of an illustrative pathway accessible by a PKS provided by the invention for producing isoprene. (A) shows the loading of the acrylyl-CoA using the DEBS propionyl-CoA specific loading domain modified to accept acrylyl-CoA, and extension with malonyl-CoA to form the beta-keto ACP bound intermediate. Parts (B)-(D) show the HMG-CoA-like mechanism involved in the replacement of the β -carbonyl group with a methyl group using PKS enzymes from the PKSX (Bacillaene) cluster from *Bacillus subtilis* (Butcher, et al. 2007. Proc Natl Acad Sci USA. 104 (5):1506-9; incorporated herein by reference). This invention is not to be limited by any proposed mechanism shown herein. In this embodiment, the penultimate product is released as the free acid and subsequently decarboxylated to isoprene in accordance with the methods of the invention by either a decarboxylase, or extracellular chemical catalysis/pyrolysis.

[0024] FIG. 13 shows a PKS provided by the invention for producing (E)-penta-1,3-diene. This figure illustrates loss of the hydroxyl group as a water molecule, but the enzymatic mechanism utilizes sulfate as a leaving group.

[0025] FIG. 14 shows precursor supply pathways in *E. coli* for producing acrylyl-CoA, as described in previous figures, and [2S]-methylmalonyl-CoA. Each enzymes depicted can be expressed in a host cell wherein each enzyme can be independently either endogenous or native to the host cell, or introduced into recombinant

[0026] FIG. 15 shows methods and materials provided by the invention for maximizing precursor supply pathways in *E. coli*. The means to maximizing acrylyl-CoA can comprise one or more of “knocking out” (eliminating or reducing the expression of) PrpC activity, knocking out YgfH activity, exogenously feeding propionate (or producing propionate endogenously), overexpressing PrpE activity to increase cytosolic pools of propionyl-CoA. From this intermediate, the introduction of the propionyl-CoA carboxylase complex (AccA/PccB) will yield methylmalonyl-CoA (Pfeifer, et al. Science. 2001 Mar. 2; 291(5509):1790-2; incorporated herein by reference). This pool of propionyl-CoA can also be utilized in the pathways described in FIGS. 8 and 9.

[0027] FIG. 16 shows an illustrative PKS provided by the invention to produce 3-hydroxy-1-octene. The PKS comprises the following elements: (i) Load module and KS1 from PikA1 (pikromycin), followed by (ii) Module 1 and KS2: AT-ACP segment from Module 5 and KS6 domain from the Nystatin PKS, (iii) Module 2: the hydroxymalonate-specific AT and contiguous ACP domains from ZmaA (zwitermicin PKS) from *Bacillus cereus*, DH, ER and KR domains from nanchangmycin PKS Module 2, and (iv) Module 3: AT-TE segment of the CurM module (curacin PKS). For the production of the precursor hydroxymalonyl-ACP, enzymes ZmaD, ZmaG, and ZmaE are also produced by or provided to the host strain. This figure illustrates loss of the hydroxyl group as a water molecule, however, it should be noted that the enzymatic mechanism utilizes sulfate as a leaving group.

[0028] FIG. 17 shows an illustrative PKS provided by the invention to produce 1-decene. The PKS comprises the following elements: (i) Load module and KS 1 from PikA1, followed by (ii) Module 1 and KS2: AT-ACP segment from Module 5 and KS6 domain from the nystatin PKS, (iii) Module 2 and KS3: AT-ACP segment from Module 15 and KS 16 domain from the nystatin PKS, (iv) Module 3 and KS4: AT-ACP segment from Module 3 and K4 domain from the oligomycin PKS, and (v) Module 4: AT-TE segment from CurM. This figure illustrates loss of the hydroxyl group as a water molecule, however, it should be noted that the enzymatic mechanism utilizes sulfate as a leaving group.

[0029] FIG. 18 shows an illustrative PKS provided by the invention to produce 1-octene. The PKS comprises the following elements: (i) Loading Module and KS1 from PikA1, followed by (ii) Module 1 and KS2: AT-ACP segment from Module 5 and KS6 domain from the nystatin PKS Module 2, (iii) and KS3: AT-ACP segment from Module 15 and KS16 domain from the nystatin PKS, and then (iv) Module 3: AT-ST segment from the CurM module. This figure illustrates loss of the hydroxyl group as a water molecule, however, it should be noted that the enzymatic mechanism utilizes sulfate as a leaving group.

DETAILED DESCRIPTION

[0030] This invention is not limited to particular embodiments described, as such may, of course, vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, because the scope of the present invention will be limited only by the appended claims.

[0031] Where a range of values is provided, each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention.

[0032] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in practicing the present invention, suitable methods and materials are now described. All publications cited are incorporated herein by reference to disclose and describe the methods and/or materials and/or results therein.

[0033] As used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an α -olefin” includes a plurality of such α -olefins, and so forth.

[0034] The term “even-chain α -olefin” refers to an α -olefin with a carbon backbone, which, disregarding any functional groups or substituents, has an even number of carbon atoms.

[0035] The term “odd-chain α -olefin” refers to an α -olefin with a carbon backbone, which, disregarding any functional groups or substituents, has an odd number of carbon atoms.

[0036] The term “functional variant” describes an enzyme that has a polypeptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to an enzyme described herein. A “functional variant” enzyme may retain amino acids residues recognized as conserved for the enzyme in nature, and/or may have non-conserved amino acid residues. Amino acids can be, relative to the native enzyme, substituted (different), inserted, or deleted, but the variant has generally similar enzymatic activity as compared to an enzyme described herein. A “functional variant” enzyme may be found in nature or be an engineered mutant (recombinant) thereof.


[0037] The objects, advantages, and features of the invention will become more apparent to those persons skilled in the art upon reading the details of the invention as more fully described below.

Polyketide Synthases (PKS)

[0038] The present invention provides recombinant polyketide synthase (PKS) enzymes capable of synthesizing an α -olefin. The PKS enzymes of the invention are not naturally occurring PKS. In some embodiments of the invention, the α -olefin is not a compound synthesized by a naturally occurring PKS. In some embodiments of the invention, the PKS is a hybrid PKS comprising modules, domains, and/or portions thereof, or functional variants thereof, from two or more PKSs. Such α -olefins include the diketides and triketides, and polyketides of more than three ketide units, such as 4, 5, or 6 or more ketide units. The α -olefin can further

include one or more functional groups in addition to the double bond that characterizes them. Such functional groups include, but are not limited to, ethyl, methyl and hydroxy side chains, internal olefins, and ketones.

[0039] In some embodiments of the invention, the α -olefin is an even-chain α -olefin having the following chemical structure:



(I)

wherein each R_1 is independently $-H$ or $-CH_3$, each R_2 is independently $-H$ or $-OH$, n is an integer, and $\alpha\beta$ is a single or double bond, with the proviso that when an $\alpha\beta$ is a double bond then the corresponding R_2 is H . In some embodiments of the invention, n is an integer from 1 to 10. n indicates the number of two-carbon-chain subunits in the carbon backbone of the α -olefin. The R_1 , R_2 , and $\alpha\beta$ within each two-carbon-subunit of a multiple subunit α -olefin is independent of the R_1 , R_2 , and $\alpha\beta$ of any other two-carbon-subunit in the molecule. In some embodiments, however, one or more, up to all, subunits have identical R_1 , R_2 , and $\alpha\beta$.

[0040] In some embodiments of the invention, the α -olefin has the following chemical structure:



(II)


wherein n is an integer from 0 to 10.

[0041] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C3-alpha olefins propylene (propene) and polymers and products derived therefrom, including but not limited to: polypropylene, acrylonitrile, propylene oxide, alcohols, cumene, acrylic acid, injection molded plastics, electronics, electrical appliances, housewares, bottle caps, toys, luggage, films, fibers, carpets, clothing, ropes, pipes, conduit, wire, cable, elastomeric polymers, acrylic fibers, nitrile rubber, acrylonitrile-butadiene-styrene (ABS) resins, styrene-acrylonitrile (SAN) resins, acrylamide, adiponitrile, polyether polyols, polyurethanes, flexible foams, rigid foams, insulation, propylene glycol, polyester resins, antifreeze, de-icing fluids, propylene glycol ethers, paints, coatings, inks, resins, cleaners, isopropanol, cosmetics, pharmaceuticals, food, ink, adhesives, 2-ethylhexanol, phthalate plasticizers, phenol, acetone, polycarbonate, phenolic resins, epoxy resins, methyl methacrylate (MMA), and acrylic esters.

[0042] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C4-alpha olefin butene and polymers and products derived therefrom, including but not limited to: polybutylene, copolymers with ethylene and/or propene, hot-melt adhesives, synthetic rubber, diesel fuel, and jet fuel.

[0043] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C4 diolefin butadiene and polymers and products derived therefrom, including but not limited to: styrene butadiene rubber (SBR),

polybutadiene rubber, acrylonitrile butadiene styrene (ABS), styrene butadiene (SB) copolymer latex, nitrile rubber, adiponitrile, chloroprene, butanediol, tetrahydrofuran, tires, adhesives; coatings, high impact polystyrene, thermoplastic resins, engineering nylons (from C12 lactam), paper coating, gaskets and seals, hoses, gloves, nylon fibers, polymers, wet suits, electrical insulation, polybutylene terephthalate, spandex, and binders. Butadiene has the following chemical structure:



[0044] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C5 α olefin: 1-pentene and polymers and products derived therefrom, including but not limited to: gasoline, polymers; adhesives, sealants, diesel fuel, and jet fuel.

[0045] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C6 α -olefin (see FIG. 1, example): 1-hexene and polymers and products derived therefrom, including but not limited to comonomer, polyethylene, polymer, high density polyethylene (HDPE), linear low density polyethylene (LLDPE), 1-heptanal, heptanoic acid, resin, film, plastic pipe, containers, diesel fuel, and jet fuel. 1-hexene has the following chemical structure:




and an illustration of a 1-hexene producing PKS is provided in FIG. 1.

[0046] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C10 α -olefin: 1-decene and polymers and products derived therefrom, including but not limited to: detergent formulations, linear alkyl benzene (LAB), linear alkyl benzene sulfonate (LABS), polyalphaolefin synthetic lubricant basestocks (PAO), heat-shrink materials, electrical insulation sleeves, rash guards in clothing, polyolefin elastomers (POE), flexible foams, footwear, seat cushions, armrests, pillows, radar coolants, strings, polyol esters, detergent alcohols, plasticizer alcohols, specialty chemicals, epoxides, derivatives thereof, comonomer, intermediate in production of epoxides, amines, oxo alcohols, synthetic lubricants, synthetic fatty acids, alkylated aromatics, emulsifiers, performance waxes, cosmetic formulations, viscosity controller, solvent, decene butene copolymer, binder, film forming, decene/PVP copolymer, food additives, glazing agent, anti-foaming agent, anti-dusting agent, white mineral oil substitute, polishing agent, well fluids, alpha olefin oligomers, and the like. 1-decene has the following chemical structure:



[0047] In one embodiment, the invention provides methods, host cells, and nucleic acids for making the C8 aromatic α -olefin: styrene and polymers and products derived therefrom, including but not limited to: homopolymers, copolymers, polystyrene, expandable polystyrene (EPS), acryloni-

trile-butadiene-styrene (ABS), resins, styrene-acrylonitrile (SAN), acrylonitrile-styrene-acrylate (ASA), styrene butadiene, styrene butadiene rubber, copolymer with maleic anhydride, terephthalate, unsaturated polyester resins, containers, closures, lids and vending cups, construction; electrical and electronic parts; domestic appliances and housings; household goods and home furnishings; and toys, sporting goods and recreational articles, packaging, thermoplastics, cutlery, CDs, insulating materials, polymer bonded explosives, consumer products, renewable plastics, renewable products, hardhats, tires, etc. In some embodiments of the invention, the aromatic α -olefin has the following chemical structure:



(III)

wherein R_3 is $-H$, $-OH$, $-NH_3$, or $-NO_2$.


[0048] Alpha olefins are commonly used in the cosmetics and skin care industry, and the present invention therefore provides useful starting materials for making cosmetics and skin care products. For example, alpha olefin sulfonate, sulfate free personal cleaners, soap, copolymer maleic acid, and the like are all used in these industries and provided by the invention. Alpha olefins provided by the invention can also be used in the flavor and fragrance industry. For example, 3-hydroxy-1-octene and 3-oxo-1-octene can be made using the methods and materials of the invention and are used in applications where a mushroom flavor/fragrance is desired.

[0049] The present invention can also be used to generate intermediates useful in the synthesis of pharmaceuticals. These olefins can be coupled via olefin metathesis to one another or other olefin intermediates obtained via traditional chemical syntheses to yield bioactive molecules useful as drugs.

[0050] In some embodiments, the α -olefin produced in accordance with the invention is (E)-deca-1,5-diene, which has the following chemical structure:




[0051] In some embodiments, the α -olefin produced in accordance with the invention has the following chemical structure:




(IV)

wherein R is one of the following structures:




-continued




[0052] In some embodiments, the α -olefin produced in accordance with the invention is a polyolefin having chemical structure (I) and comprising at least two, three, four, five, or more C—C double bonds. Such α -olefins include, but are not limited to, diolefins, such as diolefins with two C—C double bonds on the carbon backbone. Such diolefins include, but are not limited to, butadiene, isoprene, and penta-1,3-diene. Butadiene has the chemical structure shown in [0043], above.

[0053] In some embodiments, the α -olefin produced in accordance with the invention is isoprene, which has the following chemical structure:



[0054] In some embodiments, the α -olefin produced in accordance with the invention is penta-1,3-diene, which has the following chemical structure:



[0055] Complex polyketides comprise a large class of natural products that are synthesized in bacteria (mainly members of the actinomycete family; e.g. *Streptomyces*), fungi and plants. Polyketides form the macrolactone component of a large number of clinically important drugs, such as antibiotics (e.g. erythromycin, tylosin), antifungal agents (e.g. nystatin), anticancer agents (e.g. epothilone), immunosuppressives

(e.g. rapamycin), etc. Though these compounds do not resemble each other either in their structure or their mode of action, they share a common basis for their biosynthesis, which is carried out by a group of enzymes designated polyketide synthases.

[0056] Polyketide synthases (PKS) employ short chain fatty acyl CoAs in Claisen condensation reactions to produce polyketides. Unlike fatty acid synthases that utilize acetyl CoA as the starter and malonyl CoA as the extender units, and use a single module iteratively to produce the nascent acyl chains, PKSs are composed of discrete modules, each catalyzing the chain growth of a single step. Modules can differ from each other in composition, so that, overall, a number of different starters (e.g. acetyl CoA, propionyl CoA) and extenders, some of which contain stereospecific methyl (or ethyl) side chains can be incorporated into a polyketide. In addition, PKS modules do not always reduce the 3-carbonyl formed from condensation but may leave it either unreduced (ketone), partially reduced (hydroxyl, 2,3-ene), or fully reduced (3-methylene). Many PKSs employ malonyl CoA or [S]-2-methylmalonyl CoA as the starter for polyketide synthesis. In such cases, the terminal carboxyl group is usually removed by a decarboxylase domain present at the N-terminus of the loading domain of the PKS. Thus, the structure (and chirality) of the α -carbon and β -carbonyl is determined by the module of the PKS employed in the synthesis of the growing chain at each particular step. Because of the correspondence between the modules used in the synthesis and the structure of the polyketide produced, it is possible to program PKS synthesis to produce a compound of desired structure by selection and genetic manipulation of polyketide synthases.

[0057] FIG. 2 shows the various modules and the precursor utilized by each module for incorporation into the corresponding nascent acyl (polyketide) chain to give rise to a range of compounds of interest. Table 1, below, provides illustrative PKS sources for each module in FIG. 2. Each PKS source (amino acid sequence and corresponding coding sequence) is well-known to one skilled in the art and readily available. In addition, for each module in Table 1, there are other modules from other PKS (or from recombinant DNA technology) that can be used. In addition, other structures can be incorporated in the ketide or polyketide that are not shown in Table 1 and FIG. 2. For example, useful loading modules includes the benzoate loading module of soraphen PKS, the isobutyrate loading module of the lipomycin PKS and bafilomycin PKS, and the acrylate loading module from the difidicin pathway. The acrylate loading module from the difidicin PKS loads and dehydrates a hydroxypropionate molecule by the use of enzymes difA-E to yield a PKS with an aryl-ACP (Chen, 2006, J. Bact. 188:4024-4036; incorporated herein by reference).

[0058] The present invention also contemplates the use of functional variants of PKS modules, domains, and portions thereof. In one important embodiment, the invention provides a variety of recombinant modules that carry out the same enzymatic reactions conducted by the CurM module.

TABLE 1

PKS sources of the various modules.	
Module	PKS Source
S1	Spiramycin PKS Loading Domain (with and without

TABLE 1-continued

PKS sources of the various modules.	
Module	PKS Source
S2	inactivation or deletion of the KS ^Q domain) Pikromycin PKS Loading Domain (with and without inactivation or deletion of the KS ^Q domain)
S3	Spiramycin PKS Loading Domain
S4	Erythromycin PKS Loading Domain
A	Rifamycin PKS Module 2
B	Oligomycin PKS Module 1
C	Spiramycin PKS Module 1
D	Pikromycin PKS Module 2
E	Oligomycin PKS Module 3
F	Erythromycin PKS Module 3
G	Oligomycin PKS Module 5
H	Primaricin PKS Module 7
I	Tylosin PKS Module 1
J	Erythromycin PKS Module 1
K	Avermectin PKS Module 7
L	Rapamycin PKS Module 1
M	Erythromycin PKS Module 4
N	Pederin Module 2
O	Ascomycin Module 4
P	FK506 Module 4
Q	Curacin A Chain Termination Module (CurM)

[0059] All extender modules carry the β -acyl ACP synthase (commonly called the ketosynthase or KS) domain, which conducts the decarboxylative condensation step between the extender and the growing polyketide chain, and the acyl carrier protein (ACP) domain that carries the growing acyl chain and presents it to any cognate reductive domains for reduction of the β -carbonyl. Modules can differ from each other in composition so that a number of different starter and extender units, some of which contain stereospecific side chains (e.g. methyl, ethyl, propylene) can be incorporated. The acyltransferase (AT) domain of each module determines the extender unit (e.g. malonyl CoA, methylmalonyl CoA, and the like) incorporated. In addition, PKS modules do not always reduce the (3-carbonyl formed from condensation but may leave it either unreduced (ketone), partially reduced (hydroxyl, 2,3-ene) or fully reduced (3-methylene), as shown in FIG. 2. The ketoreductase (KR) domain reduces the ketone to the OH function (stereospecifically); the dehydratase (DH) domain removes water from the α and β carbons leaving an α,β trans-double bond; the enoylreductase (ER) domain reduces the double bond to a β -methylene center; the reductive state of the β -carbonyl, therefore, is determined by the presence of functional reductive domains in the corresponding module. Less commonly, modules may contain an additional C-methylation domain (yielding an additional α -methyl side chain, as in epothilone).

[0060] The Curacin A Chain Termination Module is annotated as CurM. CurM catalyzes an extension of the nascent polyketide molecule with acetate (from malonyl-CoA). The resulting beta carbonyl is reduced to a hydroxyl group by a KR domain. The resulting beta hydroxyl group is then sulfonated by the ST domain (from the common metabolic precursor 3'-phosphoadenosine-5'-phosphosulfate). The TE domain releases the 3-sulfo polyketide which then undergoes loss of sulfate and a decarboxylation to form a terminal olefin

moiety. The chain termination module of the PKS of the present invention can comprise the ST and TE domains of the CurM Chain Termination Module and variants thereof with similar activity. Additional PKS modules carrying the combination of a sulfotransferase (pfam00685)/thioesterase have been identified in nature and can be used in additional embodiments of the invention. One such olefination module (Ols) has been characterized from *Synechococcus* sp. strain PCC 7002 (Mendez-Perez et al. 2011. Appl. Env. Microbiol. 77:4264-4267 2011). Others include, but are not limited to, PKS enzymes from *Cyanothece* sp. PCC 7424, *Cyanothece* sp. PCC 7822, *Prochloron didemni* P1-Palau, *Pseudomonas entomophila* L48, and *Haliangium ochraceum* DSM 14365. The present invention also provides consensus sequences that differ from these naturally occurring sequences but encode similar enzymatic activities.

[0061] The makeup of the PKS, therefore, determines the choice of starter and extender acyl units incorporated, the extent of reduction at each condensation step, and the total number of units added to the chain. The wide diversity of structures of polyketides seen in nature is thus attributable to the diversity in PKS enzymes.

[0062] A partial list of PKS amino acid and corresponding nucleic acid coding sequences that can be used in the PKSs of the present invention includes, for illustration and not limitation, Ambruticin (U.S. Pat. No. 7,332,576); Avermectin (U.S. Pat. No. 5,252,474; MacNeil et al., 1993, Industrial Microorganisms: Basic and Applied Molecular Genetics, Baltz, Hegeman, & Skatrud, eds. (ASM), pp. 245-256; MacNeil et al., 1992, Gene 115: 119-25); Candicidin (FRO008) (Hu et al., 1994, Mol. Microbiol. 14: 163-72); Curacin A (Chang et al., 2004, *J. Nat. Prod.*, 67 (8), pp 1356-1367; Gu et al., 2009, *J. Am. Chem. Soc.*, 131 (44), pp 16033-16035); Epothilone (U.S. Pat. No. 6,303,342); Erythromycin (WO 93/13663; U.S. Pat. No. 5,824,513; Donadio et al., 1991, Science 252: 675-79; Cortes et al., 1990, Nature 348:176-8); FK506 (Motamedi et al., 1998, Eur. J. Biochem. 256:528-34; Motamedi et al., 1997, Eur. J. Biochem. 244:74-80); FK520 or ascomycin (U.S. Pat. No. 6,503,737; see also Nielsen et al., 1991, Biochem. 30:5789-96); Jerangolid (U.S. Pat. No. 7,285,405); Leptomycin (U.S. Pat. No. 7,288,396); Lovastatin (U.S. Pat. No. 5,744,350); Nemadectin (MacNeil et al., 1993, supra); Niddamycin (Kakavas et al., 1997, J. Bacteriol. 179:7515-22); Oleandomycin (Swan et al., 1994, Mol. Gen. Genet. 242:358-62; U.S. Pat. No. 6,388,099; Olano et al., 1998, Mol. Gen. Genet. 259:299-308); Pederin (PCT publication no. WO 2003/044186); Pikromycin (Xue et al., 2000, Gene 245:203-211); Pimaricin (PCT publication no. WO 2000/077222); Platenolide (EP Pat. App. 791,656); Rapamycin (Schwecke et al., 1995, Proc. Natl. Acad. Sci. USA 92:7839-43); Aparicio et al., 1996, Gene 169:9-16); Rifamycin (August et al., 1998, Chemistry & Biology, 5: 69-79); Soraphen (U.S. Pat. No. 5,716,849; Schupp et al., 1995, J. Bacteriology 177: 3673-79); Spiramycin (U.S. Pat. No. 5,098,837); and Tylosin (EP 0 791,655; Kuhstoss et al., 1996, Gene 183:231-36; U.S. Pat. No. 5,876,991); each of the foregoing references is incorporated herein by reference. Additional suitable PKS coding are readily available to one skilled in the art (e.g., by cloning and sequencing of DNA from polyketide producing organisms or by reference to GenBank).

[0063] Of the more than one hundred PKSs studies and reported on in the scientific literature, the correspondence between the modules used in the biosynthesis of, and the

structure of, the polyketide produced is understood both at the level of the protein sequence of the PKS and the DNA sequence of the corresponding genes. The organization of modules and correspondence with polyketide structure can be identified by amino acid and/or nucleic acid sequence determination. One can thus clone (or synthesize) DNA sequences corresponding to desired modules and transfer them as fully functioning units to heterologous hosts, including otherwise non-polyketide producing hosts such as *E. coli* (Pfeifer, et al., *Science* 291, 1790 (2001); incorporated herein by reference), and polyketide-producing hosts, such as *Streptomyces* (Kao et al., *Science* 265, 509 (1994); incorporated herein by reference).

[0064] Additional genes employed in polyketide biosynthesis have also been identified. Genes that determine phosphopantetheine:protein transferase (PPTase) that transfer the 4-phosphopantetheine co-factor of the ACP domains, commonly present in polyketide producing hosts, have been cloned in *E. coli* and other hosts (Weissman et al., *Chembiochem* 5, 116 (2004); incorporated herein by reference). While it is possible to re-program polyketide biosynthesis to produce a compound of desired structure by either genetic manipulation of a single PKS or by construction of a hybrid PKS composed of modules from two or more sources (see Weissman et al., supra), the present invention provides the first means for making an alpha-olefin by a recombinant PKS.

[0065] Recombinant methods for manipulating modular PKS genes to make the PKSs of the present invention are described in U.S. Pat. Nos. 5,672,491; 5,843,718; 5,830,750; 5,712,146; and 6,303,342; and in PCT publication nos. WO 98/49315 and WO 97/02358; each of which is incorporated herein by reference. A number of genetic engineering strategies have been used with various PKSs to demonstrate that the structures of polyketides can be manipulated to produce novel polyketides (see the patent publications referenced supra and Hutchinson, 1998, *Curr. Opin. Microbiol.* 1:319-329, and Baltz, 1998, *Trends Microbiol.* 6:76-83; incorporated herein by reference). In some embodiments, the components of the hybrid PKS are arranged onto polypeptides having interpolypeptide linkers that direct the assembly of the polypeptides into the functional PKS protein, such that it is not required that the PKS have the same arrangement of modules in the polypeptides as observed in natural PKSs. Suitable interpolypeptide linkers to join polypeptides and intrapolypeptide linkers to join modules within a polypeptide are described in PCT publication No. WO 00/47724, incorporated herein by reference.

[0066] The vast number of polyketide pathways that have been elucidated to date and the present invention in combination provide a variety of different options to produce α -olefins in accordance with the invention. While the products can be vastly different in size and functionality, all employ similar methods for preparing the PKS and corresponding coding sequence and for producing the desired α -olefin. The interfaces between non-cognate enzyme partners can be optimized on a case-by-case basis. ACP-linker-KS and ACP-linker-TE regions from the proteins of interest will be aligned to examine the least disruptive fusion point for the hybrid synthase. Genetic constructions will employ sequence and ligation independent cloning (SLIC), or other sequence independent cloning techniques, so as to eliminate the incorporation of genetic "scarring".

[0067] In some embodiments, the PKS that produces the α -olefin of interest comprises the sulfotransferase (ST)-

thioesterase (TE) domains from *Lyngbya majuscula* CurM or similar domains from another naturally occurring PKS or one of the recombinant domains provided by the invention. The α -olefins capable of being produced by the invention include, but are not limited to, the diketides propylene, 1-butene, and styrene and the triketides 1-hexene and 1-pentene. In one aspect of the invention, the host cell is fed or exogenously provided or endogenously produces acrylate and so produces diolefins such as 1,5-hexadiene and butadiene. In another aspect, feeding or exogenously providing or endogenous production of benzoic acid to the host cell comprising a PKS of the invention enables the production of styrene derivatives.

[0068] In some embodiments, host cells that are capable of producing diolefins are also capable of producing acrylate or acrylyl-CoA/ACP, thus eliminating the need for exogenous acrylate. By coupling one of many PKS thioesterase domains to the module loading acrylate from these precursor pathways, the PKS system is capable of producing acrylic acid. Acrylic acid can also be obtained from acrylyl-CoA or acrylyl-ACP by use of a non-PKS hydrolase in accordance with the invention. In some embodiments of the invention, host cells that are capable of producing diolefins are also capable of producing benzoate.

[0069] *L. majuscula* CurM ST-TE domains comprise the following amino acid sequence:

(SEQ ID NO: 10)

F ILSSPRSGST LLRVMLAGHS SLFSPPELHL LPFNTMKERQ
 EQLNLSYLGE GLQKTFMEVK NLDATASQAL IKDLESQNL S
 IQQVYGM LQE NIAPRLLV DK SPTYAMEPTI LERGEALFAN
 SKYIYLVRHP YSVIESFVRM RMQKLVGLGE ENPYRVAEQV
 WAKSNQNILN FLSQLEPERQ HQIRYEDLVK KPQQVLSQLC
 DFLNVPFEPE LLQPYQGDRM TGGVHQKSL S ISDPNFKHN
 TIDESLADKW KTIQLPYPLK SETQRIASQL SYELPNLVTT
 PTNQPPQVST TPSTEQPIME EKFLFEGGNQ ICLCSWGSPE
 HPVVLCIHGI LEQGLAWQEV ALPLAAQGYR VVAPDLFGHG
 RSSHLEMVTS YSSLTFLAQI DRVIQELPDQ PLLLLVGHSMG
 AMLATAIASV RPKKIKELIL VELPLPAEES KKESAVNQLT
 TCLDYLSSTP QHPIFPDVAT AASRLRQAIP SLSEEF SYIL
 AQRITQPNQG GVRWSWD AII RTRSILGLNN LPGGRSQYLE
 MLKSIQVPTT LVYGDSSKLN RPEDLQQQKM TMTQAKRVFL
 SGGHNLHIDA AAALASLILT S

[0070] *L. majuscula* CurM ST domain comprises the following amino acid sequence:

(SEQ ID NO: 11)

F ILSSPRSGST LLRVMLAGHS SLFSPPELHL LPFNTMKERQ
 EQLNLSYLGE GLQKTFMEVK NLDATASQAL IKDLESQNL S
 IQQVYGM LQE NIAPRLLV DK SPTYAMEPTI LERGEALFAN
 SKYIYLVRHP YSVIESFVRM RMQKLVGLGE ENPYRVAEQV

- continued

WAKSNQNILN FLSQLEPERQ HQIRYEDLVK KPQQVLSQLC
 DFLNVPFEPE LLQPYQGDRM TGGVHQKSL S ISDPNFKHN
 TIDESLADKW KTIQLPYPLK

[0071] *L. majuscula* CurM TE domain comprise the following amino acid sequence:

(SEQ ID NO: 12)

EKFLEFGGNQ ICLCSWGSPE HPVVLCIHGI LEQGLAWQEV
 ALPLAAQGYR VVAPDLFGHG RSSHLEMVTS YSSLTFLAQI
 DRVIQELPDQ PLLLLVGHSMG AMLATAIASV RPKKIKELIL
 VELPLPAEES KKESAVNQLT TCLDYLSSTP QHPIFPDVAT
 AASRLRQAIP SLSEEF SYIL AQRITQPNQG GVRWSWD AII
 RTRSILGLNN LPGGRSQYLE MLKSIQVPTT LVYGDSSKLN
 RPEDLQQQKM TMTQAKRVFL SGGHNLHIDA AAALASLILT
 S

[0072] In some embodiments, the PKS of the present invention comprises a naturally occurring sulfotransferase-thioesterase (ST-TE) domains, or ST or TE domain, functionally similar, but not identical, to *L. majuscula* CurM. In some embodiments, the PKS of the present invention comprises the amino acid sequences of the ST and/or TE of any of the proteins/peptides described in Tables 2-4, or functionally variants thereof. One skilled in the art can identify such *L. majuscula* CurM-like ST and/or TE domains using available bioinformatics programs. For example, the *L. majuscula* CurM ST-TE can be split in two separately functional portions by relying on its crystal structure and annotation of catalytic boundaries with programs like protein BLAST, and the sequences can be homology-modeled to get a better grasp of the boundary of catalytic domains, using *L. majuscula* CurM ST-TE as an anchoring template. Together, such methods can be employed to make solid predictions about catalytic activity and responsible amino acid regions within a larger protein.

[0073] In some embodiments, ST and/or TE domains, or functionally variants thereof, comprise one or more of the following amino acid residues (using *L. majuscula* CurM as a reference sequence): R205, H266, S100, E124, N211, and N267. In some embodiments, ST and/or TE domains, or functionally variants thereof, comprise the following amino acid residues (using *L. majuscula* CurM as a reference sequence): 8205 and H266, and optionally one or more of S100, E124, N211, and N267. In some embodiments, the PKS comprises a ST domain and a TE domains that are derived or obtained from two different organisms or sources.

TABLE 2

List of proteins/peptides comprising CurM-like ST-TE domains.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
1. polyketide synthase module [<i>Lyngbya majuscula</i> 3L]	2211 aa protein	ZP_08432359.1 GI:332712433
2. CurM [<i>Lyngbya majuscula</i>]	2147 aa protein	AAT70108.1 GI:50082961
3. beta-ketoacyl synthase [<i>Cyanothece</i> sp. PCC 7424]	2762 aa protein	YP_002377174.1 GI:218438845
4. beta-ketoacyl synthase [<i>Cyanothece</i> sp. PCC 7822]	2775 aa protein	YP_003887107.1 GI:307151723
5. polyketide synthase [<i>Prochloron didemni</i> P1-Palau]	2999 aa protein	AEH57210.1 GI:335387269
6. Chain A, Thioesterase Domain From Curacin Biosynthetic Pathway	286 aa protein	3QIT_A GI:325534050
7. polyketide synthase module [<i>Lyngbya majuscula</i> 3L]	2277 aa protein	ZP_08425908.1 GI:332705832
8. polyketide synthase [<i>Synechococcus</i> sp. PCC 7002]	2720 aa protein	YP_001734428.1 GI:170077790
9. polyketide synthase [<i>Pseudomonas entomophila</i> L48]	1217 aa protein	YP_610919.1 GI:104784421
10. KR domain-containing protein [<i>Haliangium ochraceum</i> DSM 14365]	3045 aa protein	YP_003265308.1 GI:262194099
11. OciA [<i>Planktothrix agardhii</i> NIES-205]	2858 aa protein	ABW84363.1 GI:158954787
12. OciA [<i>Planktothrix agardhii</i> NIVA-CYA 116]	3477 aa protein	ABI26077.1 GI:112824006
13. CurM [<i>Burkholderia pseudomallei</i> 668]	358 aa protein	YP_001062692.1 GI:126444569
14. amino acid adenylation domain-containing protein [<i>Cyanothece</i> sp. PCC 8802]	1470 aa protein	YP_003137597.1 GI:257059709
15. amino acid adenylation domain-containing protein [<i>Cyanothece</i> sp. PCC 8801]	1470 aa protein	YP_002372038.1 GI:218246667
16. polyketide synthase [<i>Ostreococcus lucimarinus</i> CCE9901]	18193 aa protein	XP_001416378.1 GI:145343541

TABLE 3

List of proteins/peptides comprising a CurM-like ST domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
1. polyketide synthase module [<i>Lyngbya majuscula</i> 3L]	2211 aa protein	ZP_08432359.1 GI:332712433
2. CurM [<i>Lyngbya majuscula</i>]	2147 aa protein	AAT70108.1 GI:50082961
3. beta-ketoacyl synthase [<i>Cyanothece</i> sp. PCC 7424]	2762 aa protein	YP_002377174.1 GI:218438845
4. beta-ketoacyl synthase [<i>Cyanothece</i> sp. PCC 7822]	2775 aa protein	YP_003887107.1 GI:307151723
5. polyketide synthase [<i>Prochloron didemni</i> P1-Palau]	2999 aa protein	AEH57210.1 GI:335387269
6. polyketide synthase module [<i>Lyngbya majuscula</i> 3L]	2277 aa protein	ZP_08425908.1 GI:332705832
7. polyketide synthase [<i>Synechococcus</i> sp. PCC 7002]	2720 aa protein	YP_001734428.1 GI:170077790
8. polyketide synthase [<i>Pseudomonas entomophila</i> L48]	1217 aa protein	YP_610919.1 GI:104784421
9. OciA [<i>Planktothrix agardhii</i> NIES-205]	2858 aa protein	ABW84363.1 GI:158954787
10. OciA [<i>Planktothrix agardhii</i> NIVA-CYA 116]	3477 aa protein	ABI26077.1 GI:112824006
11. CurM [<i>Burkholderia pseudomallei</i> 668]	358 aa protein	YP_001062692.1 GI:126444569
12. KR domain-containing protein [<i>Haliangium ochraceum</i> DSM 14365]	3045 aa protein	YP_003265308.1 GI:262194099
16. COG3321: Polyketide synthase modules and related proteins (ISS) [<i>Ostreococcus tauri</i>]	11541 aa protein	XP_003074830.1 GI:308800098
17. polyketide synthase [<i>Ostreococcus lucimarinus</i> CCE9901]	18193 aa protein	XP_001416378.1 GI:145343541
18. modular polyketide synthase type I [<i>Micromonas</i> sp. RCC299]	14149 aa protein	XP_002507643.1 GI:255071123

TABLE 3-continued

List of proteins/peptides comprising a CurM-like ST domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
19. hypothetical protein RBXJA2T_11932 [<i>Rubrivivax benzoatilyticus</i> JA2]	301 aa protein	ZP_08402700.1 GI:332526592
20. hypothetical protein Dshi_1965 [<i>Dinoroseobacter shibae</i> DFL 12]	310 aa protein	YP_001533306.1 GI:159044512
21. hypothetical protein glr1901 [<i>Gloeobacter violaceus</i> PCC 7421]	301 aa protein	NP_924847.1 GI:37521470
22. hypothetical protein Sros_9233 [<i>Streptosporangium roseum</i> DSM 43021]	290 aa protein	YP_003344594.1 GI:271970398
23. hypothetical protein SAV_2309 [<i>Streptomyces avermitilis</i> MA-4680]	299 aa protein	NP_823485.1 GI:29828851
24. conserved hypothetical protein [<i>Streptomyces viridochromogenes</i> DSM 40736]	289 aa protein	ZP_07307763.1 GI:302555421
25. sulfotransferase [<i>Frankia</i> sp. Eu11c]	332 aa protein	YP_004017900.1 GI:312197839
26. hypothetical protein Nit79A3_2110 [<i>Nitrosomonas</i> sp. Is79A3]	304 aa protein	YP_004695298.1 GI:339483512
27. sulfotransferase [<i>Thermobispora bispora</i> DSM 43833]	346 aa protein	YP_003651260.1 GI:296268628
28. sulfotransferase [<i>Frankia</i> sp. Eu11c]	264 aa protein	YP_004017815.1 GI:312197754
29. hypothetical protein gl11899 [<i>Gloeobacter violaceus</i> PCC 7421]	320 aa protein	NP_924845.1 GI:37521468
30. SecC motif-containing protein [<i>Shewanella loihica</i> PV-4]	359 aa protein	YP_001093305.1 GI:127512108
31. predicted protein [<i>Micromonas pusilla</i> CCMP1545]	507 aa protein	XP_003055946.1 GI:303273170
32. Putative protein-tyrosine sulfotransferase [<i>Plesiocystis pacifica</i> SIR-1]	305 aa protein	ZP_01905212.1 GI:149916710
33. hypothetical protein PB2503_07444 [<i>Parvularcula bermudensis</i> HTCC2503]	310 aa protein	YP_003854688.1 GI:304321045
34. hypothetical protein PPE_01162 [<i>Paenibacillus polymyxa</i> E681]	422 aa protein	YP_003869548.1 GI:308067943
35. putative sulfotransferase [<i>Streptomyces griseus</i> subsp. <i>griseus</i> NBRC 13350]	339 aa protein	YP_001822417.1 GI:182434698
36. hypothetical protein LYNGBM3L_54590 [<i>Lyngbya majuscula</i> 3L]	318 aa protein	ZP_08430625.1 GI:332710682
37. SecC motif-containing protein [<i>Shewanella sediminis</i> HAW-EB3]	336 aa protein	YP_001473003.1 GI:157374403
38. sulfotransferase domain protein [<i>Plesiocystis pacifica</i> SIR-1]	329 aa protein	ZP_01905835.1 GI:149917336
39. sulfotransferase [<i>Streptomyces</i> cf. <i>griseus</i> XylebKG-1]	339 aa protein	ZP_08234477.1 GI:326775212
40. hypothetical protein Sros_1208 [<i>Streptosporangium roseum</i> DSM 43021]	347 aa protein	YP_003336949.1 GI:271962753
41. sulfotransferase [<i>Trichodesmium erythraeum</i> IMS101]	430 aa protein	YP_722743.1 GI:113476682
42. hypothetical protein Sros_1207 [<i>Streptosporangium roseum</i> DSM 43021]	336 aa protein	YP_003336948.1 GI:271962752
43. sulfotransferase [<i>Flexistipes sinusarabici</i> DSM 4947]	322 aa protein	YP_004602630.1 GI:336322663
44. Protein-tyrosine sulfotransferase [<i>Harpegnathos saltator</i>]	381 aa protein	EFN77815.1 GI:307196126
45. sulfotransferase domain protein [<i>Rhodobacteriales bacterium</i> HTCC2083]	346 aa protein	ZP_05076043.1 GI:254462627
46. PREDICTED: similar to Transport and Golgi organization 13 CG32632-PB [<i>Tribolium castaneum</i>]	382 aa protein	XP_968004.1 GI:91090216
47. sulfotransferase [<i>Psychromonas ingrahamii</i> 37]	335 aa protein	YP_943667.1 GI:119945987
48. hypothetical protein sll5046 [<i>Synechocystis</i> sp. PCC 6803]	316 aa protein	NP_942202.1 GI:38505581
49. sulfotransferase domain-containing protein [<i>Roseobacter denitrificans</i> OCh 114]	340 aa protein	YP_680960.1 GI:110677953
50. putative sulfotransferase [<i>Burkholderia multivorans</i> CGD2M]	271 aa protein	ZP_03574132.1 GI:221201092
51. sulfotransferase [<i>Kangiella koreensis</i> DSM 16069]	317 aa protein	YP_003146110.1 GI:256822147
52. Protein-tyrosine sulfotransferase [<i>Acromyrmex echinator</i>]	381 aa protein	EGI65733.1 GI:332025570

TABLE 3-continued

List of proteins/peptides comprising a CurM-like ST domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
53. sulfotransferase [<i>Flexistipes sinusarabici</i> DSM 4947]	325 aa protein	YP_004602624.1 GI:336322657
54. nodulation protein noeE [<i>Magnetospirillum magneticum</i> AMB-1]	433 aa protein	YP_420424.1 GI:83310160
55. glycosyl transferase family 2 [<i>Paenibacillus polymyxa</i> SC2]	421 aa protein	YP_003945463.1 GI:310640705
56. protein-tyrosine sulfotransferase 2 [<i>Paenibacillus polymyxa</i> MI]	423 aa protein	CCC84070.1 GI:343095861
57. sulfotransferase [<i>Pedobacter</i> sp. BAL39]	346 aa protein	ZP_01884054.1 GI:149277914
58. sulfotransferase: SEC-C motif protein [<i>Shewanella</i> sp. HN-41]	333 aa protein	ZP_08568256.1 GI:336313314
59. sulfotransferase domain protein [<i>Lyngbya majuscula</i> 3L]	344 aa protein	ZP_08430778.1 GI:332710841
60. sulfotransferase domain-containing protein [Rhodopirellula baltica WH47]	325 aa protein	EGF25969.1 GI:327539348
61. hypothetical protein MettrDRAFT_3778 [<i>Methylosinus trichosporium</i> OB3b]	396 aa protein	ZP_06890062.1 GI:296448163
62. PREDICTED: MGC82552 protein-like [<i>Saccoglossus kowalevskii</i>]	436 aa protein	XP_002733820.1 GI:291227699
63. Sulfotransferase domain superfamily [<i>Microcoleus chthonoplastes</i> PCC 7420]	318 aa protein	ZP_05029988.1 GI:254416234
64. tyrosylprotein sulfotransferase-2 [<i>Ictalurus punctatus</i>]	356 aa protein	NP_001187093.1 GI:318064902
65. family 2 glycosyl transferase [<i>Nitrosococcus halophilus</i> Nc4]	1043 aa protein	YP_003528062.1 GI:292492623
66. PREDICTED: protein-tyrosine sulfotransferase [<i>Apis mellifera</i>]	380 aa protein	XP_624657.2 GI:328780257
67. tyrosine sulfotransferase [<i>Culex quinquefasciatus</i>]	395 aa protein	XP_001864662.1 GI:170057846
68. hypothetical protein L8106_07576 [<i>Lyngbya</i> sp. PCC 8106]	281 aa protein	ZP_01622104.1 GI:119489297
69. hypothetical protein NIDE3002 [<i>Candidatus Nitrospira defluvii</i>]	375 aa protein	YP_003798623.1 GI:302038301
70. SecC motif-containing protein [<i>Shewanella frigidimarina</i> NCIMB 400]	342 aa protein	YP_749583.1 GI:114562070
71. sulfotransferase [<i>Acarochloris marina</i> MBIC11017]	294 aa protein	YP_001519982.1 GI:158338805
72. protein-tyrosine sulfotransferase 2 [<i>Danio rerio</i>]	356 aa protein	NP_956713.1 GI:41056257
73. PREDICTED: protein-tyrosine sulfotransferase-like [<i>Bombus terrestris</i>]	380 aa protein	XP_003394254.1 GI:340711379
74. GG17794 [<i>Drosophila erecta</i>]	504 aa protein	XP_001978257.1 GI:194895457
75. hypothetical protein Swit_1252 [<i>Sphingomonas wittichii</i> RW1]	308 aa protein	YP_001261755.1 GI:148554173
76. putative enzyme [<i>Lyngbya</i> sp. PCC 8106]	305 aa protein	ZP_01618957.1 GI:119484340
77. sulfotransferase [<i>Trichodesmium erythraeum</i> IMS101]	344 aa protein	YP_722339.1 GI:113476278
78. transport and golgi organization 13, isoform C [<i>Drosophila melanogaster</i>]	346 aa protein	NP_001096973.1 GI:161077803
79. hypothetical protein BRAFLDRAFT_89531 [<i>Branchiostoma floridae</i>]	454 aa protein	XP_002590725.1 GI:260791416
80. hypothetical protein L8106_19296 [<i>Lyngbya</i> sp. PCC 8106]	318 aa protein	ZP_01620966.1 GI:119487094
81. TyrosylProtein SulfoTransferase family member (tpst-1) [<i>Caenorhabditis elegans</i>]	380 aa protein	NP_499646.3 GI:71992370
82. methionine biosynthesis protein MetW, putative [<i>Nitrosococcus oceani</i> AFC27]	1039 aa protein	ZP_05048086.1 GI:254434578
83. tyrosylprotein sulfotransferase 2 [<i>Xenopus laevis</i>]	375 aa protein	NP_001088427.1 GI:148235112
84. glycosyl transferase family protein [<i>Nitrosococcus oceani</i> ATCC 19707]	1037 aa protein	YP_343263.1 GI:77164738
85. GM17618 [<i>Drosophila sechellia</i>]	478 aa protein	XP_002042697.1 GI:195352394
86. GE17090 [<i>Drosophila yakuba</i>]	508 aa protein	XP_002100486.1 GI:195478327

TABLE 3-continued

List of proteins/peptides comprising a CurM-like ST domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
87. GI14854 [<i>Drosophila mojavensis</i>]	459 aa protein	XP_002010160.1 GI:195131443
88. GD17135 [<i>Drosophila simulans</i>]	501 aa protein	XP_002106871.1 GI:195566606
89. GF22576 [<i>Drosophila ananassae</i>]	498 aa protein	XP_001965589.1 GI:194766965
90. transport and golgi organization 13, isoform B [<i>Drosophila melanogaster</i>]	499 aa protein	NP_727717.1 GI:24641809
91. GL20242 [<i>Drosophila persimilis</i>]	515 aa protein	XP_002023360.1 GI:195165053
92. PREDICTED: protein-tyrosine sulfotransferase-like [<i>Acyrtosiphon pisum</i>]	392 aa protein	XP_001942867.2 GI:328706076
93. PREDICTED: similar to MGC82552 protein [<i>Gallus gallus</i>]	379 aa protein	XP_415794.2 GI:118100226
94. protein-tyrosine sulfotransferase A [<i>Loa loa</i>]	384 aa protein	XP_003139556.1 GI:312073519
95. GA26942 [<i>Drosophila pseudoobscura pseudoobscura</i>]	521 aa protein	XP_001354726.2 GI:198468492
96. GK16105 [<i>Drosophila willistoni</i>]	466 aa protein	XP_002067611.1 GI:195439384
97. PREDICTED: protein-tyrosine sulfotransferase-like [<i>Nasonia vitripennis</i>]	396 aa protein	XP_001606792.1 GI:156543274
98. PREDICTED: protein-tyrosine sulfotransferase 1-like [<i>Monodelphis domestica</i>]	450 aa protein	XP_001362570.2 GI:334324786
99. predicted protein [<i>Nematostella vectensis</i>]	272 aa protein	XP_001630972.1 GI:156378079
100. AGAP000900-PA [<i>Anopheles gambiae</i> str. PEST]	392 aa protein	EAA12079.6 GI:333469474

TABLE 4

List of proteins/peptides comprising a CurM-like TE domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
37. hypothetical protein lpl0509 [<i>Legionella pneumophila</i> str. Lens]	282 aa protein	YP_125875.1 GI:54293460
38. putative lipase LipA [<i>Legionella pneumophila</i> 130b]	282 aa protein	AAM73852.1 GI:21666982
39. Alpha/beta hydrolase [gamma proteobacterium IMCC2047]	294 aa protein	ZP_08648517.1 GI:339055924
40. hypothetical protein lpp0533 [<i>Legionella pneumophila</i> str. Paris]	282 aa protein	YP_122871.1 GI:54296502
41. Putative hydrolase or acyltransferase of alpha/beta superfamily [<i>Rheinheimera</i> sp. A13L]	279 aa protein	ZP_08572335.1 GI:336317483
42. lipase A [<i>Legionella pneumophila</i> subsp. <i>pneumophila</i> str. Philadelphia 1]	283 aa protein	YP_094512.1 GI:52840713
43. alpha/beta fold family hydrolase [<i>Shewanella oneidensis</i> MR-1]	288 aa protein	NP_718168.1 GI:24374125
44. alpha/beta hydrolase [<i>Azotobacter vinelandii</i> DJ]	300 aa protein	YP_002798221.1 GI:226943148
45. lipase [<i>Pseudomonas syringae</i> pv. mori str. 301020]	284 aa protein	EGH20834.1 GI:330888173
46. alpha/beta hydrolase fold protein [<i>Dechlorosoma suillum</i> PS]	288 aa protein	EGW60665.1 GI:345129761
47. hydrolase, alpha/beta fold family [<i>Moritella</i> sp. PE36]	291 aa protein	ZP_01900040.1 GI:149911422
48. lipase [<i>Pseudomonas syringae</i> pv. lachrymans str. M301315]	284 aa protein	EGH85562.1 GI:330987459

TABLE 4-continued

List of proteins/peptides comprising a CurM-like TE domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
49. lipase [<i>Pseudomonas syringae</i> pv. tabaci ATCC 11528]	284 aa protein	EGH90697.1 GI:331010641
50. Alpha/beta hydrolase fold [<i>Pseudomonas syringae</i> pv. syringae B728a]	284 aa protein	YP_235108.1 GI:66045267
51. serine hydrolase-like 2 [<i>Xenopus laevis</i>]	304 aa protein	NP_001079604.1 GI:147899135
52. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. japonica str. M301072PT]	284 aa protein	EGH30625.1 GI:330899206
53. alpha/beta hydrolase fold protein [<i>Shewanella halifaxensis</i> HAW-EB4]	291 aa protein	YP_001674055.1 GI:167623761
54. lipase [<i>Pseudomonas syringae</i> pv. aesculi str. 0893_23]	284 aa protein	EGH02171.1 GI:330867462
55. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. morsprunorum str. M302280PT]	284 aa protein	EGH09818.1 GI:330875669
56. putative hydrolase [marine gamma proteobacterium HTCC2143]	308 aa protein	ZP_01616002.1 GI:119475649
57. alpha/beta fold family hydrolase [<i>Pseudomonas syringae</i> pv. actinidiae str. M302091]	284 aa protein	EGH65633.1 GI:330965373
58. putative alpha/beta hydrolase [<i>Sphingobium japonicum</i> UT26S]	290 aa protein	YP_003545632.1 GI:294012172
59. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. aptata str. DSM 50252]	284 aa protein	EGH78853.1 GI:330980750
60. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. pisi str. 1704B]	284 aa protein	EGH43451.1 GI:330940344
61. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. syringae FF5]	284 aa protein	ZP_06500867.1 GI:289679977
62. hydrolase [gamma proteobacterium NOR51-B]	299 aa protein	ZP_04957287.1 GI:254282319
63. predicted Hydrolase or acyltransferase (alpha/beta hydrolase superfamily) protein [<i>Marinobacter algicola</i> DG893]	305 aa protein	ZP_01893017.1 GI:149375245
64. lipase A [<i>Legionella longbeachae</i> D-4968]	281 aa protein	ZP_06187778.1 GI:270159122
65. alpha/beta hydrolase fold protein [<i>Pseudomonas fluorescens</i> WH6]	284 aa protein	ZP_07774389.1 GI:312959874
66. alpha/beta hydrolase fold protein [<i>Alicyclophilus denitrificans</i> K601]	300 aa protein	YP_004387755.1 GI:330824452
67. hydrolase [<i>Sorangium cellulosum</i> 'So ce 56']	322 aa protein	YP_001615653.1 GI:162453286
68. alpha/beta fold family hydrolase [<i>Shewanella violacea</i> DSS12]	296 aa protein	YP_003557221.1 GI:294141243
69. lipase [<i>Pseudomonas syringae</i> pv. phaseolicola 1448A]	284 aa protein	YP_274221.1 GI:71736540
70. putative esterase [uncultured microorganism]	293 aa protein	BAI49930.1 GI:269913831
71. alpha/beta fold family hydrolase [<i>Cellvibrio japonicus</i> Ueda107]	298 aa protein	YP_001982425.1 GI:192359104
72. alpha/beta hydrolase fold protein [<i>Pseudomonas fulva</i> 12-X]	287 aa protein	YP_004474637.1 GI:333900764
73. alpha/beta hydrolase [gamma proteobacterium HdN1]	283 aa protein	YP_003810829.1 GI:304311231
74. putative hydrolase [<i>Nocardia farcinica</i> IFM 10152]	249 aa protein	YP_117116.1 GI:54022874
75. alpha/beta hydrolase fold protein [<i>Haliangium ochraceum</i> DSM 14365]	289 aa protein	YP_003269090.1 GI:262197881
76. Alpha/beta hydrolase fold protein [<i>Pseudomonas syringae</i> pv. syringae 642]	284 aa protein	ZP_07264074.1 GI:302187401
77. Alpha/beta hydrolase fold protein [<i>Limnobacter</i> sp. MED105]	310 aa protein	ZP_01916760.1 GI:149928530
78. putative lipase LipA [<i>Legionella drancourtii</i> LLAP12]	280 aa protein	ZP_05108808.1 GI:254495899
79. hydrolase, alpha/beta fold family [<i>Pseudomonas syringae</i> pv. tomato T1]	284 aa protein	ZP_03396309.1 GI:213968164

TABLE 4-continued

List of proteins/peptides comprising a CurM-like TE domain.		
Ref. Protein/peptide [organism or source]	No. of amino acid residues	Accession No.
80. alpha/beta hydrolase fold protein [<i>Rhodopseudomonas palustris</i> CGA009]	340 aa protein	NP_946347.1 GI:39934071
81. lipase, putative [<i>Pseudomonas syringae</i> pv. glycinea str. B076]	284 aa protein	EFW80985.1 GI:320324913
82. alpha/beta fold family hydrolase [<i>Pseudomonas syringae</i> pv. tomato str. DC3000]	284 aa protein	NP_792039.1 GI:28869420
83. hydrolase or acyltransferase [<i>Azoarcus</i> sp. BH72]	300 aa protein	YP_933620.1 GI:119898407
84. alpha/beta superfamily hydrolase [<i>Shewanella piezotolerans</i> WP3]	293 aa protein	YP_002311621.1 GI:212635096
85. putative hydrolase [<i>Aromatoleum aromaticum</i> EbN1]	292 aa protein	YP_158988.1 GI:56477399
86. putative hydrolase [<i>Pseudomonas fluorescens</i> SBW25]	284 aa protein	YP_002871482.1 GI:229589363
87. alpha/beta hydrolase fold protein [<i>Rhodopseudomonas palustris</i> TIE-1]	289 aa protein	YP_001990203.1 GI:192289598
88. hydrolase [<i>Pseudomonas aeruginosa</i> PAO1]	286 aa protein	NP_250313.1 GI:15596819
89. putative hydrolase [<i>Pseudomonas aeruginosa</i> 39016]	286 aa protein	ZP_07792860.1 GI:313106637
90. hydrolase, alpha/beta fold family protein [marine gamma proteobacterium HTCC2207]	286 aa protein	ZP_01223987.1 GI:90416054
91. PA1622 [synthetic construct]	287 aa protein	AAT50924.1 GI:49083048
92. lipase [<i>Pseudomonas syringae</i> pv. maculicola str. ES4326]	284 aa protein	EGH59298.1 GI:330959038
93. hydrolase [<i>Pseudomonas stutzeri</i> DSM 4166]	282 aa protein	AEA83820.1 GI:327480510
94. alpha/beta hydrolase [<i>Chromohalobacter salexigens</i> DSM 3043]	289 aa protein	YP_574516.1 GI:92114588
95. alpha/beta hydrolase fold [<i>Marinobacter aquaeolei</i> VT8]	306 aa protein	YP_958843.1 GI:120554492
96. hydrolase [<i>Pseudomonas stutzeri</i> A1501]	285 aa protein	YP_001172415.1 GI:146282262
97. Hydrolase or acetyltransferase [<i>Leptospira biflexa</i> serovar Patoc strain 'Patoc 1 (Ames)']	287 aa protein	YP_001964755.1 GI:189912866
98. hypothetical hydrolase/acyltransferase [<i>Photobacterium profundum</i> 3TCK]	299 aa protein	ZP_01219631.1 GI:90411621
99. putative hydrolase [<i>Pseudomonas aeruginosa</i> PA7]	286 aa protein	YP_001349005.1 GI:152984242
100. hydrolase [<i>Oxalobacter formigenes</i> HOxBLS]	289 aa protein	ZP_04576152.1 GI:237745672

[0074] In some embodiments of the invention, a precursor molecule, such as propionate or acrylate, is provided to the PKS to produce a polyketide of interest. The precursor molecule can be fed or exogenously provided to or endogenously produced by the host cell comprising the PKS, or the host cell can produce the enzymes capable of biosynthesizing the precursor molecule from a simpler molecule that can be fed or exogenously provided to the host cell or the host cell naturally endogenously produces. For example, *Streptomyces* species produces propionyl-CoA as part of its innate metabolism, thus eliminating the need for exogenous propionate provision.

[0075] In some embodiments of the invention, the PKS capable of producing an α -olefin of interest comprises CurM, the terminal PKS from the curacin biosynthesis pathway (Chang, 2004) or a similar module. CurM is a monomodular PKS protein containing an unusual sulfotransferase domain. This domain sulfonates the beta hydroxyl group of the pen-

ultimate product and the combination of the ST-TE domains catalyze a decarboxylation and functional dehydration (with sulfate as the leaving group) to yield the terminal olefin. FIG. 1 illustrates how domains from CurM can be coupled to other PKS enzymes to produce an α -olefin, such as 1-hexene, in accordance with the methods and materials of the invention. In the example shown in FIG. 1, first PKS ORF encodes a loading module specific for propionate (via the CoA) and an extension module that incorporates acetate (via malonyl-CoA) and fully reduces the β -carbonyl. In this example shown in FIG. 1, the loading domain is from the erythromycin PKS (Donadio et al. 1991. Science 675-679; incorporated herein by reference) and module 5 is from the nystatin PKS (Brautaset et al. 2000. Chemistry & Biology 7:395-403; incorporated herein by reference), but there are other modules that can be used to provide the same product. The second and third proteins that constitute the multi-subunit PKS in this example come from the curacin PKS and corresponding gene

cluster (see Chang et al. 2004. Journal of Natural Products 67:1356-1367; sequence updated in Gu et al. J Am Chem. Soc. 2009 Nov. 11; 131(44):16033-5; both of which are incorporated herein by reference). Using this PKS, the first two modules can be replaced with any of several well characterized modules to yield several dozen different α -olefins. Increasing the number of upstream modules to three or more increases the number of different products into the hundreds and higher.

[0076] To ensure appropriate interactions between the two PKS proteins in this and related examples, one can use the acyl-carrier protein (ACP) and C-terminus from CurM's native enzyme partner, CurL. In general, native C- and N-terminal docking partners can be used in the combinatorial PKS enzymes of the invention. Other cognate domains from different PKS enzymes can also be used.

[0077] FIG. 3A shows an exemplary PKS for producing a triketide α -olefin. FIGS. 3B and 3C show exemplary extensions of this model, demonstrating how additional modules can be employed to yield longer, fully saturated, linear α -olefins.

[0078] Incorporation of the avermectin loading domain into a PKS of the invention provides access to a number of other α -olefins. Some examples of this aspect of the invention to make both known and novel α -olefins are shown in FIG. 4.

[0079] In some embodiments, the PKS of the invention produces a butadiene with a pendant acid moiety, such that the butadiene is suitable for subsequent crosslinking. FIG. 5 shows such a PKS that comprises a set of enzymes comprising an HMG-like system found in several PKS enzymes and corresponding gene clusters. This system converts the α -carbonyl to a number of different chemical moieties, most pertinently an exomethylene. Briefly, one of the previously described systems for incorporating an acrylate starter (DEBS (Donadio et al. 1991. supra) or difficidin (Chen et al. 2006. J. Bacteriol. 188(11):4024-36; incorporated herein by

reference) loading module) can be fused to an HMG-like module, such as JamE from the jamaicamide cluster (Edwards et al. 2004. ChemBiol. 11(6):817-33; incorporated herein by reference), and a TE domain at the C-terminus. Such a bimodular PKS enzyme can be co-expressed with the genes encoding accessory proteins required for the incorporation of the desired chemistry. In this example these enzymes are JamH, JamG and JamI (Edwards et al., 2004, supra).

[0080] In some embodiments of the invention, the PKS comprises a CurM chain termination module of *Lyngbya majuscula* CurM or functionally equivalent module. In some embodiments of the invention, the PKS comprises the ST and TE domains of the curM chain termination module and sequences derived from a different CurM module or another PKS entirely. In some embodiments of the invention, the PKS comprises the KR, ACP, ST and TE domains of the CurM chain termination module and sequences derived from a different CurM module or another PKS entirely. In some embodiments of the invention, the PKS comprises the AT, KR, ACP, ST and TE domains of the CurM chain termination module and sequences derived from a different CurM module or another PKS entirely.

[0081] In some embodiments, the PKS of the invention comprises an acrylate loading module, such as the acrylate loading module from the difficidin PKS (Chen et al., 2006, supra), which incorporates the acrylyl moiety from a hydroxypropionate precursor involving the enzymes difA-E.

[0082] The present invention also provides a PKS comprising an acrylate loading module coupled to a thioesterase domain, wherein the PKS is capable of producing acrylate (acrylic acid). The erythromycin PKS, for example and without limitation, includes suitable such modules and domains.

[0083] The following depict the amino acid sequences of SEQ ID NO:1-9

[0084] *L. majuscula* CurM (GenBank: ACV42478.1) has the following amino acid sequence (SEQ ID NO:1):

```

1 msnvskttqg dvssqevlqv lqemrsrlea vnkaktepia ivgmacrfpg gandpstywr
61 llhdgidait pvpphrwdvn ahyepnpeip gkaytkqggf iegvdqfdpl ffgispreai
121 sldpqyrlll evtwealena gqtwtlnkns ktsvfmgvst ddyaslsnpi linnrslgvg
181 rishllglqg sniqldtacs sslvaihlac qslrsgesnl alvggvnlil spistigrct
241 mkalspdgrc ktfdaaangy ggaegcgvvv lkrlsdaitd gdlisalirg sainhdgpss
301 gltvpngmaq kqviqqalsn arlephqvsy Leahgtgtal gdpieieala aiygknrvpd
361 qplvvgsvkt nighleaaag vsalikvvla lqhgeipphl hlkqpppyvd wdklpikipt
421 slmpwnceak priagissfg isgtnahlll eevpelikgq kakgksendl erplhiltls
481 tktekaleel vsryqnhwet ypelaisdvc ytantgraqf nhrlaviasg seeltqklrq
541 htageevgv fsgkvpnsgr eskvaflftg ggsqylnmgr qlyetqptfr qaldtcdhil
601 rpyldnplle ilypqdaqks ndspldqtgy tqpalfsiey allklweswg ikpnnvmghs
661 vgeyvaatva gvfsledglk liaargrlmq glpaggemvs vmaseskvle tlkamsledk
721 vaiaaingpe sivilsgeaea iramathles vgiktkqlqv shafhsplme pmlaeifeava
781 nqityhqpri piisnvtgtk adksiatagy wvnhrqpvr faqgmatlhq qgyetfleig
841 akpillgmgk qclspdvgrw lpslrhgvdw wqqilsslqg lyvqgakvdw sgfdrdysre
901 kvvlptypfq rerywvetsi nqqqvcsge pnlqgtpegt sttivkllsq gntkelaekv

```


- continued

961 ektsdlppeq lkllpdllas lsqghqgela rlttkkwfyk vqwisqaikp qrnksnnqvc
 1021 hwliitdskg lgkslathlq qlgnecsvvy qadnyqnyep giyhinpshp qefeqvyqti
 1081 fengklplqk vihlwsltda seqdlttetl eqaqlwgcs tlhlqtivk npnstppklw
 1141 mitrgtqpvl sptekltvat splwglgrti asehpqlwgg lvdldpqqse devevllqqi
 1201 idsqkedhla vnrkiyvar llkhipqesq plslrsdaty litgglgalg lktaawmaek
 1261 garnlvlisr rqpseqaqt iqsleelgtq kvlsadisv esdvanileq igtslppllg
 1321 vihaagvldd gllqqtner ftkvmapkvn gtwnlhkltq hlsldffvcf ssmssllgsp
 1381 gggnyaaana fmdavvhyrr emglpqlsin wggwseggma trlasqhqr mqttagisli
 1441 peqqiqvlee lvrtqstaqv gvlpvdswvl akqfssanps sllellqqe tssektderi
 1501 leklqaapit erqdilknyi qlvvaktlgi npskistddn fvelgmdslm gmevvnlsg
 1561 dldfiiypre fyerptidsl tqylsaelse dnlatqpspt sleifatkss psgnsarpas
 1621 vssrlpgiif ilssprsgst llrvmlaghs slfspplhl lpfntmkerq eqlnlsylge
 1681 glqktfmevk nldatasgal ikdlesqnl iqvygmlqe niaprllvdk sptyamepti
 1741 lergealfan skyiylvrhp ysviesfvr rmqklvlgge enpyrvaeqv waksnqnln
 1801 flsqleperq hqiryedlvk kpqqvlsqlc dflnvpfepe llqpyqgdrm tggvhqksls
 1861 isdnpflkhn tidesladkw ktiqlpyplk setqriasql syelpnlvtt ptnqqqvst
 1921 tpsteqpime ekflefggnq icicswgspe hpvvlcihgi legglawqev alplaaqgyr
 1981 vvapdlfghg rsshlemvts ysslftlaqi drvigelpdq plllvghsmg amlataiasv
 2041 rpkkikelil velplaees kkesavnlt tclldylsstp qhpifpdvat aasrlrqaip
 2101 slseefsyil agritqpnqg gvrwsdaii rtrsilglmn lpggrsqyle mlksiqvptt
 2161 lvygdsskln rpedlqqqkm tmtqakrvfl sgghnlhida aaalasilt s

[0085] HexORF1 has the following amino acid sequence (SEQ ID NO:2):

MADLSKLSDSRTAQPGRIVRPWPLSGCNESALRARARQLRAHLDRFPDAG
 VEGVGAALAHDEQADAGPHRAVVVASSTSELLDGLAAVADGRPHASVVRG
 VARPSAPVVVFVFPQGAQWAGMAGELLGESRVFAAAMDACARAFEPVTDW
 TLAQVLDSPEQSRRVEVVQPALFAVQTSALALWRSFGVTPDAVVGHSIGE
 LAAAHVCGAAGAADAARAAALWSREMIPLVGNMGMAAVALSADEIEPRIA
 RWDDDVVLAVNGPRSVLLTGSPEPVARRVQELSAEGVRAQVINVSMAAH
 SAQVDDIAEGMRSALAWFAPGGSEVPFYASLTGGAVDTRELVADYWRFS
 RLPVRFDEAIRSALEVGPGTFVEASPHVLAALQQLDAEGSSAAVPT
 LQRGQGMRRFLAAAQAFVAVDWTAAAYDDVGAEPGSLPEFAPAESE
 DEPAESGVDWNAPPHVLRERLLAVVNGETAALAGREADAEATFRELGLDS
 VLAAQLRAKVSAAIGREVNIALLYDHPTPRALAEALAAAGTEVAQRETRAR
 TNEAAPGEPVAVVAMACRLPGGVSTPEEFWELLESGRDAVAGLPTDRGWD
 LDSLFHPDPTSGTAHQGGGFLTEATAFDPAFFGMSPREALAVDPQORL
 MLELSWEVLERAGIPPTSLQASPTGVFVGLIPQYGPRLAEGGEGVEGYL
 MTGTTT SVASGRIAYTLGLEGPAISVDTACSSSLVAVHLACQSLRRGESS

- continued

LAMAGGVTVMPTPGMLVDFSRMNSLAPDGRCKAFSAGANGFGMAEGAGML
 LLERLSDARRNGHPVLAVLRGTAVNSDGASNGLSAPNGRAQVRVIQQALA
 ESGLGPADIDAVEAHGTGTRLDPIEARALFEAYGRDREQLHLGSKSN
 LGHTQAAAGVAGVIKMLVAMRAGTLPRTLHASERSKEIDWSSGAI SLLDE
 PEPWPAGARPRRAGVSSFGVSGTNAHVIVEEAPESSADAVAESGVRVPVP
 VVPWVVSARSAEGLAAQAERLARFVGERSDQDPVDIGFSLVRSRSLLEHR
 AVVLGKGRDDLAVGLASLASDGSATGVVSGVARGRARVAFGFSGQGAQRV
 GMGAELASVYPVFAEALAEVTGALGLDPEVFGDVRDLGRTEVTQAALFAF
 EVAVRLLLESFGVRPDVLIHSGIETIAAYVAGVFSLGDAALVGARGRL
 MQALPAGGVMVAVQAGEAEVVALEGFADRVSAAVNGPSSVVVSGEAEA
 VEQVVARLGKVKSKRLRVSHAFHSPLMEPMLADFRQVAEQITYNEPQLPV
 VSNVSGRLAEPGELTTPDYWVRHVREAVRFGDGVRALAADGVGLVEVGP
 DSVLTALARESLEDGEDGLRAVPLLRKDRPEPETLLTGVAQAFTHGVQVDW
 PALLPGRRVELPTYAFQRRRYWLEDADPTGGDPAALGLTAADHPLLGA
 VPLAEDQGIVITSRLSLRTHPWLADHEIGGTVLLPGAGLVEIALRAGDEV
 GCGRVEELTLEIPLVVPQEGGVTVQIRVGAPDESGWRPMTVHSRTDPEEE
 WTRHVSGLVSPDVPTERYDLGAWPPAGATPVELDGFYEAYARLGYAYGPS

-continued

FQGLRAAWRRGDEVFAEVS LPVEEQETAGRFTLHPALLDAALQSAGAGAF
 FDSGGSMRLPFAWSGVS VFAAGASTVRVRLSPAGPDAVTVALADPTGAPV
 ALVERLLIPEMSPEQLERVRGEEKEAPYVLDWVPVEVPADDLVRPERWTL
 LGGADAGVGLDVAGAFASLEPSDGAPEFVVLPCVPPTSPTRAADVRSQSTL
 QALTVLQNWVTDERHADSRLVLVTRRAVGVGAHDDV PDLTHAALWGLVRS
 AQTENPGRFLLVDLDEGAELAEVLP GALGSGESQVAVRAGRVLAAARLARS
 GSGGAELVPPAGAPWRLD TTSPTLENLALVPSAEEPLGPLDVRVSVRAA
 GLNFRDVLIALGMYPGDARMGEGAGVVT DVGSEVTTLAPGDRVMGMLS S
 AFGPTAVSDHRALVRVPDDWSFEQAASVPTVFATAYYGLVDLAE LRAGQS
 VLVHAAAGGVGMAAVQLARHLGAEVFGTASTGKWDSL RAGGLDAEHIASS
 RTVEFEETFLAATAGRGVDVLD SLAGEFVDASLRL LPRGGRFVEMGKAD
 IRDAERVAADHPGV TYRSFDLLEAGLDRFQEI L TEVVRLFERGVLRLHPV
 TAWDVRRAAEAFRFV SQARHVGNVLMPRVWDRDGT VLI TGGTGALGAL
 VARHLVAEHGMRNVLLAGRRGVDAPGARELLAELE TAGAQVSVVACDVAD
 RDAVAELIAKVPVEHPLTAVVHTAGVVADATL TALDAERVDTVLRKVDA
 VLHLHEATRGLDLAGFVLFSSASGI FSGPGQGN YAAANSFIDAF AHHRA
 QGLPALSLAWGLWARTSGMAGQLGHDDVARISRTGLAPI TDDQGMALLDA
 ALGAGRPLLVPVRLDRAALRSQATAGT LPPILRGLVRATVRR AASTAAAQ
 GPSLAERLAGLPVTEHERI VVELVRADLAAVLGHSSAGIDPGRAFQDMG
 IDSLTAVELRNRLNGATGLRLAASLVFDYPTPNALATHI LDELALDTAGA
 GAAGEPDGPAPAPADEARFRRVINSIPLDRIRRAGLLDALLGLAGTSADT
 AASDDFDQEEDGPAIASMDVDDLVR IALGESD T TADITEGTD RS*

[0086] HexORF1' has the following amino acid sequence (SEQ ID NO:3):

MADLSKLSDSRTAQPGRIVRPWL SGCNESALRARARQLRAHLDRFPDAG
 VEGVGAALAHDEQADAGPHRAVVVASS TSELLDGLAAVADGRPHASVVRG
 VARPSAPVVVFVPGQGAQWAGMAGELLGESRVFAAAMDACARAFEPVTDW
 TLAQVLDSP EQSRRVEVQPALFAVQTS LAALWRSFGVTPDAVVGH SIGE
 LAAAHVCGAAGAADAARAAALWSREMIPLVGN GDMAAVALSADEIEPRIA
 RWDDDVVLAVNGPRSVLLTGSPEPVARRVQELS AEGVRAQVINVSMAAH
 SAQVDDIAEGMR SALAWFAPGGSEVPFYASLTGGAVDTRELVADYWRRSF
 RLPVRFDEAIRSALEVGPGTFVEAS PHPVLAAALQQTLD AEGSSAAVPT
 LQRGQGMRRFLAAAQAF TGGVAVDWTAAYDDVGAEPGSLPEFAPAE EEE
 DEPAESGVDWNAPPHVLRERLLAVVNGETAALAGREADAEATFRELGLDS
 VLAAQLRAKVSAAGREVNIALLYDHPTPRALAEALAGTEVAQRETRAR
 TNEAAPGEPVAVVAMACRLPGGVSTPEEFWELLS EGRDAVAGLPTDRGWD
 LDSLFHPDPTRSGTAHQGGGFLTEATAFDPAFFGMSPREALAVDPQORL

-continued

MLELSWEVLERAGIPPTSLQASPTGVFVGLIPQEYGPRLAEGGEGVEGYL
 MTGTTT SVASGRIAYTLGLEGPAISVDTACSSSLVAVHLACQSLRRGESS
 LAMAGGVTVMP TP GMLVDFSRMNSLAPDGRCKAFSAGANGFGMAEGAGML
 LLERLSDARRNGHPVLAVLRGTAVNSD GASNGLSAPNGRAQVRVIQQALA
 ESGLGPADIDAVEAHGTGTRLDPIEARALFEAYGRDREQPLHLG SVKSN
 LGHTQAAAGVAGVIK MVLAMRAGTLPRTLHASERSKEIDWSSGAI SLLDE
 PEPWPAGARPRRAGVSSFGVSGTNAHVIV EEAPESSADAVAESGVRVPVP
 VVPWVVSARS AEGLAAQAERLARFVGERSDQDPVDIGFSLVRSRSLLEHR
 AVVLGKGRDDL VAGLASLASDGSATGVVSGVARGRARVAFGFSGQGAQRV
 GMGAELASVYPVFAEALAEVTGALGLDPEVFGDVDR LGRTEVTQAALFAF
 EVAVRLL ESFGVRPDVLI GHSIGEIAAAYVAGV FSLGDAAALVGARGRL
 MQALPAGGVMVAVQAGEAEVVAALEGFADRVSLAAVNGPSSVVVSGEAEA
 VEQVVARLGKVKSKRLRVSHAFHSP LMEPMLADFRQVAEQI TYNEPQLPV
 VSNVSGRLAEPGELTTPDYWVRHVREAVRFGDGV RALAADGVGLVEVGP
 DSVLTALARESLDGEDGLRAVPLLRKDRPEPETLLTGVAQAFTHGVQVDW
 PALLPGRRVELPT YAFQRRRYWLEDADPTGGDPAALGLTAADHPLL GAA
 VPLAEDQGI VITSRLSLRTHPWLADHEI GGTVLLPGAGLVEIALRAGDEV
 GCGRVEELTLEIPLVVPQEGGVTVQIRV GAPDES GWRPMTVHSRTDPEEE
 WTRHVSGLVSPDVPTERYDLGAWPPAGATPV ELDFYEA YARLGYAYGPS
 FQGLRAAWRRGDEVFAEVS LPVEEQETAGRFTLHPALLDAALQSAGAGAF
 FDSGGSMRLPFAWSGVS VFAAGASTVRVRLSPAGPDAVTVALADPTGAPV
 ALVERLLIPEMSPEQLERVRGEEKEAPYVLDWVPVEVPADDLVRPERWTL
 LGGADAGVGLDVAGAFASLEPSDGAPEFVVLPCVPPTSPTRAADVRSQSTL
 QALTVLQNWVTDERHADSRLVLVTRRAVGVGAHDDV PDLTHAALWGLVRS
 AQTENPGRFLLVDLDEGAELAEVLP GALGSGESQVAVRAGRVLAAARLARS
 GSGGAELVPPAGAPWRLD TTSPTLENLALVPSAEEPLGPLDVRVSVRAA
 GLNFRDVLIALGMYPGDARMGEGAGVVT DVGSEVTTLAPGDRVMGMLS S
 AFGPTAVSDHRALVRVPDDWSFEQAASVPTVFATAYYGLVDLAE LRAGQS
 VLVHAAAGGVGMAAVQLARHLGAEVFGTASTGKWDSL RAGGLDAEHIASS
 RTVEFEETFLAATAGRGVDVLD SLAGEFVDASLRL LPRGGRFVEMGKAD
 IRDAERVAADHPGV TYRSFDLLEAGLDRFQEI L TEVVRLFERGVLRLHPV
 TAWDVRRAAEAFRFV SQARHVGNVLMPRVWDRDGT VLI TGGTGALGAL
 VARHLVAEHGMRNVLLAGRRGVDAPGARELLAELE TAGAQVSVVACDVAD
 RDAVAELIAKVPVEHPLTAVVHTAGVVADATL TALDAERVDTVLRKVDA
 VLHLHEATRGLDLAGFVLFSSASGI FSGPGQGN YAAANSFIDAF AHHRA
 QGLPALSLAWGLWARTSGMAGQLGHDDVARISRTGLAPI TDDQGMALLDA
 ALGAGRPLLVPVRLDRAALRSQATAGT LPPILRGLVRATVRR AASTAAAQ
 GPSLAERLAGLPVTEHERI VVELVRADLAAVLGHSAERVPADQAF AELG
 VDSL TAVELRNRLNGATGLRLAASLVFDYPTPNALATHI LDELALDTAGA

- continued

GAGGEPDGPAPAPADEARFRRVINSIPLDRIRRAGLLDALLGLAGTSADT
AASDDFDQEEEDGPAIASMDVDDLVRIALGESDTTADITEGTDRS*

[0087] HexORF2 has the following amino acid sequence (SEQ ID NO:4):

MSSASSEKIVEALRASLTENERLRRLNQELAAAHEPVAIVSMACRFP
GGVESPEDFWDLISEGRDAVSGLPDNRGWDLDALYDPDPEAQGKTYVR
EGAFLYDAAEFDAELFGISPREALAMPQQRLLMETSWEVLERAGIRP
DSLARGKPVGVFTGGITSDYVTRHYASGTAPQLPSGVESHFMTGSAGSV
FSGRIAYTYGFEGPAVTVDTACSSSLVALHMAAQSLRQGECSLAFAGG
VAVLPNPGTFVGFQRALS PDGRCKAFSADADGTGWGEGAGLVLLEK
LSDARRNGHPVLAILRGS AVNQDGASNGLTAPNGPSQQRVIRAALANA
RLSPDDVDVVEAHGTGTPLGDPIEAQALQATYGRSRS AERPLWLGSVK
SNVAHAQAAAGVASVIKVMALRHRLLPKTLHADERSPHIDWHSGAVE
LLTEAREWSRTEGRARRAGVSSFGISGTNAHVIIIEAPELIKQKAKG
KSENDLERPLHILTLSTKTEKALEELVSRYQNHWETYPELAISDVCYT
ANTGRAQFNHRLAVIASGSEELTQKLRQHTAGEEVGVFSGKVPNSGS
ESKVAFLFTGQGSQYLNMGRLYETQPTFRQALDTCDHILRPYLDNPL
LEILYPQDAQKSNDSPLDQTYTQPALFSIEYALLKLWESWGIKPNVV
MGHSVGEYVAATVAGVFSLEDGLKLI AARGRLMQGLPAGGEMVSVMAS
ESKVLLETLKAMSLKVAIAAINGPESIVI SGAEAIRAMATHLESVG
IKTKQLQVSHAFHSPLMPEMLAEFEAVANQITYHQPRIPIISNVTGTK
ADKS IATAQYWNHVRQPVRF AQGMATLHQOQYETFL EIGAKPILLGM
GKQCLSPDVGWVWPLSLRHGVDEWQQILSSLGQLYVQGAKVDWSGFDRD
YSREKVVLPTYPFQRERYWVETSINQQQVVCSGEPNLQGTPEGSTTTI
VKLLSQGNTKELAEKVEKTS DLPPEQLKLLPDLLASLSQQHQQELARL
TTKKWFYKVQWISQAIKPQRNKSNNQVCHWLI LTDSKGLGKSLATHLQ
QLGNECSVVYQADNYQNYEPGIYHINPSHPQEFQVYQTI FENGKLP
QKVIHLWSLDTASEQDLTTETLEQAQLWGCSTLHLLQTLVKPNPSTP
PKLWMI TRGTQPVLSPTKELTVATSPLWGLGRTIASEHPQLWGGVLVDL
DPQSEDEVEVLLQQIIDSQKEDHLAVRNRKI YVARLLKHIPQESQPL
SLRSDATYLI TGGLGALGLKTAAWMAEKGARNLVLI SRRQPSEQAQQT
IQSLEELGTQVKVLSADISVESDVANILEQIQTS LPPLLGVIHAAGVL
DDGLLQQTNWERFTKVMAPKVN GTWNHKL TQHLSDFFVCFSSMSSL
LGSFGQNYAANAFMDAVVHYRREMGLPGLS INWGGWSEGGMATRLA
SQHQNRMQTAGISLISPEQGIQVLEELVRTQSTAQVGVLPVDWSVLAK
QFSSANPSSLLELLQOETSSEKTDERILEKLQAAPITERQDILKNYI
QLVVAKTLGINPSKISTDDNFVELGMDSLMGMEVVNKLSGDLDFI IYP
REFYERPTIDSLTQYLSAELSEDNLATQPSPTSLEIFATKSSPSGNSA

- continued

RPASVSSRLPGIIFILSSPRSGSTLLRVMLAGHSSLFSPPELHLLPFN
TMKERQEQLNLSYLGEGLQKTFMEVKNLDATASQALIKDLESQNLISIQ
QVYGMLOENIAPRLLVDKSPTYAMEPTILERGEALFANSKYIYLVRHP
YSVIESFVRMRMQKLVGLGEENPYRVAEQVWAKSNQNILNFLSQLEPE
RQHQIRYEDLVKKPQQVLSQLCDFLNVPFEPELLQPYQGDRTGGVHQ
KSLSISDPNFKHNTIDESLADKWKTIQLPYPLKSETQRIASQLSYEL
PNLVTTPTNQQPQVSTTPSTEQPI MEKFLFEGGNQICLCSWGSPEHP
VVLCIHGI LEQGLAWQEVALPLAAQYR VVAPDLFGHGRSSHLEMTS
YSSLTFLAQIDRVIQELPDQPLLLVGHSMGAMLATAIASVRPKKIKEL
ILVELPLPAEESKESAVNQLTTCLDYLSSTPQHPIFPDVATAASRLR
QAIPSLSEEFYILAQRITQPNQGGVRSWDAIIRTRSIGLNNLPGG
RSQYLEMLKSIQVPTTLVYGDSSKLNRPEDLQQQKMTMTQAKRVFLSG
GHNLHIDAAAALASLILTS*

[0088] The amino acid sequence of a PKS capable of producing 1-butene has the following amino acid sequence (SEQ ID NO:5):

MADLSKLSDSRTAQGRIVRPWPLSGCNESALRARARQLRAHLDRFPD
AGVEGVGAALAHDEQADAGPHRAVVASSTSELLDGLAAVADGRPHAS
VVRGVARPSAPVVFVFPQGAQWAGMAGELLGESRVFAAAMDACARAF
EPVTDWTLAQVLD SPEQSRRVEVVQPALFAVQTS LAALWRSFGVTPDA
VVGHSIGELAAAHVCGAAGAADAARAAALWSREMIPLVGNGDMAAVAL
SADEIEPRIARWDDVVLAGVNGPRSVLLTGSPEPVARRVQELSAEGV
RAQVINVSMAAHS AQVDDIAEGMRSALAWFAPGGSEVPFYASLTGGAV
DTRELVADYWRRSFRLPVRFDEAIRSAL EVGPGTFVEAS PHPVLAAAL
QQTLD AEGSSAAVPTLQRGQGMRRFL LAAAQAFTGGVAVDWTAAYD
DVGAEPGSLPEFAPAEEDDEPAESGVDWNAPPHVLRERLLAVNGETA
ALAGREADAEATFRELGLD SVLAAQLRAKVSA AIGREVNIALLYDHPT
PRALAEALSSGTEVAQRETRARTNEAAPGEP IAVVAMACRLPGGVSTP
EEFWELLS EGRDAVAGLPTDRGWDLD SLFHPDPTRS GTAHQRGGGFLT
EATAFDPAFFGMSPREALAVDPQQRLLMEL SWEVLERAGIPPTSLQAS
PTGVFVGLIPQEYGPRLAEGGEGVEGYLMTGTTT SVASGRIAYTLGLE
GPAISVDTACSSSLVAVHLACQSLRRGESSLAMAGGVTVMP TPGLMVD
FSRMNSLAPDGRCKAFSAGANGFGMAEGAGMLLLERLSDARRNGHPVL
AVLRGTAVNSDGASNGLSAPNGRAQVRVIQQALAESGLGPADIDAVEA
HGTGTRLGDP IEARALFEAYGRDREQPLHLG SVKSNLGH TQAAAGVAG
VIKMLAMRAGTLPRTLHASERSKEIDWSSGAISLLDEPEPWAGARP
RRAGVSSFGISGTNAHAIIEAPELIKQKAKGKSENDLERPLHILTL
STKTEKALEELVSRYQNHWETYPELAISDVCYTANTGRAQFNHRLAVI
ASGSEELTQKLRQHTAGEEVGVFSGKVPNSGSESKVAFLFTGQGSQY

- continued

LNMGRQLYETQPTFRQALDTCDHILRPYLDNPLLEILYPQDAQKSND
 PLDQGTGYPALFSIEYALLKLWESWGIKPNVVMGHSVGEYVAATVAG
 VFSLEDGLKLI AARGRLMQGLPAGGEMVSVMASESKVLETLKAMSLED
 KVAIAAINGPESIVISGEAEAIRAMATHLESVGIKTKQLQVSHAFHSP
 LMPEMLAEFEAVANQITYHQPRIPISNVTGTKADKSIATAQYVWNHV
 RQPVRFAQGMATLHQQGYETFLEIGAKPILLGMGKQCLSPDVGVWLPS
 LRHGVDWQOILSSLGQLYVQAKVDWSGFDRDYSREKVVLPYTPFQR
 ERYWVETSINQQQVCSGEPNLQGTPEGTSTTIVKLLSQGNTKELAEK
 VEKTSDLPPPEQLKLLPDLLASLSQQHQELARLTTKKWFYKQWISQA
 IKPQRNKSNNQVCHWLI LTDSKGLGKSLATHLQQLGNECSVVYQADNY
 QNYEPGIYHINPSHPQEFQVYQTI FENGKLPQKVIHLWSLDTASEQ
 DLTTELEQAQLWGGSTLHLLQTLVKNPNSTPPKLWMITRGTQPVLS
 PTEKLTVATSPWGLGRTIASEHPQLWGGGLVDLDPQSEDEVEVLLQQ
 IIDSQKEDHLAVRNKI YVARLLKHIPQESQPLSLRSDATYLI TGGLG
 ALGLKTAAWMAEKGARNLVLISRRQPSEQAQQTIQSLEELGTQVKVLS
 ADISVESDVANILEQIQTSLPPLLGVIIHAAGVLDLGGLLQQTNERFTK
 VMAPKVNGTWNHKLQHLSDLDFVCFSSMSSLGSPGQGNIAANAF
 MDAVVHYRREMGLPGLSINWGGWSEGGMATRLASQHQNRMQTAGISLI

- continued

SPEQGIQVLEELVVRTQSTAQVGVLPVDWSVLAKQFSSANPSSLLELL
 QQETSSEKTDERILEKLQAAPITERQDILKNYIQLVVAKTLGINPSKI
 STDDNFVELGMDSLMGMEVVNKLSGDLDFIYPREFYERPTIDSLTQY
 LSAELSEDNLATQPSPTSLEIFATKSSPSGNSARPASVSSRLPGIIFI
 LSSPRSGSTLLRVMLAGHSSLFSPPELHLLPFNTMKERQEQNLNSYL
 EGLQKTFMEVKNLDATASQALIKDLESQNLISIQQVYGMQENIAPRL
 VDKSPTYAMEPTILERGEALFANSKYIYLVRHPYSVIESFVRMRMQL
 VGLGEENPYRVAEQVWAKSNQNI LNFLSQLEPERQHQIRYEDLVKKPQ
 QVLSQLCDFLNVFPPEPELLQPYQGDRMTGGVHQSLSISDPNFKHNT
 IDESLADKWKTIQLPYPLKSETQRIASQLSYELPNLVTTPTNQPPQVS
 TTPSTEQPI MEEKFLEFGGNQICLCSWGSPEHPVVL CIHGLEQGLAW
 QEVALPLAAQGYRVVAPDLFGHGRSSHLEMTSYSSLTFLAQIDRVIQ
 ELPDQPLLLVGHSMGAMLATAIASVRPKKIKELILVELPLPAEESKKE
 SAVNQLTCLDYLSSTPQHPIFPDVATAASRLRQAI PSLSEEFYILA
 QRITQPNQGGVRWSWDAAIIRTRSILGLNNLPGGRSQYLEMLKSIQVPT
 TLVYGDSSKLNRPEDLQQQKMTMTQAKRVFLSGGHNHIDAAAALASL
 ILTS*

[0089] The amino acid sequence of a PKS capable of producing propene has the following amino acid sequence (SEQ ID NO:6):

MAGHGDATAQKAQDAEKSEDSDAIAVIGMCRFPGAPGTAEFWQLLSSGADAVVTAADGRR
 RGTIDAPADFDAAFFGMSPREAAATDPQQRLVLELGWEALEDAGIVPESLRGEAASVFGAM
 NDDYATLLHRAGAPTDYATATGLQHSMIANRLSYFLGLRGPVLDVDTGQSSSLVAVALAVES
 LRGGTSGIALAGGVNLVLAEEGSAAMERVGALSPDGRCHTFDARANGYVRGEGGAI VVLKPL
 ADALADGDRVYCVVRGVATGNDGGGPGLTVPDRAGQEA VLRAACDQAGVVPADVRFVLEHGT
 GTPAGDPVEAEALGAVYGTGRPANEPLL VGSVKTNI GHLEGAAGIAGFVKAALCLHERALPA
 SLNFETPNPAIPLERLRKLVQTAHAALQPGTGGGPLLAGVS AFGMGGTNC HVVLEETPGGRQ
 PAETGQADACLF SASPMLLLSARSEQALRAQAARLREHLED SGADPLDIAYSLATTRTRFEH
 RAAVPCGDPDRLS SALAALAAGQTPRGVRI GSTDADGRLALLFTGQGAQHPGMGQELYTTDP
 HFAAALDEVCEELQRCGTQNLREVMFTPDQPDLLDRTEYTQPALFALQ TALYRTL TARGTQA
 HLVLGHSVGEITAAHIAGVLDLPDAARLI TARAHVMGQLPHGGAMLSVQAAEHLDLQLAHTH
 GVEIAAVNGPTHCVLSGPRTALEETAQHLREQNVRHTWLKVSHAFHSALMDPMLGAFRDTLN
 TLNYQPPTIPLISNLTGQIADPNHLCTPDYWIDHARHTVRFADAVQTAHHQGTTTYLEIGPH
 PTLTLLHHTLDNPTTPTLHRRERPEPETLQAI AAVGVRTDGIDWAVLCGASRPRRVELPT
 YAFQRRTHWAPGLTPNHAPADRPAEPQRAMAVGPVSREALVRLVGETTASVGLDGPDEVA
 LDRPFTSQGLDSMTAVELAGLLGTAAGVALDPTLVYELPTPRAVADHLAKTLLGESAADADQ
 EVNGRTGEAEAKAGDPIAVIGIGCRFPGGVATPDDLWELVASGTDAI STFP TDRGWLDGLY
 DPDPSTPGKSYVRHGGFLHDAAQFDAEFFGISPREATAMPQQRLLETSWEALERAGVVPE
 SLRGGRTGVFVGT TAPEYGPRLHEGTDGYEGFLLTGTTASVASGRIAYALGTRGPALTVDTA

- continued

C S S S L V A L H L A V Q S L R R G E C D L A L A G G T T V M S G P G M F V E F S R Q R G L A P D G R C K A F S A D A D G T
 A W A E G V G M L L V E R L S D A E R L G H R V L A V V R G T A V N Q D G A S N G L T A P S G P A Q Q Q V I R D A L S D A G
 L S A D D I D A V E A H G T G T A L G D P I E A G A L L A T Y G H P K R Q T P V W L G S L K S N I G H T Q A A A G I A G I I
 K M V Q A L R H D T L P R T L H A D H P S S K V D W D A G P L Q L L T D A R P W P A D P D R P R R A G I S A F G V S G T N A
 H V V L E E P P E L I K G Q K A K G S E N D L E R P L H I L T L S T K T E K A L E E L V S R Y Q N H W E T Y P E L A I S D
 V C Y T A N T G R A Q F N H R L A V I A S G S E E L T Q K L R Q H T A G E E V V G V F S G K V P N S G S E S K V A F L F T G
 Q G S Q Y L N M G R Q L Y E T Q P T F R Q A L D T C D H I L R P Y L D N P L L E I L Y P Q D A Q K S N D S P L D Q T G Y T Q
 P A L F S I E Y A L L K L W E S W G I K P N V M G H S V G E Y V A A T V A G V F S L E D G L K L I A A R G R L M Q G L P A
 G G E M V S V M A S E S K V L E T L K A M S L E D K V A I A A I N G P E S I V I S G E A E A I R A M A T H L E S V G I K T K
 Q L Q V S H A F H S P L M E P M L A E F E A V A N Q I T Y H Q P R I P I I S N V T G T K A D K S I A T A Q Y W V N H V R Q P
 V R F A Q G M A T L H Q Q G Y E T F L E I G A K P I L L G M G K Q C L S P D V G V W L P S L R H G V D E W Q Q I L S S L G Q
 L Y V Q G A K V D W S G F D R D Y S R E K V V L P T Y P F Q R E R Y W V E T S I N Q Q Q V V C S G E P N L Q G T P E G T S T
 T I V K L L S Q G N T K E L A E K V E K T S D L P P E Q L K L L P D L L A S L S Q Q H Q Q E L A R L T T K K W F Y K V Q W I
 S Q A I K P O R N K S N N Q V C H W L I L T D S K G L G K S L A T H L Q Q L G N E C S V V Y Q A D N Y Q N Y E P G I Y H I N
 P S H P Q E F E Q V Y Q T I F E N G K L P L Q K V I H L W S L D T A S E Q D L T T E T L E Q A Q L W G C G S T L H L L Q T L
 V K N P N S T P P K L W M I T R G T Q P V L S P T E K L T V A T S P L W G L G R T I A S E H P Q L W G G L V D L D P Q G S E
 D E V E V L L Q Q I I D S Q K E D H L A V R N R K I Y V A R L L K H I P Q E S Q P L S L R S D A T Y L I T G G L G A L G L K
 T A A W M A E K G A R N L V L I S R R Q P S E Q A Q Q T I Q S L E E L G T Q V K V L S A D I S V E S D V A N I L E Q I Q T S
 L P P L L G V I H A A G V L D D G L L Q Q T N W E R F T K V M A P K V N G T W N L H K L T Q H L S L D F F V C F S S M S S L
 L G S P G Q G N Y A A A N A F M D A V V H Y R R E M G L P G L S I N W G G W S E G M A T R L A S Q H Q N R M Q T A G I S L
 I S P E Q G I Q V L E E L V R T Q S T A Q V G V L P V D W S V L A K Q F S S A N P S S L L L E L L Q Q E T S S E K T D E R I
 L E K L Q A A P I T E R Q D I L K N Y I Q L V V A K T L G I N P S K I S T D D N F V E L G M D S L M G M E V V N K L S G D L
 D F I I Y P R E F Y E R P T I D S L T Q Y L S A E L S E D N L A T Q P S P T S L E I F A T K S S P S G N S A R P A S V S S R
 L P G I I F I L S S P R S G S T L L R V M L A G H S S L F S P P E L H L L P F N T M K E R Q E Q L N L S Y L G E G L Q K T F
 M E V K N L D A T A S Q A L I K D L E S Q N L S I Q Q V Y G M L Q E N I A P R L L V D K S P T Y A M E P T I L E R G E A L F
 A N S K Y I Y L V R H P Y S V I E S F V R M R M Q K L V G L G E E N P Y R V A E Q V W A K S N Q N I L N F L S Q L E P E R Q
 H Q I R Y E D L V K K P Q Q V L S Q L C D F L N V P F E P E L L Q P Y Q G D R M T G G V H Q K S L S I S D P N F L K H N T I
 D E S L A D K W K T I Q L P Y P L K S E T Q R I A S Q L S Y E L P N L V T T P T N Q Q P Q V S T T P S T E Q P I M E E K F L
 E F G G N Q I C L C S W G S P E H P V V L C I H G I L E Q G L A W Q E V A L P L A A Q G Y R V V A P D L F G H G R S S H L E
 M V T S Y S S L T F L A Q I D R V I Q E L P D Q P L L L V G H S M G A M L A T A I A S V R P K K I K E L I L V E L P L P A E
 E S K K E S A V N Q L T T C L D Y L S T P Q H P I F P D V A T A A S R L R Q A I P S L S E E F S Y I L A Q R I T Q P N Q G
 G V R W S W D A I I R T R S I L G L N N L P G G R S Q Y L E M L K S I Q V P T T L V Y G D S S K L N R P E D L Q Q Q K M T M
 T Q A K R V F L S G G H N L H I D A A A A L A S L I L T S

[0090] The amino acid sequence of a PKS capable of producing styrene has the following amino acid sequence (SEQ ID NO:7):

M T K E Y T R P Q S A P L T E G D L L T L I V A H L A E R L R M D A R F I D V H E P F S R H G L D S R G A V D L V V D L R T
 A L G R P L S P V V V W Q H P T P D A L A R H L A G G A D A R E G Q A R A D S A Y E R P G A P N E P I A I V G M A C R F P G
 A P D V D S Y W R L L S G G V D A V T E V P A G R W D M D A F Y D R D P R S L G D V S T L R G G F I D D V D R F D A M F F G

- continued

ISPREAVSMDPQQRLMLELAWEALEDAGIVAERLKESTGVFFGCIWDDYVTLIHQRGRGAI
AQHTVTGNHRSI IANRVSYTLDLRGPSMTVDSACSSALVTIHMACESTRSGESTLALAGGVN
LNIAPESTIGVHKFGGLSPDGRCTTFDARANGYVRGEGGGVVVLKRLSSAIADGDP I I CVIR
GSAVMNDGASNGLTGPNPLAQEAVLRTAYERAGVNPADVQYVELHGTGTQLGDPVEASALGA
VLGKRRPAERPLLVSAGTINVGHLEGAAGIVGLLKAALCLKHKQLAPNLNFETPNPHI PFAE
LNLKVQGALGPWPMRPLVCGVSSFGLGGTNAHVVLSEWASLEAELHPLAAESPEALREEV
QRRLLTMTSLVGRAPLSFLCGRSAAQORSAKEHRLAVTARSFEELKQRLGFLHEKHVSVSA
GRVDLGAAPKVVFVAGQQAQWFGMGRALLQREPVRTTIEQCSSFIQQNLGWSLLDELMTD
RESSRLDEIDVSLPAI I SIEIALAAQWRAGVPEAFVVGHSTGEIAAAHVAGVLSI EDAMRT
ICAYGRI IIRKLRGKGMGLVALSWEDAGKELTGYEGRLFRAIEHSADSTVLAGEPDALDALL
QALERKNVFCRRVAMDVAPHCPQVDCLRDELFDALREVRPNKAQIPIVSEVTGTALDGERFD
ASHWVRNFGDPALFSTAIHLLQEGFDIFLELTPHPLALPAIESNLRRSGRRGVVLP SLRRN
EDERGMVLDTLGLVLYVRGAPVRWDNVYPAAFESMPLPSTAGGGKPLPPMLLI SARTDAALA
AQARLRAHLDSHLDELVDVAYS LAATRTHFERRAVVVARDRAGILDGLDALAHGGS AALL
GRSAAHGKLA I LFTGQGSQRPTMGRALYDAFPVFRGALDAAAHLDRDLDRPLRDVLFAPDG
SEQAARLDQTAFTQPALFALEVALFELLQS FGLKPALLLGH S I GELVAAHVAGVLSLQDACT
LVAARAKLMQALPQGGAMVTLQASEQEARDLLQAAEGRVSLAAVNGHLS TVVAGDEDAVLKI
ARQVEALGRKATRLRVSHAFHSPHMDGMLDDFRRVAQGLTFHPARIP I I SNVTGARATDQEL
ASPETWVRHVRD TVRFLDGVRTLHAEGARAFLELGPHPVLSALAQDALGHDEGPS PCAFLPT
LRKGRDDAEFTAALGALHAAGLTPDWNAFFAPFAPCKVPLPTYTTFQRERFWLDASTAHAAS
ATPAAALEGRFWQAVESGDIDTSSSELHVDGDEQRAALALVLP TLSSFRHKRQEQS TVDAWR
YRVTWKPLTTAATPADLAGTWLLVPSALGDDALLATL TEALTRRGARVLALRVSDIHIGRS
ALVEHLREALAETAPLRGVLSLLALDEHRLADRSALPAGLALS LALVQGLDDLAIEAPLWLF
TRGAVSIGHSDPITHPTQAMIWGLGRVVGLEHPPERWGGVLDVVSAGVDES AVGRLLPALAQRH
DEDQLALRPAGLYARRI VRAPLGDAPPAREFRPRGTILITGGTGALGAHVARW LARQGAEHL
ILISRRGAEAPGASELHAELNALGVRTTAAACDVADRSALQALLD S I PSDCPLTAVFHTAGA
RDDGLIGDMTPERI ERVLAPKLD SALHLHELT KNSALDAFVLYASLSGVLGNPGQANYAAAN
AFLDALAEHRRSLGLTATSVAWGGWGGGMATERVAAQLQQRGLLQMAPSLALAALAAQALQQ
DETTITVADIDWSRFAPAFSVARQRP LLRDLPEAQRALQASEGASSEHG PATGLLDELRSRS
ESEQLDLLATLVRGETATVLGHAEASHVDPDKGFMDLGLDSLMTVELRRRLQKATGVKLPPT
LAFDHPSPHRVAFFLRDSLSEDNLATQPSPTSLEIFATKSSPSGNSARPASVSSRLPGIIFI
LSSPRSGSTLLRVMLAGHSSLFSPPELHLLPFNTMKERQQLNLSYLGEGLQKTFMEVKNL D
ATASQALIKDLESQNL SIQQVYGMLOENIAPRLLVDKSPTYAMEPTILERGEALFANSKYIY
LVRHPYSVIESFVRMRMQLVGLGEENPYRVAEQVWAKSNQNILNFLSQLEPERQHQIRYED
LVKPKQQVLSQLCDFLNVFPEPELLQPYQDRMTGGVHQSLSISDPNFLKHNTIDESLADK
WKTIQLPYPLKSETQRIASQLSYELPNLVTTPTNQPPQVSTTPSTEQPI MEEKFLEFGGNQI
CLCSWGSPEHPVVL CIHGILEQGLAWQEVALPLAAQGYRVVAPDLFGHGRSSHLEMVTSYSS
LTFLAQIDRVIQELPDQPLLLVGHSMGAMLATAIASVRPKKIKELILVELPLPAESKKESA
VNQLTTCLDYLSSTPQHPIFPDVATAASRLRQAI PSLSEEF SYILAQRI TQPNQGGVRWSWD

- continued

AIIRTRSILGLNNLPGGRSQYLEMLKSIQVPTTLVYGDSSKLNRPEDLQQQKMTMTQAKRVF
LSGGHNLHIDAAAALASLILTS

[0091] The amino acid sequence of a PKS (pentene ORF1) capable of producing pentene has the following amino acid sequence (SEQ ID NO:8):

MRAPYGNRQVNRFLREFRAKRPFCVSPHFLAEFSESRQTTGSAGVTAPIIDRPGVSMAPKS
GAQRSSDI AVVGMS CRLPGAPGIDEFWHLLTTGGS AIERRADGTWRGSLDGAADFDAFFDM
TPRQAAAADPQORLMLELGTALENAGIVPGSLAGTDTGVFVGIADDYAALLHRSATPVSG
HTATGLSRGMAANRLSYLLGLGGPSLAVDSAQSSSLVAVHLACESLRRGESDLAIVGGVSLI
LAEDSTAGMELMGALSPDGRCHTFDARANGYVRGEGGACVVLKPLERLADGDRVHCVVVRS
AVNNDGGGSLTTPHREAQAAVLRAYERAGVGPDQVS YVELHGTGTPVGDPEAAAALGAVL
GTAHGRNAPLSVGSVKTNVGHLEAAAGLVGFVKAALCVREGVPPSLNHATPNPAI PMDRLN
LRVPTRLEPWPHPDDRATGRLRLAGVSSFGMGGTNAHVVEEAPLPEAGEPVGAGVPLAVVP
VVVSGRSAGAVAELASRLNESVRSRDLVDVGLSSVSRVFEHRSVVLGDSAEALSAGLDAL
AADGVSPVLVSGVASVGGGRSVFVFPAGVWKWAGMALGLWAESAVFAESMARCEAAAFAGLVE
WRLADVLDGGAALEREVDVQPASFAVMVSLAALWRS LGVVPDAVVGHSQGEIAAAVVAGGLS
LEDGARVVVLRARVAEEVLSGGG IASVRLSRAEVEERLAGGGGGLSVAVVNAPSSTVVAGEL
GDLDRFVAACEAEGVRARRLEFGYASHSRFVEPVRERLLEGLADVVRGRIPFYSTVEAAE
FDTAGLDAEYWFGNLRRPVRFQETVERLLADGFRVFEVCGAHPVLTGAVQETAETAGREI CS
VGS LRREDEGLRRFLTSAAEAFVQGEVSWPVLFDTGTARTVDLPTYPFQRRHHWAPDGSAS
AAPTRDIRPDETA AVPADTMDLAGQLRADVASLPTTEQIARLLDQVRDGVATVGLDARDEV
RAEATFKELGVE SLTGVELKNHLRARTGLHVPTSLI YDCPTPLAAHYLRDELLGRPAEQAV
VPAGIPVDEPIAIVGMGCR LPGGVSSPEGLWDLVASGVDAVSPFPTDRGWDVGG LFDPEPGV
PGRSVYREGGLHEAGEFDAGFFGI SPREALAMPQQRLLLETSWEALERAGIDPHTLRGRS
TGVYAGVMAQEYGPRLHEGADGYEGYLLTGSSSSVASGRI SYVLGLEGPAVTVDTACSSSLV
ALHLAVRALRSGECDLALAGGATVMAEPMFV EFSRQRGLSAHGRCKAYS DSADGTGWAEGA
GVLLVERLSDAVRHGRRVLAVVRS AVNQDGASNGLTAPNGRSQSRLIRQALADARLGVADV
DVVEGHGTGTRLGDP IEAQALLATYQORDAGRPLRLGSLKSNVGH TQAAAGVAGVI KMVMAM
RHGVLPKTLHVDEPTAEVDWSAGAVSLLREQEAWPRGERVRRAGVSSFGVSGTNAHVILEQP
PGVPSQSAGPGSGSVVDVPVPMVSGKTPEALS AQATALMTYLDERPVS SLDVGYSLALT
RSALDERAVVLGSDRETL LCGVKALSAGHEASGLVTG SVGAGGRIGFVFSGQGGQWLGMRG
LYRAFPVFAAAFDEACAELDAHLGQEIGVREV VSGSDAQLLDRTLWAQSGLFALQVGLLKL L
DSWGV RPSVVLGH SVGELAAAFAAGVVSLSGAARLVAGRARLMQALP SGGGMLAVPAGEELL
WSLLADQGD RVGIAAVNAAGSVVLSGDRDVLDDLAGRLDQGI RSRWLRVSHAFHSYRMDPM
LAEFAELARTVDYRRCEVPIVSTLTGDLDDAGRMSGPDYVVRQVREPVRFADGVQALVEHDV
ATVVELGPDGALSALIQECVAASDHAGRLS AVPAMRRNQDEAQKVM TALAHVHVRGGAVDWR
SFFAGTGAKQIELPTYAFQRQRYWLVP SDSGDVGTGAGLAGAEHPLL GAVVPVAGGDEVLLTG
RISVRTHPWLAEHRVLGEVIVAGTALLEIALHAGERLGCERVEELTLEAPLVLPERGAIQVQ

- continued

LRVGAPENSGRRPMALYSRPEGAAEHDWTRHATGRLAPGRGEAAGDLADWPAPGALPVDLDE
FYRDLAELGLEYGPIFQGLKAAWRQGDVEVYAEALPGTEDSGFGVHPALDAAALHATAVRDM
DDARLPFQWEGVSLHAKAAPALRVRVVPAGDDAKSLLVCDGTGRPVI SVDRLVLRSAARRT
GARRQAHQARLYRLSWPTVQLPTSAQPPSCVLLGTSEVSADIQVYPDLRSLTAALDAGAEPP
GVVIAPTPPGGRTADVRETRHALDLVQGWLSQRLNESRLLLVTOGAVAVEPEPVTDLA
QAALWGLLRSTQTEHPDRFVLVDVPEPAQLLPALPGVLACGEPQLALRRGGAHAPRLAGLGS
DDVLPVPDGTGWRLEATRPGSLDGLALVDEPTATAPLGDGEVRIAMRAAGVNFRLDALIALGM
YPGVASLGSEGAGVVETGPGVTGLAPGDRVMGMIPKAFGPLAVADHRMVTRI PAGWSFARA
ASVP IVFLTAYYALVDLAGLRPGESLLVHSAAGGVGMAAIQLARHLGAEVYATASEDKWQAV
ELSRHHLASSRTCDFEQQLGATGGRGVDVVLNSLAGEFADASLRMLPRGGRFLELGKTDVR
DPVEVADAHPGVSYQAFDTVEAGPQRI GEMLHELVELFEGRVLEPLPVTAWDVRQAPEALRH
LSQARHVGLVLTMPVWDAAGTVLVTGGTGALGAEVARHLVIERGVRNLVLSRRGPAASG
AAELVAQLTAYGAEVSLQACDVADRETAKVLASIPDEHPLTAVVHAAGVLDGVSSESLTVE
RLDQVLRPKVDGARNLLELIDPDVALVLFSSVSGVLGSGGQGNAAAANSFLDALAQQRQSRG
LPTRSLAWGPWAEHGMASLREAEQDRLARSGLLPI STEEGLSQFDAACGGAHTVVAPVRFSS
RLSDGNAIKFSVLQGLVGPVHRVKAATADDAESLRKRLGRLPDAEQHRI LLDLVRMHVA AVL
GFAGSQEI TADGTFKVLGFDSLTVVELRNRINGATGLRLPATLVFNYPPTDALAAHLVTALS
ADRLAGTFEELDRWAANLPTLARDEATRAQITTRLQAILQSLADVSGGTGGGSVPDRLRSAT
DDEL FQLLDNDLELP

[0092] The amino acid sequence of a PKS (pentene ORF2) capable of producing pentene has the following amino acid sequence (SEQ ID NO:9):

MSNEEKLREYLRRALVDLHQARERLHEAESGEREPIAIVAMGCRYPPGGVQDPEGLWKLVASG
GDAIGEPADRGWHLDELYDPDPDQPGTCYTRHGGFLHDAGEFDAGFFDISPREALAMPQQ
RLLLEISWETVESAGMDPRSLRGSRTGVFAGLMYEGYDTGAHRAGEGVEGYLGTGNAGSVAS
GRVAYAFGFEGPAVTVDTACSSSLVALHLACQSLRQGECDLALAGGVTVMSTPERFVEFSRQ
RGLAPDGRCKSFAAAADGTGWGEGAGLVLLERLSDARRNGHRVLAVVRGSAVNQDGASNGLT
APNGLAQERVIQQVLTSAGLSASDVDAVEAHGTGTRLGDP IEAQALIAAYGQDRDRDRPLWL
GSVKSNIGHTQAAAGVAGVIKVMAMRHGELPRTLHVDEPNSHVDWSAGAVRLLTENIRWPG
TGTRRAGVSSFGVSGTNAHVIVGDYAQQKSPAPPATQDRPWHLTL SAKNAQALNALQKSY
GDYLAQHPSVDPRDLCL SANTGRSPLKERRFFVFKQVADLQOTLNQDFLAQPRLS SPAKIAF
LFTGQGSQYYGMGQQLYQTS PVFRQVLDECRLWQTYSP EAPALTDLLYGNHNPDLVHETVY
TQPLLF AVEYAI AQWLWSGVTPDFCMGHSVGEYVAACLAGVFLADGMKLI TARGKLMHAL
PSNGSMAAVFADKTVIKPYLSEHLTVGAENGSHLVLSGKTPCLEASIHKLQSQGIKTKPLKV
SHAFHSPMAPMLAEFREIAEQITFHPPRIPLISNVTGGQIEAEIAQADYWKHVSQPVKFV
QSIQTLAQAGVNVYLEIGVKPVLLSMGRHCLAEQEA VWLPSLRPHSEPWPEILTSLGKLYEQ
GLNIDWQTEAGDRRRKLI LPTYPFQRQRYWFNQGSWQTVETESVNP GPDDLNDWLYQVAWT
PLDTLPPAPEPSAKLWLI LGDRHDHQP IEAQFKNAQRVYLGQSNHFPTNAPWEVSADALDNL
FTHVGSQNLGILYLCPGEDPEDLDEIQKQTS GFALQLIQTLYQOKIAVPCWFVTHQSQRV

- continued

LETDAVTGFAQGGLWGLAQAI ALEHPELWGGI IDVDDSLPNFAQI CQQRQVQQLAVRHQKLY
 GAQLKKQPSLPQKNLQIQPQQTYLVTTGGLGAI GRKIAQWLAAAGA EKVI LVSRRAPAADQQT
 LPTNAVVPYPCDLADAAQVAKLFQTYPHIKGIFHAAGTLADGLLQQQTWQKFQTVAAAKMKGT
 WHLHRHSQKLDLDFVLFSSVAGVLGSPGQGN YAAANRGM AAI AQYRQAQGLPALAIHWGPW
 AEGGMANSLSNQNLAWLPPQGLTILEKVLGAQGEMGVFKPDWQNLAKQFPEFAKTHYFAAV
 IPSAEAVPPTASIFDKLINLEASQRADYLLDYLRRSVAQILKLEIEQIQSHDSLDDLGMDSL
 MIM EAIASLKQDLQMLYPREIYERPRLDVLTAYLAAEFTKAHDSEAATAAAAIPSQSLSVK
 TKKQWQKPDHKNPNPIAFILSSPRSGSTLLRVMLAGHPGLYSPPELHLLPFETMGRHQELG
 LSHLGEGLQRALMDLENLTPEASQAKVNQWVKANTPIADIYAYLQRQAEQRLLIDKSPSYGS
 DRHILDHSEILFDQAKYIHLVRHPYAVIESFTRLRMDKLLGAEQQNPYALAESIWRTSNRNI
 LDLGRTVGADRYLQVIYEDLVRDPRKVL TNICDFLGVD FDEALLNPYSGDRLTDGLHQQSMG
 VGDPNFLQHKTI DPALADKWR S I TLPALQLDTIQ LAETFAYDLPQEPQLTPQTQSLPSMVE
 RFVTVRGL ETCLCEWGD RHQPLVLLLHGILEQ GASWQLIAPQLAAQGYWV VAPDLRGHGKSA
 HAQSY SMLDFLADVDALAKQLGDRPFTLVGHSMGSI IGAMYAGIRQTQVEKLI L VETIVPND
 IDDAETGNHLTTHLDYLAAPPQHPIFPSLEVAARRLRQATPQLPKDLSAFLTQRSTKSVEKG
 VQWRWDAFLRTRAGIEFNGISRRRYLALLKDIQAPI TLIYGDQSEFNRPADLQAIQAALPQA
 QRLTVAGGHNLHFENPQAI AQIVYQQLQTPVPKTQ

Nucleic Acids Encoding the PKS

[0093] The present invention provides recombinant nucleic acids that encode the PKSs of the invention. The recombinant nucleic acids include double-stranded and single-stranded DNAs and RNA derived therefrom. The recombinant nucleic acids of the invention include those that encode an open reading frame (ORF) of a PKS of the present invention. The recombinant nucleic acids of the invention also include, in a variety of embodiments, promoter sequences for transcribing the ORF in a suitable host cell. The recombinant nucleic acids of the invention include, in some embodiments, sequences sufficient for having the recombinant nucleic acid stably replicate in a host cell, such as sequences that provide a replicon capable of stable maintenance in a host cell or sequences that direct homologous recombination of the nucleic acid into a chromosome of the host cell. In some embodiments, the nucleic acid is a plasmid, including but not limited to plasmids containing an origin of replication. The present invention also provides vectors, such as expression vectors, comprising another recombinant nucleic acid of the present invention. The present invention provides host cell comprising any of the recombinant nucleic acids and/or capable of expressing a PKS of the present invention. In some embodiments, the host cell, when cultured under suitable conditions, is capable of producing an α -olefin of the invention.

[0094] It will be apparent to one of skill in the art that a variety of recombinant vectors can be utilized in the practice of the invention. As used herein, "vector" refers to polynucleotide elements that are used to introduce recombinant nucleic acid into cells for either expression or replication (or both). Selection and use of such vectors generally is routine in the art. An "expression vector" is a recombinant nucleic acid capable of expressing (producing proteins encoded by) DNA coding sequences (and corresponding mRNA) that are opera-

tively linked with regulatory sequences, such as promoters. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, a recombinant virus, or other vector that, upon introduction into an appropriate host cell that when cultured under appropriate conditions, results in expression of the DNA coding sequence. Appropriate expression vector elements suitable for use in accordance with the present invention are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal as well as those that integrate into the host cell genome.

[0095] The vectors of the invention include those chosen to contain control sequences operably linked to the resulting coding sequences in a manner that expression of the coding sequences may be effected in an appropriate host. Suitable control sequences include those that function in eukaryotic and prokaryotic host cells. If the cloning vectors employed to obtain PKS genes lack control sequences for expression operably linked to the PKS-encoding nucleotide sequences, the nucleotide sequences are inserted into appropriate expression vectors. This can be done individually, or using a pool of isolated encoding nucleotide sequences, which can be inserted into "host" vectors, the resulting vectors transformed or transfected into host cells, and the resulting cells plated out into individual colonies. Suitable control sequences for single cell cultures of various types of organisms are well known in the art. Control systems for expression in yeast are widely available and are routinely used. Control elements include promoters, optionally containing operator sequences, and other elements depending on the nature of the host, such as ribosome binding sites. Particularly useful promoters for prokaryotic hosts include those from PKS gene clusters that result in the production of polyketides as secondary metabo-

lites, including those from Type I or aromatic (Type II) PKS gene clusters. Examples are act promoters, tcm promoters, spiramycin promoters, and the like. However, other bacterial promoters, such as those derived from the genes encoding sugar metabolizing enzymes, such as those that metabolize galactose, lactose (lac) and maltose, are also useful. Additional examples include promoters derived from the genes encoding biosynthetic enzymes such as those that encode the enzymes for tryptophan (trp) biosynthesis, the β -lactamase (bla) gene promoter, bacteriophage lambda PL promoter, and the T5 promoter. In addition, synthetic promoters, such as the tac promoter (U.S. Pat. No. 4,551,433; incorporated herein by reference), can be used to construct an expression vector of the invention.

[0096] As noted, particularly useful control sequences are those which themselves, or with suitable regulatory systems, activate expression during transition from growth to stationary phase in the vegetative mycelium. Illustrative control sequences, vectors, and host cells of these types include the modified *Streptomyces coelicolor* CH999 and vectors described in PCT publication No. WO 96/40968 and similar strains of *Streptomyces lividans*. See U.S. Pat. Nos. 5,672,491; 5,830,750; 5,843,718; and 6,177,262, each of which is hereby incorporated by reference. Other regulatory sequences may also be desirable; these include those that allow for regulation of expression of the PKS sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.

[0097] Selectable markers can also be included in the recombinant expression vectors of the invention. A variety of markers are known that are useful in selecting for transformed cell lines; these generally are any gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers include, for example, genes that confer antibiotic resistance or sensitivity to a host cell.

[0098] The various PKS nucleotide sequences, or a mixture of such sequences, can be cloned into one or more recombinant vectors as individual cassettes, with separate control elements or under the control of a single promoter. The PKS encoding subunits or components can include flanking restriction sites to allow for the easy deletion and insertion of other PKS encoding subunits. The design of such restriction sites is known to those of skill in the art and can be accomplished using the techniques described in the scientific literature, such as site-directed mutagenesis and PCR. Methods for introducing the recombinant vectors of the present invention

into suitable hosts are known to those of skill in the art and include the use of CaCl_2 or other agents, such as other divalent cations, lipofection, DMSO, protoplast transformation, conjugation, and electroporation.

Host Cells Comprising the PKS

[0099] The present invention provides host cells comprising the recombinant nucleic acid and/or PKS of the present invention. In many embodiments, the host cell, when cultured, is capable of producing an α -olefin. The host cell can be a eukaryotic or a prokaryotic cell. Suitable eukaryotic cells include yeast cells, such as from the genus *Saccharomyces*, *Candida*, or *Schizosaccharomyces*. A suitable species from the genus *Saccharomyces* is *Saccharomyces cerevisiae*. A suitable species from the genus *Schizosaccharomyces* is *Schizosaccharomyces pombe*. Suitable prokaryotic cells include, but are not limited to, the gram negative *Escherichia coli* and the gram positive *Streptomyces* species, such as *S. coelicolor* and *S. lividans*.

[0100] The PKSs of the invention can be in a host cell, and can be isolated and purified. The PKS can synthesize the α -olefin in vivo (in a host cell) or in vitro (in a cell extract or where all necessary chemical components or starting materials are provided). The present invention provides methods of producing the α -olefin using any of these in vivo or in vitro means.

[0101] In some embodiments of the invention, the host cell comprises a PKS which produces butadiene comprising a loading module comprising an acrylyl-ACP starter, such as a DEBS propionyl-CoA specific loading domain which is modified to accept acrylyl-CoA, and one or more nucleic acids encoding and capable of expressing biosynthetic enzymes for synthesizing acrylyl-CoA from propionate (see FIG. 8). An example of a set of such enzymes is propionyl-CoA ligase (synthetase) (EC 6.2.1.17) and acyl-CoA dehydrogenase (mammalian) (EC 1.3.99.3), and functional variants thereof. In some embodiments, the host cell comprises a nucleic acid encoding and capable of expressing an enzyme, or functional variant thereof, capable of converting propionate into propionyl-CoA, and an enzyme, or functional variant thereof, capable of converting propionyl-CoA into acrylyl-CoA. An enzyme capable of converting propionate into propionyl-CoA is the propionyl-CoA ligase encoded by the prpE gene of *Salmonella typhimurium*. An enzyme capable of converting propionyl-CoA into acrylyl-CoA is the mammalian acyl-CoA dehydrogenase. A host cell comprising this system is provided with propionate, such as by exogenously feeding propionate to the host cell, or produces propionate endogenously.

[0102] The amino acid sequence of the propionyl-CoA ligase encoded by the prpE gene in *Salmonella typhimurium* (GenBank accession no. NP_459366) comprises:

(SEQ ID NO: 13)

```

1 msfsefyqrs inepeafwae qarridwrqp ftqtlldhsrp pfarwfcggt tnlchnavdr
61 wrdkqpeala liayssetde ertftfsqlh devnivaaml lslgvqrgdr vlvympmiae
121 aqitllacar igaihsvvfg gflashvaar iddarpaliv sadagarggk ilpykklldd
181 aiaqaqhqpk hvllvdrsla kmawvdgrdl dfatlrqqhl gasvpvawle snetscilyt
241 sgttgkpkgv qrdvgyava latsmdtifg gkaggvffca sdigwvghs yivyapllag
301 mativyeglp typdcgvwwk ivekyqvnrm fsaptairvl kkfptaqirn hdlsslealy

```


-continued

361 lagepldept aswvtetlgv pvidnywqte sgwpimalar alddrpsrlg spgvpmgyn
 421 vqllnevtge pcginekgml viegplppgc iqtiwgddar fvktywslfn rqvyatfdwg
 481 irdaegyfyfi lgrtddvini aghrlgtrei eesissyvni aevavvgikd alkgqvavaf
 541 vipkqsdtla dreaardeen aimalvndqi ghfgrpahvw fvsqpktrs gkmlrrtiqa
 601 egrdpqdl ttiddpaslq qirqaiee

[0103] The amino acid sequence of the acyl-CoA dehydrogenase of *Mus musculus* (GenBank accession no. Q07417) comprises:

(SEQ ID NO: 14)
 1 maaallrar gplrralgvr dwrrlhtvyq svelpethqm lrqtcrdfae kelvpiaaql
 61 drehlftaq vkkmegll amdvpelsg aglylaysi aleesiraca stgvimsvnn
 121 slylgpilkf gsaqqkqwi tpftngdkig cfalsepgng sdagaastta reegdswwin
 181 gtkawitnsw easatvvas tdrsrqngi saflvpmp tp gtlgkkek lgrasstan
 241 lifedcripk enllgepgmg fkiamqtdm grigiasqal giaqasldca vkyaenraf
 301 gapltklqni qfkladmala lesarlltwr aamlkdnkfp ftkesamrkl aaseaatais
 361 aiqilgsm gyvtempaer yyrdaritei yegtseiqr lviaghllrsy rs

[0104] In some embodiments, the host cell of the invention comprises a PKS which produces butadiene and comprises a loading module comprising an acrylyl-ACP starter, such as a DEBS propionyl-CoA specific loading domain which is modified to accept acrylyl-CoA, and one or more nucleic acids encoding and capable of expressing biosynthetic enzymes for synthesizing acrylyl-CoA from pyruvate (see FIG. 9). An example of a set of such enzymes is lactate dehydrogenase (EC 6.2.1.17), lactate CoA transferase (EC 2.8.3.1), propionyl-CoA ligase (synthetase) (EC 6.2.1.17), and lactoyl-CoA dehydratase (EC 4.2.164), or functional

variants thereof. In some embodiments, the host cell comprises one or more nucleic acids encoding and capable of expressing these four enzymes. A host cell comprising this system is provided with propionate and a suitable organic molecule that the host cell can directly or indirectly convert into a pyruvate, and these compounds are either exogenously fed to or produced by the host cell. For example, if the host cell is *E. coli*, a suitable organic molecule is glucose.

[0105] The amino acid sequence of the lactate dehydrogenase encoded by the *ldhA* gene of *E. coli* (GenBank accession no. CAQ31881) comprises:

(SEQ ID NO: 15)
 1 taktangcea vcifvnddgs rpvleelkxh gvkyialrca gfnvdlada kelglkvrvy
 61 paydpeavae haigmmmtln rrihrayqrt rdanfslegl tgftmygkta gvigtkigv
 121 amrlilkfmg mrlldfpyp saaalelve yvdlptlfse sdvislhcp ltpenyhllne
 181 aafdqmknv mivntsr gal idsqaaieal knqkigslgm dvyenerdlf fedksndviq
 241 ddvfrllsac hnlvftghqa fltaealtsi sqttlqnl sn lekgetcpne lv

[0106] The amino acid sequence of the lactate CoA transferase encoded by the *pct* gene of *Clostridium propionicum* (GenBank accession no. CAB77207) comprises:

(SEQ ID NO: 16)
 1 mrkvpiitad eaaklikgd tvttsgfvgn aipealdrav ekrfletgep knityvycgs
 61 qgnrdrgae hfaheglkr yiaghwatvp algkmamenk meaynvsqga lchlfrdias
 121 hkpgvftkvg igtfdprng ggkvn ditke divelveikg qeylfypafp ihvalirgty
 181 adesgnitfe kevaplegts vcqavknsgg ivvvqvervv kagtdprhv kvpgiyvdyv
 241 vvadpedhqg sldceydpal sgehrrepev geplplsakk vigrrgaiel ekdvavnlgv

-continued

301 gapeyvasva deegivdfmt ltaesgaigg vpaggvrfga synadalidq gyqfdyydgg
 361 gldlcyglga ecdekgninv srfgpriagc ggfinitqnt pkvffcgtft agglkvkied
 421 gkviivqegk qkkflkaveq itfngdvala nkqqvtyite rcvfllkedg lhlseiapgi
 481 qtqildvm dfapiidrda ngqiklmdaa lfaeglmglk emks

[0107] The amino acid sequence of the lactoyl-CoA dehydratase encoded by the *pct* gene of *Clostridium proponicum* (GenBank accession no. CAB77206) comprises:

(SEQ ID NO: 17)

1 efkiaivddd laqesrqiry dvlldgeggpl yrmakawqqm ygcslatdtk kgrgrmlink
 61 tiqtgadaiv vammkfcde ewdypvmyre feekgvkslm ievdqvsssf eqiktrlqsf
 121 veml

[0108] In some embodiments, the host cell of the invention comprises a PKS which produces butadiene and comprises a loading module comprising an acrylyl-ACP starter, such as a DEBS propionyl-CoA specific loading domain which is modified to accept acrylyl-CoA, and one or more nucleic acids encoding and capable of expressing biosynthetic enzymes for synthesizing acrylyl-CoA from acetyl CoA (see FIG. 10). An example of a set of such enzymes is acetyl-CoA carboxylase (EC 6.4.1.2), malonyl-CoA reductase (EC 1.2.1.75), 3-hydroxypropionate:CoA ligase, and 3-hydroxypropionyl-CoA hydratase (EC 4.2.1.17), or functional variants thereof. In some embodiments, the host cell comprises one or more nucleic acids encoding and capable of expressing the four enzymes described. A host cell comprising this system can be engineered to produce increased titers of acetyl-CoA.

[0109] In some embodiments, the host cell of the invention comprises a PKS which produces butadiene and comprises a loading module comprising an acrylyl-ACP starter, such as a DEBS propionyl-CoA specific loading domain which is modified to accept acrylyl-CoA, and one or more nucleic acids encoding and capable of expressing biosynthetic enzymes for synthesizing acrylyl-CoA from propionate (see FIG. 15). An example of a set of such enzymes is propionyl-CoA ligase (synthetase) (EC 6.2.1.17), lactoyl-CoA dehydratase (EC 4.2.1.64), lactate dehydrogenase (EC 6.2.1.17), lactate CoA transferase (EC 2.8.3.1), or functional variants thereof. A host cell comprising this system is provided with propionate, either by exogenous feeding or by endogenous production.

[0110] In some embodiments, the host cell of the invention comprises a PKS which produces 3-methyl-2,4-pentadienoic acid and comprises the modules shown in FIG. 12 including a loading module comprising an acrylyl-ACP starter, such as a DEBS propionyl-CoA specific loading domain which is modified to accept acrylyl-CoA, and one or more nucleic acids encoding and capable of expressing biosynthetic enzymes for synthesizing acrylyl-CoA (see FIG. 12). There are several methods for enabling a host cell to synthesize acrylyl-CoA described above. 3-methyl-2,4-pentadienoic acid can be enzymatically, catalytically, or pyrolytically converted to isoprene.

Methods of Producing α -olefins Using the PKS

[0111] The present invention provides a method of producing an α -olefin comprising: providing a host cell of the present invention, and culturing said host cell in a suitable

culture medium such that the α -olefin is produced. The method can further comprise isolating said α -olefin from the host cell and/or the culture medium. The method can further comprise polymerizing the α -olefin to itself and/or any other suitable organic molecule(s), including but not limited to other compounds comprising a C—C double bond. A variety of methods for heterologous expression of PKS genes and host cells suitable for expression of these genes and production of polyketides are described, for example, in U.S. Pat. Nos. 5,843,718; 5,830,750 and 6,262,340; WO 01/31035, WO 01/27306, and WO 02/068613; and U.S. Patent Application Pub. Nos. 20020192767 and 20020045220; each of which is incorporated herein by reference.

[0112] The present invention provides for a composition comprising an α -olefin isolated from a host cell from which the α -olefin is produced, and trace residues and/or contaminants of the host cell. Such trace residues and/or contaminants include cellular material produced by the lysis of the host cell. The present invention also provides α -olefins in substantially pure form.

[0113] Certain α -olefins produced by the PKSs of the present invention can be used as fuels. In some embodiments of the invention, an α -olefin produced in accordance with the invention can be used as a “green” jet fuel. The α -olefin can be catalytically oligomerized, including but not limited to dimerized, and optionally purified. The resulting products can be dimerized again to yield a mixture of branched molecules that are then catalytically hydrogenated. For example, 1-butene produced by a PKS of the present invention can be catalytically dimerized and purified. The resulting octene products can be dimerized again to yield a mixture of branched C16 molecules that are then catalytically hydrogenated. Oligomers of butene have been validated by the US Navy as both jet and diesel fuel replacements (Harvey, 2011. Journal of Chemical Technology and Biotechnology 86(1): 2-9.). Additional benefit may come from making branched, or aromatic, α -olefins using the avermectin (or other) loading modules, as described herein.

[0114] Thus, among others, the present invention has one or more of the following advantages: (1) it reduces the dependence on oil for producing certain chemicals, and (2) it serves as a means of capture and sequestration of carbon from the atmosphere.

[0115] The invention having been described, the following examples are offered to illustrate and not limit the subject invention.

EXAMPLES

[0116] Constructs can be conveniently designed at the amino acid level and then, back translation and DNA synthesis, such as that offered commercially by service providers such as DNA 2.0, can be conducted to yield the desired nucleic acid, which may be optimized for expression in a particular host cell type. Subsequent plasmid assembly can be conducted using standard molecular biology techniques.

Example 1

Production of 1-Hexene Using a PKS-Based Enzyme System

[0117] In one embodiment of the invention, PKS modules from three different organisms were used to construct a triketide pathway designed for the production of 1-hexene. In this embodiment, the 1-hexene synthase consists of two ORFs. HexORF1 combines EryA1 loading module+KS1 and AT-ACP from IdmO, HexORF2 utilizes the KS domain from IdmP and AT-TE domains from CurM. In another embodiment of this invention the loop I region of the indanomycin sourced ACP in HexORF1, SSSAGIDPGRAFQDMGI, is swapped with ASAERVPADQAF AELGV, the segment of ACP directly following EryA1. Both of these designs were back translated using software designed to optimize expression in *E. coli*. The genes are synthesized and ligated into two pairs of compatible, *E. coli* expression vectors that are subsequently transformed into *E. coli* BAP-1. The amino acid sequences for HexORF1, HexORF1', and HexORF2 are provided as SEQ ID NOs: 2-4, respectively.

[0118] Experiments have been performed demonstrating *E. coli* BAP-1 utilizing exogenously added propionate. In both examples of 1-hexene production, overnight cultures of a pBbA7C-HexORF1' (or pBbA7C-HexORF1)+pBbS7k-HexORF2 cotransformed strain were grown from a single colony and used to inoculate (1% v/v) three 50-mL cultures of LB medium supplemented with 0.5% glucose and 10% glycerol in 250 mL screw cap (unsealed) flask. Cultures were grown to an OD600 of 1.0 to 1.2, induced with 50 uM IPTG and grown at (30° C.) for an additional 3 hours. Then 100 mM propionate was supplemented to the culture and a Teflon septum was used to seal the cap. The cultures were then grown at 20° C. for 24 hours after which 1-butene was detectable in the headspace of the culture using solid phase micro extraction followed by GC-MS.

Example 2

Production of Butadiene Using a PKS-Based Enzyme System

[0119] An example of a PKS system for producing butadiene is shown in FIGS. 6 and 7. The system built to produce 1-butene, described below, was fed acrylate to produce butadiene. Otherwise, all experimental details are as described as that for 1-butene production, above. While the limits of detection were inadequate to determine productivity in this instance, the invention provides several routes to increasing butadiene productivity, including: adding an acrylate specific

CoA ligase to the host strain, adding an acrylate importer to the host strain, and/or utilizing a host strain less sensitive to acrylate toxicity.

Example 3

Production of 1-Butene Using a PKS-Based Enzyme System

[0120] An illustrative PKS system for producing 1-butene was constructed using the AT-TE PKS domains from CurM and the loading module for propionyl-CoA+KS1 from EryA1. For in vivo 1-butene production, overnight cultures of *E. coli* BAP1 carrying pBbS7k-Butene (PKS protein sequence provided as SEQ ID NO:5) were grown from a single colony and used to inoculate (1% v/v) three 50-mL cultures of LB medium supplemented with 0.5% glucose and 10% glycerol in 250 mL screw cap (unsealed) flask. Cultures were grown to an OD600 of 1.0 to 1.2, induced with 50 uM IPTG and grown at (30° C.) for an additional 3 hours. Then 100 mM propionate was supplemented to the culture and a Teflon septum was used to seal the cap. The cultures were then grown at 20° C. for 24 hours after which 1-butene was detectable in the headspace of the culture using solid phase micro extraction followed by GC-MS.

Example 4

Production of Isoprene Using a PKS-Based Enzyme System

[0121] An example of a PKS system for producing isoprene is shown in FIG. 12.

Example 5

Production of (E)-penta-1,3-diene Using a PKS-Based Enzyme System

[0122] An example of a PKS system for producing (E)-penta-1,3-diene is shown in FIG. 13.

Example 6

Production of Propene (Propylene) Using a PKS-Based Enzyme System

[0123] An illustrative propene synthase of the invention is a single enzyme consisting of the loading module+KS1 from the niddamycin PKS (Kakavas, 1997) fused to AT-TE domains from CurM (Chang, 2004; Gu, 2009) (the amino acid sequence for this construct is provided as SEQ ID NO:6). For in vivo propene production, overnight cultures of *E. coli* BAP1 carrying pBbS7k-propene were grown from a single colony and used to inoculate (1% v/v) three 50-mL cultures of LB medium supplemented with 0.5% glucose and 10% glycerol in 250 mL screw cap (unsealed) flask. Cultures were grown to an OD600 of 1.0 to 1.2, induced with 50 uM IPTG and grown at (30° C.) for an additional 3 hours. Then a Teflon septum was used to seal the cap. The cultures were then grown at 20° C. for 24 hours after which propene was detectable in the headspace of the culture using solid phase micro extraction followed by GC-MS.

Example 7

Production of Styrene Using a PKS-Based Enzyme System

[0124] An illustrative styrene synthase of the invention was constructed by fusing the ST and TE domains from CurM onto the loading and first extension modules from the soraphen PKS (Schupp, 1995; Wilkinson, 2001). The amino acid sequence for this construct is provided as SEQ ID NO:7. For styrene biosynthesis in the system illustrated, a pool of benzoyl-CoA is provided. To facilitate production of this essential precursor, the styrene synthase construct was coexpressed with an *E. coli* codon optimized gene encoding benzoate-CoA ligase, *badA*, from *Rhodopseudomonas palustris* (England, et al., J. Bacteriol. 1995 November; 177(22):6545-51.) and fed exogenous benzoate. For in vivo styrene production, overnight cultures of *E. coli* BAP1 carrying pBbs7k-SS1 (SS1 encodes SEQ ID NO:7) were grown from a single colony and used to inoculate (1% v/v) three 50-mL cultures of LB medium supplemented with 0.5% glucose and 10% glycerol in 250 mL screw cap (unsealed) flask. Cultures were grown to an OD600 of 1.0 to 1.2, induced with 50 uM IPTG and grown at (30° C.) for an additional 3 hours. Then 100 mM benzoic acid was supplemented to the culture and a Teflon septum was used to seal the cap. The cultures were then grown at 20° C. for 24 hours after which styrene was detect-

able in the headspace of the culture using solid phase micro extraction followed by GC-MS.

Example 8

Production of Pentene Using a PKS-Based Enzyme System

[0125] An illustrative pentene synthase of the invention was designed as two ORFs. The first ORF is built using the chalcone PKS loading module+KS 1 fused to spinosad AT-ACP PKS module two. The second ORF is the KS from spinosad M3 fused to the olefination module (Ols) from *Synecchococcus* sp. PCC7002 (Mendez-Perez, et al., Appl Environ Microbiol. 2011 June; 77(12):4264-7). The amino acid sequences for these chimeric proteins are provided as SEQ ID NO:8 and 9.

[0126] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 19

<210> SEQ ID NO 1

<211> LENGTH: 2211

<212> TYPE: PRT

<213> ORGANISM: *Lyngbya majuscula*

<400> SEQUENCE: 1

Met Ser Asn Val Ser Lys Thr Thr Gln Gln Asp Val Ser Ser Gln Glu
1 5 10 15

Val Leu Gln Val Leu Gln Glu Met Arg Ser Arg Leu Glu Ala Val Asn
20 25 30

Lys Ala Lys Thr Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Phe
35 40 45

Pro Gly Gly Ala Asn Asp Pro Ser Thr Tyr Trp Arg Leu Leu His Asp
50 55 60

Gly Ile Asp Ala Ile Thr Pro Val Pro Pro His Arg Trp Asp Val Asn
65 70 75 80

Ala His Tyr Glu Pro Asn Pro Glu Ile Pro Gly Lys Ala Tyr Thr Lys
85 90 95

Gln Gly Gly Phe Ile Glu Gln Val Asp Gln Phe Asp Pro Leu Phe Phe
100 105 110

Gly Ile Ser Pro Arg Glu Ala Ile Ser Leu Asp Pro Gln Tyr Arg Leu
115 120 125

Leu Leu Glu Val Thr Trp Glu Ala Leu Glu Asn Ala Gly Gln Thr Trp
130 135 140

Thr Asn Leu Lys Asn Ser Lys Thr Ser Val Phe Met Gly Val Ser Thr
145 150 155 160

Asp Asp Tyr Ala Ser Leu Ser Asn Pro Ile Leu Ile Asn Asn Arg Ser

-continued

165					170					175					
Leu	Gly	Val	Gly	Arg	Ile	Ser	His	Leu	Leu	Gly	Leu	Gln	Gly	Ser	Asn
			180					185					190		
Ile	Gln	Leu	Asp	Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Ile	His	Leu
		195					200					205			
Ala	Cys	Gln	Ser	Leu	Arg	Ser	Gly	Glu	Ser	Asn	Leu	Ala	Leu	Val	Gly
	210					215					220				
Gly	Val	Asn	Leu	Ile	Leu	Ser	Pro	Ile	Ser	Thr	Ile	Gly	Arg	Cys	Thr
225					230					235					240
Met	Lys	Ala	Leu	Ser	Pro	Asp	Gly	Arg	Cys	Lys	Thr	Phe	Asp	Ala	Ala
				245					250					255	
Ala	Asn	Gly	Tyr	Gly	Gln	Ala	Glu	Gly	Cys	Gly	Val	Val	Val	Leu	Lys
			260					265					270		
Arg	Leu	Ser	Asp	Ala	Ile	Thr	Asp	Gly	Asp	Leu	Ile	Ser	Ala	Leu	Ile
		275					280					285			
Arg	Gly	Ser	Ala	Ile	Asn	His	Asp	Gly	Pro	Ser	Ser	Gly	Leu	Thr	Val
	290					295					300				
Pro	Asn	Gly	Met	Ala	Gln	Lys	Gln	Val	Ile	Gln	Gln	Ala	Leu	Ser	Asn
305					310					315					320
Ala	Arg	Leu	Glu	Pro	His	Gln	Val	Ser	Tyr	Leu	Glu	Ala	His	Gly	Thr
				325					330					335	
Gly	Thr	Ala	Leu	Gly	Asp	Pro	Ile	Glu	Ile	Glu	Ala	Leu	Ala	Ala	Ile
			340					345					350		
Tyr	Gly	Lys	Asn	Arg	Pro	Val	Asp	Gln	Pro	Leu	Val	Val	Gly	Ser	Val
		355					360					365			
Lys	Thr	Asn	Ile	Gly	His	Leu	Glu	Ala	Ala	Ala	Gly	Val	Ser	Ala	Leu
	370					375					380				
Ile	Lys	Val	Val	Leu	Ala	Leu	Gln	His	Gln	Glu	Ile	Pro	Pro	His	Leu
385					390					395					400
His	Leu	Lys	Gln	Pro	Asn	Pro	Tyr	Val	Asp	Trp	Asp	Lys	Leu	Pro	Ile
			405						410					415	
Lys	Ile	Pro	Thr	Ser	Leu	Met	Pro	Trp	Asn	Cys	Glu	Ala	Lys	Pro	Arg
			420					425					430		
Ile	Ala	Gly	Ile	Ser	Ser	Phe	Gly	Ile	Ser	Gly	Thr	Asn	Ala	His	Leu
		435					440					445			
Leu	Leu	Glu	Glu	Val	Pro	Glu	Leu	Ile	Lys	Gly	Gln	Lys	Ala	Lys	Gly
		450				455					460				
Lys	Ser	Glu	Asn	Asp	Leu	Glu	Arg	Pro	Leu	His	Ile	Leu	Thr	Leu	Ser
465					470					475					480
Thr	Lys	Thr	Glu	Lys	Ala	Leu	Glu	Glu	Leu	Val	Ser	Arg	Tyr	Gln	Asn
			485						490					495	
His	Trp	Glu	Thr	Tyr	Pro	Glu	Leu	Ala	Ile	Ser	Asp	Val	Cys	Tyr	Thr
		500						505					510		
Ala	Asn	Thr	Gly	Arg	Ala	Gln	Phe	Asn	His	Arg	Leu	Ala	Val	Ile	Ala
		515					520					525			
Ser	Gly	Ser	Glu	Glu	Leu	Thr	Gln	Lys	Leu	Arg	Gln	His	Thr	Ala	Gly
	530					535					540				
Glu	Glu	Val	Val	Gly	Val	Phe	Ser	Gly	Lys	Val	Pro	Asn	Ser	Gly	Ser
545					550					555					560
Glu	Ser	Lys	Val	Ala	Phe	Leu	Phe	Thr	Gly	Gln	Gly	Ser	Gln	Tyr	Leu
				565					570					575	

-continued

Asn	Met	Gly	Arg	Gln	Leu	Tyr	Glu	Thr	Gln	Pro	Thr	Phe	Arg	Gln	Ala
			580					585					590		
Leu	Asp	Thr	Cys	Asp	His	Ile	Leu	Arg	Pro	Tyr	Leu	Asp	Asn	Pro	Leu
		595					600					605			
Leu	Glu	Ile	Leu	Tyr	Pro	Gln	Asp	Ala	Gln	Lys	Ser	Asn	Asp	Ser	Pro
	610					615					620				
Leu	Asp	Gln	Thr	Gly	Tyr	Thr	Gln	Pro	Ala	Leu	Phe	Ser	Ile	Glu	Tyr
	625				630					635					640
Ala	Leu	Leu	Lys	Leu	Trp	Glu	Ser	Trp	Gly	Ile	Lys	Pro	Asn	Val	Val
				645					650					655	
Met	Gly	His	Ser	Val	Gly	Glu	Tyr	Val	Ala	Ala	Thr	Val	Ala	Gly	Val
			660					665					670		
Phe	Ser	Leu	Glu	Asp	Gly	Leu	Lys	Leu	Ile	Ala	Ala	Arg	Gly	Arg	Leu
		675					680					685			
Met	Gln	Gly	Leu	Pro	Ala	Gly	Gly	Glu	Met	Val	Ser	Val	Met	Ala	Ser
	690					695					700				
Glu	Ser	Lys	Val	Leu	Glu	Thr	Leu	Lys	Ala	Met	Ser	Leu	Glu	Asp	Lys
	705				710					715					720
Val	Ala	Ile	Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Ile	Val	Ile	Ser	Gly
				725					730					735	
Glu	Ala	Glu	Ala	Ile	Arg	Ala	Met	Ala	Thr	His	Leu	Glu	Ser	Val	Gly
			740					745					750		
Ile	Lys	Thr	Lys	Gln	Leu	Gln	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu
		755					760						765		
Met	Glu	Pro	Met	Leu	Ala	Glu	Phe	Glu	Ala	Val	Ala	Asn	Gln	Ile	Thr
	770					775					780				
Tyr	His	Gln	Pro	Arg	Ile	Pro	Ile	Ile	Ser	Asn	Val	Thr	Gly	Thr	Lys
	785				790					795					800
Ala	Asp	Lys	Ser	Ile	Ala	Thr	Ala	Gln	Tyr	Trp	Val	Asn	His	Val	Arg
				805					810					815	
Gln	Pro	Val	Arg	Phe	Ala	Gln	Gly	Met	Ala	Thr	Leu	His	Gln	Gln	Gly
			820					825					830		
Tyr	Glu	Thr	Phe	Leu	Glu	Ile	Gly	Ala	Lys	Pro	Ile	Leu	Leu	Gly	Met
		835					840					845			
Gly	Lys	Gln	Cys	Leu	Ser	Pro	Asp	Val	Gly	Val	Trp	Leu	Pro	Ser	Leu
	850					855					860				
Arg	His	Gly	Val	Asp	Glu	Trp	Gln	Gln	Ile	Leu	Ser	Ser	Leu	Gly	Gln
	865				870					875					880
Leu	Tyr	Val	Gln	Gly	Ala	Lys	Val	Asp	Trp	Ser	Gly	Phe	Asp	Arg	Asp
				885					890					895	
Tyr	Ser	Arg	Glu	Lys	Val	Val	Leu	Pro	Thr	Tyr	Pro	Phe	Gln	Arg	Glu
			900					905					910		
Arg	Tyr	Trp	Val	Glu	Thr	Ser	Ile	Asn	Gln	Gln	Gln	Val	Val	Cys	Ser
		915					920					925			
Gly	Glu	Pro	Asn	Leu	Gln	Gly	Thr	Pro	Glu	Gly	Thr	Ser	Thr	Thr	Ile
	930					935					940				
Val	Lys	Leu	Leu	Ser	Gln	Gly	Asn	Thr	Lys	Glu	Leu	Ala	Glu	Lys	Val
	945				950					955					960
Glu	Lys	Thr	Ser	Asp	Leu	Pro	Pro	Glu	Gln	Leu	Lys	Leu	Leu	Pro	Asp
				965					970					975	
Leu	Leu	Ala	Ser	Leu	Ser	Gln	Gln	His	Gln	Gln	Glu	Leu	Ala	Arg	Leu
			980					985						990	

-continued

Thr	Thr	Lys	Lys	Trp	Phe	Tyr	Lys	Val	Gln	Trp	Ile	Ser	Gln	Ala	Ile
		995					1000					1005			
Lys	Pro	Gln	Arg	Asn	Lys	Ser	Asn	Asn	Gln	Val	Cys	His	Trp	Leu	
	1010					1015					1020				
Ile	Leu	Thr	Asp	Ser	Lys	Gly	Leu	Gly	Lys	Ser	Leu	Ala	Thr	His	
	1025					1030					1035				
Leu	Gln	Gln	Leu	Gly	Asn	Glu	Cys	Ser	Val	Val	Tyr	Gln	Ala	Asp	
	1040					1045					1050				
Asn	Tyr	Gln	Asn	Tyr	Glu	Pro	Gly	Ile	Tyr	His	Ile	Asn	Pro	Ser	
	1055					1060					1065				
His	Pro	Gln	Glu	Phe	Glu	Gln	Val	Tyr	Gln	Thr	Ile	Phe	Glu	Asn	
	1070					1075					1080				
Gly	Lys	Leu	Pro	Leu	Gln	Lys	Val	Ile	His	Leu	Trp	Ser	Leu	Asp	
	1085					1090					1095				
Thr	Ala	Ser	Glu	Gln	Asp	Leu	Thr	Thr	Glu	Thr	Leu	Glu	Gln	Ala	
	1100					1105					1110				
Gln	Leu	Trp	Gly	Cys	Gly	Ser	Thr	Leu	His	Leu	Leu	Gln	Thr	Leu	
	1115					1120					1125				
Val	Lys	Asn	Pro	Asn	Ser	Thr	Pro	Pro	Lys	Leu	Trp	Met	Ile	Thr	
	1130					1135					1140				
Arg	Gly	Thr	Gln	Pro	Val	Leu	Ser	Pro	Thr	Glu	Lys	Leu	Thr	Val	
	1145					1150					1155				
Ala	Thr	Ser	Pro	Leu	Trp	Gly	Leu	Gly	Arg	Thr	Ile	Ala	Ser	Glu	
	1160					1165					1170				
His	Pro	Gln	Leu	Trp	Gly	Gly	Leu	Val	Asp	Leu	Asp	Pro	Gln	Gly	
	1175					1180					1185				
Ser	Glu	Asp	Glu	Val	Glu	Val	Leu	Leu	Gln	Gln	Ile	Ile	Asp	Ser	
	1190					1195					1200				
Gln	Lys	Glu	Asp	His	Leu	Ala	Val	Arg	Asn	Arg	Lys	Ile	Tyr	Val	
	1205					1210					1215				
Ala	Arg	Leu	Leu	Lys	His	Ile	Pro	Gln	Glu	Ser	Gln	Pro	Leu	Ser	
	1220					1225					1230				
Leu	Arg	Ser	Asp	Ala	Thr	Tyr	Leu	Ile	Thr	Gly	Gly	Leu	Gly	Ala	
	1235					1240					1245				
Leu	Gly	Leu	Lys	Thr	Ala	Ala	Trp	Met	Ala	Glu	Lys	Gly	Ala	Arg	
	1250					1255					1260				
Asn	Leu	Val	Leu	Ile	Ser	Arg	Arg	Gln	Pro	Ser	Glu	Gln	Ala	Gln	
	1265					1270					1275				
Gln	Thr	Ile	Gln	Ser	Leu	Glu	Glu	Leu	Gly	Thr	Gln	Val	Lys	Val	
	1280					1285					1290				
Leu	Ser	Ala	Asp	Ile	Ser	Val	Glu	Ser	Asp	Val	Ala	Asn	Ile	Leu	
	1295					1300					1305				
Glu	Gln	Ile	Gln	Thr	Ser	Leu	Pro	Pro	Leu	Leu	Gly	Val	Ile	His	
	1310					1315					1320				
Ala	Ala	Gly	Val	Leu	Asp	Asp	Gly	Leu	Leu	Gln	Gln	Thr	Asn	Trp	
	1325					1330					1335				
Glu	Arg	Phe	Thr	Lys	Val	Met	Ala	Pro	Lys	Val	Asn	Gly	Thr	Trp	
	1340					1345					1350				
Asn	Leu	His	Lys	Leu	Thr	Gln	His	Leu	Ser	Leu	Asp	Phe	Phe	Val	
	1355					1360					1365				
Cys	Phe	Ser	Ser	Met	Ser	Ser	Leu	Leu	Gly	Ser	Pro	Gly	Gln	Gly	

-continued

His	Pro	Tyr	Ser	Val	Ile	Glu	Ser	Phe	Val	Arg	Met	Arg	Met	Gln
1760						1765					1770			
Lys	Leu	Val	Gly	Leu	Gly	Glu	Glu	Asn	Pro	Tyr	Arg	Val	Ala	Glu
1775						1780					1785			
Gln	Val	Trp	Ala	Lys	Ser	Asn	Gln	Asn	Ile	Leu	Asn	Phe	Leu	Ser
1790						1795					1800			
Gln	Leu	Glu	Pro	Glu	Arg	Gln	His	Gln	Ile	Arg	Tyr	Glu	Asp	Leu
1805						1810					1815			
Val	Lys	Lys	Pro	Gln	Gln	Val	Leu	Ser	Gln	Leu	Cys	Asp	Phe	Leu
1820						1825					1830			
Asn	Val	Pro	Phe	Glu	Pro	Glu	Leu	Leu	Gln	Pro	Tyr	Gln	Gly	Asp
1835						1840					1845			
Arg	Met	Thr	Gly	Gly	Val	His	Gln	Lys	Ser	Leu	Ser	Ile	Ser	Asp
1850						1855					1860			
Pro	Asn	Phe	Leu	Lys	His	Asn	Thr	Ile	Asp	Glu	Ser	Leu	Ala	Asp
1865						1870					1875			
Lys	Trp	Lys	Thr	Ile	Gln	Leu	Pro	Tyr	Pro	Leu	Lys	Ser	Glu	Thr
1880						1885					1890			
Gln	Arg	Ile	Ala	Ser	Gln	Leu	Ser	Tyr	Glu	Leu	Pro	Asn	Leu	Val
1895						1900					1905			
Thr	Thr	Pro	Thr	Asn	Gln	Gln	Pro	Gln	Val	Ser	Thr	Thr	Pro	Ser
1910						1915					1920			
Thr	Glu	Gln	Pro	Ile	Met	Glu	Glu	Lys	Phe	Leu	Glu	Phe	Gly	Gly
1925						1930					1935			
Asn	Gln	Ile	Cys	Leu	Cys	Ser	Trp	Gly	Ser	Pro	Glu	His	Pro	Val
1940						1945					1950			
Val	Leu	Cys	Ile	His	Gly	Ile	Leu	Glu	Gln	Gly	Leu	Ala	Trp	Gln
1955						1960					1965			
Glu	Val	Ala	Leu	Pro	Leu	Ala	Ala	Gln	Gly	Tyr	Arg	Val	Val	Ala
1970						1975					1980			
Pro	Asp	Leu	Phe	Gly	His	Gly	Arg	Ser	Ser	His	Leu	Glu	Met	Val
1985						1990					1995			
Thr	Ser	Tyr	Ser	Ser	Leu	Thr	Phe	Leu	Ala	Gln	Ile	Asp	Arg	Val
2000						2005					2010			
Ile	Gln	Glu	Leu	Pro	Asp	Gln	Pro	Leu	Leu	Leu	Val	Gly	His	Ser
2015						2020					2025			
Met	Gly	Ala	Met	Leu	Ala	Thr	Ala	Ile	Ala	Ser	Val	Arg	Pro	Lys
2030						2035					2040			
Lys	Ile	Lys	Glu	Leu	Ile	Leu	Val	Glu	Leu	Pro	Leu	Pro	Ala	Glu
2045						2050					2055			
Glu	Ser	Lys	Lys	Glu	Ser	Ala	Val	Asn	Gln	Leu	Thr	Thr	Cys	Leu
2060						2065					2070			
Asp	Tyr	Leu	Ser	Ser	Thr	Pro	Gln	His	Pro	Ile	Phe	Pro	Asp	Val
2075						2080					2085			
Ala	Thr	Ala	Ala	Ser	Arg	Leu	Arg	Gln	Ala	Ile	Pro	Ser	Leu	Ser
2090						2095					2100			
Glu	Glu	Phe	Ser	Tyr	Ile	Leu	Ala	Gln	Arg	Ile	Thr	Gln	Pro	Asn
2105						2110					2115			
Gln	Gly	Gly	Val	Arg	Trp	Ser	Trp	Asp	Ala	Ile	Ile	Arg	Thr	Arg
2120						2125					2130			
Ser	Ile	Leu	Gly	Leu	Asn	Asn	Leu	Pro	Gly	Gly	Arg	Ser	Gln	Tyr
2135						2140					2145			

-continued

Leu Glu Met Leu Lys Ser Ile Gln Val Pro Thr Thr Leu Val Tyr
 2150 2155 2160

Gly Asp Ser Ser Lys Leu Asn Arg Pro Glu Asp Leu Gln Gln Gln
 2165 2170 2175

Lys Met Thr Met Thr Gln Ala Lys Arg Val Phe Leu Ser Gly Gly
 2180 2185 2190

His Asn Leu His Ile Asp Ala Ala Ala Ala Leu Ala Ser Leu Ile
 2195 2200 2205

Leu Thr Ser
 2210

<210> SEQ ID NO 2
 <211> LENGTH: 2694
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: EryA1 loading module + KS1 and AT-ACP from IdmO

<400> SEQUENCE: 2

Met Ala Asp Leu Ser Lys Leu Ser Asp Ser Arg Thr Ala Gln Pro Gly
 1 5 10 15

Arg Ile Val Arg Pro Trp Pro Leu Ser Gly Cys Asn Glu Ser Ala Leu
 20 25 30

Arg Ala Arg Ala Arg Gln Leu Arg Ala His Leu Asp Arg Phe Pro Asp
 35 40 45

Ala Gly Val Glu Gly Val Gly Ala Ala Leu Ala His Asp Glu Gln Ala
 50 55 60

Asp Ala Gly Pro His Arg Ala Val Val Val Ala Ser Ser Thr Ser Glu
 65 70 75 80

Leu Leu Asp Gly Leu Ala Ala Val Ala Asp Gly Arg Pro His Ala Ser
 85 90 95

Val Val Arg Gly Val Ala Arg Pro Ser Ala Pro Val Val Phe Val Phe
 100 105 110

Pro Gly Gln Gly Ala Gln Trp Ala Gly Met Ala Gly Glu Leu Leu Gly
 115 120 125

Glu Ser Arg Val Phe Ala Ala Ala Met Asp Ala Cys Ala Arg Ala Phe
 130 135 140

Glu Pro Val Thr Asp Trp Thr Leu Ala Gln Val Leu Asp Ser Pro Glu
 145 150 155 160

Gln Ser Arg Arg Val Glu Val Val Gln Pro Ala Leu Phe Ala Val Gln
 165 170 175

Thr Ser Leu Ala Ala Leu Trp Arg Ser Phe Gly Val Thr Pro Asp Ala
 180 185 190

Val Val Gly His Ser Ile Gly Glu Leu Ala Ala Ala His Val Cys Gly
 195 200 205

Ala Ala Gly Ala Ala Asp Ala Ala Arg Ala Ala Ala Leu Trp Ser Arg
 210 215 220

Glu Met Ile Pro Leu Val Gly Asn Gly Asp Met Ala Ala Val Ala Leu
 225 230 235 240

Ser Ala Asp Glu Ile Glu Pro Arg Ile Ala Arg Trp Asp Asp Asp Val
 245 250 255

Val Leu Ala Gly Val Asn Gly Pro Arg Ser Val Leu Leu Thr Gly Ser
 260 265 270

-continued

Leu Ala Glu Gly Gly Glu Gly Val Glu Gly Tyr Leu Met Thr Gly Thr
 690 695 700
 Thr Thr Ser Val Ala Ser Gly Arg Ile Ala Tyr Thr Leu Gly Leu Glu
 705 710 715 720
 Gly Pro Ala Ile Ser Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala
 725 730 735
 Val His Leu Ala Cys Gln Ser Leu Arg Arg Gly Glu Ser Ser Leu Ala
 740 745 750
 Met Ala Gly Gly Val Thr Val Met Pro Thr Pro Gly Met Leu Val Asp
 755 760 765
 Phe Ser Arg Met Asn Ser Leu Ala Pro Asp Gly Arg Cys Lys Ala Phe
 770 775 780
 Ser Ala Gly Ala Asn Gly Phe Gly Met Ala Glu Gly Ala Gly Met Leu
 785 790 795 800
 Leu Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu
 805 810 815
 Ala Val Leu Arg Gly Thr Ala Val Asn Ser Asp Gly Ala Ser Asn Gly
 820 825 830
 Leu Ser Ala Pro Asn Gly Arg Ala Gln Val Arg Val Ile Gln Gln Ala
 835 840 845
 Leu Ala Glu Ser Gly Leu Gly Pro Ala Asp Ile Asp Ala Val Glu Ala
 850 855 860
 His Gly Thr Gly Thr Arg Leu Gly Asp Pro Ile Glu Ala Arg Ala Leu
 865 870 875 880
 Phe Glu Ala Tyr Gly Arg Asp Arg Glu Gln Pro Leu His Leu Gly Ser
 885 890 895
 Val Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly Val Ala Gly
 900 905 910
 Val Ile Lys Met Val Leu Ala Met Arg Ala Gly Thr Leu Pro Arg Thr
 915 920 925
 Leu His Ala Ser Glu Arg Ser Lys Glu Ile Asp Trp Ser Ser Gly Ala
 930 935 940
 Ile Ser Leu Leu Asp Glu Pro Glu Pro Trp Pro Ala Gly Ala Arg Pro
 945 950 955 960
 Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala His
 965 970 975
 Val Ile Val Glu Glu Ala Pro Glu Ser Ser Ala Asp Ala Val Ala Glu
 980 985 990
 Ser Gly Val Arg Val Pro Val Pro Val Val Pro Trp Val Val Ser Ala
 995 1000 1005
 Arg Ser Ala Glu Gly Leu Ala Ala Gln Ala Glu Arg Leu Ala Arg
 1010 1015 1020
 Phe Val Gly Glu Arg Ser Asp Gln Asp Pro Val Asp Ile Gly Phe
 1025 1030 1035
 Ser Leu Val Arg Ser Arg Ser Leu Leu Glu His Arg Ala Val Val
 1040 1045 1050
 Leu Gly Lys Gly Arg Asp Asp Leu Val Ala Gly Leu Ala Ser Leu
 1055 1060 1065
 Ala Ser Asp Gly Ser Ala Thr Gly Val Val Ser Gly Val Ala Arg
 1070 1075 1080
 Gly Arg Ala Arg Val Ala Phe Gly Phe Ser Gly Gln Gly Ala Gln

-continued

1085						1090								1095
Arg Val	Gly Met	Gly Ala	Glu Leu	Ala Ser	Val Tyr	Pro Val	Phe							
1100			1105				1110							
Ala Glu	Ala Leu	Ala Glu	Val Thr	Gly Ala	Leu Gly	Leu Asp	Pro							
1115			1120				1125							
Glu Val	Phe Gly	Asp Val	Asp Arg	Leu Gly	Arg Thr	Glu Val	Thr							
1130			1135				1140							
Gln Ala	Ala Leu	Phe Ala	Phe Glu	Val Ala	Val Val	Arg Leu	Leu							
1145			1150				1155							
Glu Ser	Phe Gly	Val Arg	Pro Asp	Val Leu	Ile Gly	His Ser	Ile							
1160			1165				1170							
Gly Glu	Ile Ala	Ala Ala	Tyr Val	Ala Gly	Val Phe	Ser Leu	Gly							
1175			1180				1185							
Asp Ala	Ala Ala	Leu Val	Gly Ala	Arg Gly	Arg Leu	Met Gln	Ala							
1190			1195				1200							
Leu Pro	Ala Gly	Gly Val	Met Val	Ala Val	Gln Ala	Gly Glu	Ala							
1205			1210				1215							
Glu Val	Val Ala	Ala Leu	Glu Gly	Phe Ala	Asp Arg	Val Ser	Leu							
1220			1225				1230							
Ala Ala	Val Asn	Gly Pro	Ser Ser	Val Val	Val Ser	Gly Glu	Ala							
1235			1240				1245							
Glu Ala	Val Glu	Gln Val	Val Ala	Arg Leu	Gly Lys	Val Lys	Ser							
1250			1255				1260							
Lys Arg	Leu Arg	Val Ser	His Ala	Phe His	Ser Pro	Leu Met	Glu							
1265			1270				1275							
Pro Met	Leu Ala	Asp Phe	Arg Gln	Val Ala	Glu Gln	Ile Thr	Tyr							
1280			1285				1290							
Asn Glu	Pro Gln	Leu Pro	Val Val	Ser Asn	Val Ser	Gly Arg	Leu							
1295			1300				1305							
Ala Glu	Pro Gly	Glu Leu	Thr Thr	Pro Asp	Tyr Trp	Val Arg	His							
1310			1315				1320							
Val Arg	Glu Ala	Val Arg	Phe Gly	Asp Gly	Val Arg	Ala Leu	Ala							
1325			1330				1335							
Ala Asp	Gly Val	Gly Val	Leu Val	Glu Val	Gly Pro	Asp Ser	Val							
1340			1345				1350							
Leu Thr	Ala Leu	Ala Arg	Glu Ser	Leu Asp	Gly Glu	Asp Gly	Leu							
1355			1360				1365							
Arg Ala	Val Pro	Leu Leu	Arg Lys	Asp Arg	Pro Glu	Pro Glu	Thr							
1370			1375				1380							
Leu Leu	Thr Gly	Val Ala	Gln Ala	Phe Thr	His Gly	Val Gln	Val							
1385			1390				1395							
Asp Trp	Pro Ala	Leu Leu	Pro Gly	Gly Arg	Arg Val	Glu Leu	Pro							
1400			1405				1410							
Thr Tyr	Ala Phe	Gln Arg	Arg Arg	Tyr Trp	Leu Glu	Asp Ala	Asp							
1415			1420				1425							
Pro Thr	Gly Gly	Asp Pro	Ala Ala	Leu Gly	Leu Thr	Ala Ala	Asp							
1430			1435				1440							
His Pro	Leu Leu	Gly Ala	Ala Val	Pro Leu	Ala Glu	Asp Gln	Gly							
1445			1450				1455							
Ile Val	Ile Thr	Ser Arg	Leu Ser	Leu Arg	Thr His	Pro Trp	Leu							
1460			1465				1470							

-continued

Ala	Asp	His	Glu	Ile	Gly	Gly	Thr	Val	Leu	Leu	Pro	Gly	Ala	Gly
1475						1480					1485			
Leu	Val	Glu	Ile	Ala	Leu	Arg	Ala	Gly	Asp	Glu	Val	Gly	Cys	Gly
1490						1495					1500			
Arg	Val	Glu	Glu	Leu	Thr	Leu	Glu	Ile	Pro	Leu	Val	Val	Pro	Gln
1505						1510					1515			
Glu	Gly	Gly	Val	Thr	Val	Gln	Ile	Arg	Val	Gly	Ala	Pro	Asp	Glu
1520						1525					1530			
Ser	Gly	Trp	Arg	Pro	Met	Thr	Val	His	Ser	Arg	Thr	Asp	Pro	Glu
1535						1540					1545			
Glu	Glu	Trp	Thr	Arg	His	Val	Ser	Gly	Val	Leu	Ser	Pro	Asp	Val
1550						1555					1560			
Pro	Thr	Glu	Arg	Tyr	Asp	Leu	Gly	Ala	Trp	Pro	Pro	Ala	Gly	Ala
1565						1570					1575			
Thr	Pro	Val	Glu	Leu	Asp	Gly	Phe	Tyr	Glu	Ala	Tyr	Ala	Arg	Leu
1580						1585					1590			
Gly	Tyr	Ala	Tyr	Gly	Pro	Ser	Phe	Gln	Gly	Leu	Arg	Ala	Ala	Trp
1595						1600					1605			
Arg	Arg	Gly	Asp	Glu	Val	Phe	Ala	Glu	Val	Ser	Leu	Pro	Val	Glu
1610						1615					1620			
Glu	Gln	Glu	Thr	Ala	Gly	Arg	Phe	Thr	Leu	His	Pro	Ala	Leu	Leu
1625						1630					1635			
Asp	Ala	Ala	Leu	Gln	Ser	Ala	Gly	Ala	Gly	Ala	Phe	Phe	Asp	Ser
1640						1645					1650			
Gly	Gly	Ser	Met	Arg	Leu	Pro	Phe	Ala	Trp	Ser	Gly	Val	Ser	Val
1655						1660					1665			
Phe	Ala	Ala	Gly	Ala	Ser	Thr	Val	Arg	Val	Arg	Leu	Ser	Pro	Ala
1670						1675					1680			
Gly	Pro	Asp	Ala	Val	Thr	Val	Ala	Leu	Ala	Asp	Pro	Thr	Gly	Ala
1685						1690					1695			
Pro	Val	Ala	Leu	Val	Glu	Arg	Leu	Leu	Ile	Pro	Glu	Met	Ser	Pro
1700						1705					1710			
Glu	Gln	Leu	Glu	Arg	Val	Arg	Gly	Glu	Glu	Lys	Glu	Ala	Pro	Tyr
1715						1720					1725			
Val	Leu	Asp	Trp	Val	Pro	Val	Glu	Val	Pro	Ala	Asp	Asp	Leu	Val
1730						1735					1740			
Arg	Pro	Glu	Arg	Trp	Thr	Leu	Leu	Gly	Gly	Ala	Asp	Ala	Gly	Val
1745						1750					1755			
Gly	Leu	Asp	Val	Ala	Gly	Ala	Phe	Ala	Ser	Leu	Glu	Pro	Ser	Asp
1760						1765					1770			
Gly	Ala	Pro	Glu	Phe	Val	Val	Leu	Pro	Cys	Val	Pro	Pro	Thr	Ser
1775						1780					1785			
Pro	Thr	Arg	Ala	Ala	Asp	Val	Arg	Gln	Ser	Thr	Leu	Gln	Ala	Leu
1790						1795					1800			
Thr	Val	Leu	Gln	Asn	Trp	Val	Thr	Asp	Glu	Arg	His	Ala	Asp	Ser
1805						1810					1815			
Arg	Leu	Val	Leu	Val	Thr	Arg	Arg	Ala	Val	Gly	Val	Gly	Ala	His
1820						1825					1830			
Asp	Asp	Val	Pro	Asp	Leu	Thr	His	Ala	Ala	Leu	Trp	Gly	Leu	Val
1835						1840					1845			
Arg	Ser	Ala	Gln	Thr	Glu	Asn	Pro	Gly	Arg	Phe	Leu	Leu	Val	Asp
1850						1855					1860			

-continued

Leu	Asp	Glu	Gly	Ala	Glu	Leu	Ala	Glu	Val	Leu	Pro	Gly	Ala	Leu
1865						1870					1875			
Gly	Ser	Gly	Glu	Ser	Gln	Val	Ala	Val	Arg	Ala	Gly	Arg	Val	Leu
1880						1885					1890			
Ala	Ala	Arg	Leu	Ala	Arg	Ser	Gly	Ser	Gly	Gly	Ala	Glu	Leu	Val
1895						1900					1905			
Pro	Pro	Ala	Gly	Ala	Pro	Trp	Arg	Leu	Asp	Thr	Thr	Ser	Pro	Gly
1910						1915					1920			
Thr	Leu	Glu	Asn	Leu	Ala	Leu	Val	Pro	Ser	Ala	Glu	Glu	Pro	Leu
1925						1930					1935			
Gly	Pro	Leu	Asp	Val	Arg	Val	Ser	Val	Arg	Ala	Ala	Gly	Leu	Asn
1940						1945					1950			
Phe	Arg	Asp	Val	Leu	Ile	Ala	Leu	Gly	Met	Tyr	Pro	Gly	Asp	Ala
1955						1960					1965			
Arg	Met	Gly	Gly	Glu	Gly	Ala	Gly	Val	Val	Thr	Asp	Val	Gly	Ser
1970						1975					1980			
Glu	Val	Thr	Thr	Leu	Ala	Pro	Gly	Asp	Arg	Val	Met	Gly	Met	Leu
1985						1990					1995			
Ser	Ser	Ala	Phe	Gly	Pro	Thr	Ala	Val	Ser	Asp	His	Arg	Ala	Leu
2000						2005					2010			
Val	Arg	Val	Pro	Asp	Asp	Trp	Ser	Phe	Glu	Gln	Ala	Ala	Ser	Val
2015						2020					2025			
Pro	Thr	Val	Phe	Ala	Thr	Ala	Tyr	Tyr	Gly	Leu	Val	Asp	Leu	Ala
2030						2035					2040			
Glu	Leu	Arg	Ala	Gly	Gln	Ser	Val	Leu	Val	His	Ala	Ala	Ala	Gly
2045						2050					2055			
Gly	Val	Gly	Met	Ala	Ala	Val	Gln	Leu	Ala	Arg	His	Leu	Gly	Ala
2060						2065					2070			
Glu	Val	Phe	Gly	Thr	Ala	Ser	Thr	Gly	Lys	Trp	Asp	Ser	Leu	Arg
2075						2080					2085			
Ala	Gly	Gly	Leu	Asp	Ala	Glu	His	Ile	Ala	Ser	Ser	Arg	Thr	Val
2090						2095					2100			
Glu	Phe	Glu	Glu	Thr	Phe	Leu	Ala	Ala	Thr	Ala	Gly	Arg	Gly	Val
2105						2110					2115			
Asp	Val	Val	Leu	Asp	Ser	Leu	Ala	Gly	Glu	Phe	Val	Asp	Ala	Ser
2120						2125					2130			
Leu	Arg	Leu	Leu	Pro	Arg	Gly	Gly	Arg	Phe	Val	Glu	Met	Gly	Lys
2135						2140					2145			
Ala	Asp	Ile	Arg	Asp	Ala	Glu	Arg	Val	Ala	Ala	Asp	His	Pro	Gly
2150						2155					2160			
Val	Thr	Tyr	Arg	Ser	Phe	Asp	Leu	Leu	Glu	Ala	Gly	Leu	Asp	Arg
2165						2170					2175			
Phe	Gln	Glu	Ile	Leu	Thr	Glu	Val	Val	Arg	Leu	Phe	Glu	Arg	Gly
2180						2185					2190			
Val	Leu	Arg	His	Leu	Pro	Val	Thr	Ala	Trp	Asp	Val	Arg	Arg	Ala
2195						2200					2205			
Ala	Glu	Ala	Phe	Arg	Phe	Val	Ser	Gln	Ala	Arg	His	Val	Gly	Lys
2210						2215					2220			
Asn	Val	Leu	Val	Met	Pro	Arg	Val	Trp	Asp	Arg	Asp	Gly	Thr	Val
2225						2230					2235			
Leu	Ile	Thr	Gly	Gly	Thr	Gly	Ala	Leu	Gly	Ala	Leu	Val	Ala	Arg

-continued

2240	2245	2250
His Leu Val Ala Glu His Gly Met Arg Asn Val Leu Leu Ala Gly 2255 2260 2265		
Arg Arg Gly Val Asp Ala Pro Gly Ala Arg Glu Leu Leu Ala Glu 2270 2275 2280		
Leu Glu Thr Ala Gly Ala Gln Val Ser Val Val Ala Cys Asp Val 2285 2290 2295		
Ala Asp Arg Asp Ala Val Ala Glu Leu Ile Ala Lys Val Pro Val 2300 2305 2310		
Glu His Pro Leu Thr Ala Val Val His Thr Ala Gly Val Val Ala 2315 2320 2325		
Asp Ala Thr Leu Thr Ala Leu Asp Ala Glu Arg Val Asp Thr Val 2330 2335 2340		
Leu Arg Ala Lys Val Asp Ala Val Leu His Leu His Glu Ala Thr 2345 2350 2355		
Arg Gly Leu Asp Leu Ala Gly Phe Val Leu Phe Ser Ser Ala Ser 2360 2365 2370		
Gly Ile Phe Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn 2375 2380 2385		
Ser Phe Ile Asp Ala Phe Ala His His Arg Arg Ala Gln Gly Leu 2390 2395 2400		
Pro Ala Leu Ser Leu Ala Trp Gly Leu Trp Ala Arg Thr Ser Gly 2405 2410 2415		
Met Ala Gly Gln Leu Gly His Asp Asp Val Ala Arg Ile Ser Arg 2420 2425 2430		
Thr Gly Leu Ala Pro Ile Thr Asp Asp Gln Gly Met Ala Leu Leu 2435 2440 2445		
Asp Ala Ala Leu Gly Ala Gly Arg Pro Leu Leu Val Pro Val Arg 2450 2455 2460		
Leu Asp Arg Ala Ala Leu Arg Ser Gln Ala Thr Ala Gly Thr Leu 2465 2470 2475		
Pro Pro Ile Leu Arg Gly Leu Val Arg Ala Thr Val Arg Arg Ala 2480 2485 2490		
Ala Ser Thr Ala Ala Ala Gln Gly Pro Ser Leu Ala Glu Arg Leu 2495 2500 2505		
Ala Gly Leu Pro Val Thr Glu His Glu Arg Ile Val Val Glu Leu 2510 2515 2520		
Val Arg Ala Asp Leu Ala Ala Val Leu Gly His Ser Ser Ser Ala 2525 2530 2535		
Gly Ile Asp Pro Gly Arg Ala Phe Gln Asp Met Gly Ile Asp Ser 2540 2545 2550		
Leu Thr Ala Val Glu Leu Arg Asn Arg Leu Asn Gly Ala Thr Gly 2555 2560 2565		
Leu Arg Leu Ala Ala Ser Leu Val Phe Asp Tyr Pro Thr Pro Asn 2570 2575 2580		
Ala Leu Ala Thr His Ile Leu Asp Glu Leu Ala Leu Asp Thr Ala 2585 2590 2595		
Gly Ala Gly Ala Ala Gly Glu Pro Asp Gly Pro Ala Pro Ala Pro 2600 2605 2610		
Ala Asp Glu Ala Arg Phe Arg Arg Val Ile Asn Ser Ile Pro Leu 2615 2620 2625		

-continued

Asp Arg Ile Arg Arg Ala Gly Leu Leu Asp Ala Leu Leu Gly Leu
 2630 2635 2640
 Ala Gly Thr Ser Ala Asp Thr Ala Ala Ser Asp Asp Phe Asp Gln
 2645 2650 2655
 Glu Glu Asp Gly Pro Ala Ile Ala Ser Met Asp Val Asp Asp Leu
 2660 2665 2670
 Val Arg Ile Ala Leu Gly Glu Ser Asp Thr Thr Ala Asp Ile Thr
 2675 2680 2685
 Glu Gly Thr Asp Arg Ser
 2690

<210> SEQ ID NO 3
 <211> LENGTH: 2694
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: EryA1 loading module + KS1 and AT-ACP from IdmO

<400> SEQUENCE: 3

Met Ala Asp Leu Ser Lys Leu Ser Asp Ser Arg Thr Ala Gln Pro Gly
 1 5 10 15
 Arg Ile Val Arg Pro Trp Pro Leu Ser Gly Cys Asn Glu Ser Ala Leu
 20 25 30
 Arg Ala Arg Ala Arg Gln Leu Arg Ala His Leu Asp Arg Phe Pro Asp
 35 40 45
 Ala Gly Val Glu Gly Val Gly Ala Ala Leu Ala His Asp Glu Gln Ala
 50 55 60
 Asp Ala Gly Pro His Arg Ala Val Val Val Ala Ser Ser Thr Ser Glu
 65 70 75 80
 Leu Leu Asp Gly Leu Ala Ala Val Ala Asp Gly Arg Pro His Ala Ser
 85 90 95
 Val Val Arg Gly Val Ala Arg Pro Ser Ala Pro Val Val Phe Val Phe
 100 105 110
 Pro Gly Gln Gly Ala Gln Trp Ala Gly Met Ala Gly Glu Leu Leu Gly
 115 120 125
 Glu Ser Arg Val Phe Ala Ala Ala Met Asp Ala Cys Ala Arg Ala Phe
 130 135 140
 Glu Pro Val Thr Asp Trp Thr Leu Ala Gln Val Leu Asp Ser Pro Glu
 145 150 155 160
 Gln Ser Arg Arg Val Glu Val Val Gln Pro Ala Leu Phe Ala Val Gln
 165 170 175
 Thr Ser Leu Ala Ala Leu Trp Arg Ser Phe Gly Val Thr Pro Asp Ala
 180 185 190
 Val Val Gly His Ser Ile Gly Glu Leu Ala Ala Ala His Val Cys Gly
 195 200 205
 Ala Ala Gly Ala Ala Asp Ala Ala Arg Ala Ala Ala Leu Trp Ser Arg
 210 215 220
 Glu Met Ile Pro Leu Val Gly Asn Gly Asp Met Ala Ala Val Ala Leu
 225 230 235 240
 Ser Ala Asp Glu Ile Glu Pro Arg Ile Ala Arg Trp Asp Asp Asp Val
 245 250 255
 Val Leu Ala Gly Val Asn Gly Pro Arg Ser Val Leu Leu Thr Gly Ser
 260 265 270
 Pro Glu Pro Val Ala Arg Arg Val Gln Glu Leu Ser Ala Glu Gly Val

-continued

275					280					285					
Arg	Ala	Gln	Val	Ile	Asn	Val	Ser	Met	Ala	Ala	His	Ser	Ala	Gln	Val
290					295					300					
Asp	Asp	Ile	Ala	Glu	Gly	Met	Arg	Ser	Ala	Leu	Ala	Trp	Phe	Ala	Pro
305					310					315					320
Gly	Gly	Ser	Glu	Val	Pro	Phe	Tyr	Ala	Ser	Leu	Thr	Gly	Gly	Ala	Val
				325					330					335	
Asp	Thr	Arg	Glu	Leu	Val	Ala	Asp	Tyr	Trp	Arg	Arg	Ser	Phe	Arg	Leu
			340					345					350		
Pro	Val	Arg	Phe	Asp	Glu	Ala	Ile	Arg	Ser	Ala	Leu	Glu	Val	Gly	Pro
		355					360					365			
Gly	Thr	Phe	Val	Glu	Ala	Ser	Pro	His	Pro	Val	Leu	Ala	Ala	Ala	Leu
	370					375					380				
Gln	Gln	Thr	Leu	Asp	Ala	Glu	Gly	Ser	Ser	Ala	Ala	Val	Val	Pro	Thr
385					390					395					400
Leu	Gln	Arg	Gly	Gln	Gly	Gly	Met	Arg	Arg	Phe	Leu	Leu	Ala	Ala	Ala
				405					410					415	
Gln	Ala	Phe	Thr	Gly	Gly	Val	Ala	Val	Asp	Trp	Thr	Ala	Ala	Tyr	Asp
			420					425						430	
Asp	Val	Gly	Ala	Glu	Pro	Gly	Ser	Leu	Pro	Glu	Phe	Ala	Pro	Ala	Glu
		435					440					445			
Glu	Glu	Asp	Glu	Pro	Ala	Glu	Ser	Gly	Val	Asp	Trp	Asn	Ala	Pro	Pro
	450					455					460				
His	Val	Leu	Arg	Glu	Arg	Leu	Leu	Ala	Val	Val	Asn	Gly	Glu	Thr	Ala
465					470					475					480
Ala	Leu	Ala	Gly	Arg	Glu	Ala	Asp	Ala	Glu	Ala	Thr	Phe	Arg	Glu	Leu
				485					490					495	
Gly	Leu	Asp	Ser	Val	Leu	Ala	Ala	Gln	Leu	Arg	Ala	Lys	Val	Ser	Ala
			500					505					510		
Ala	Ile	Gly	Arg	Glu	Val	Asn	Ile	Ala	Leu	Leu	Tyr	Asp	His	Pro	Thr
		515					520					525			
Pro	Arg	Ala	Leu	Ala	Glu	Ala	Leu	Ala	Ala	Gly	Thr	Glu	Val	Ala	Gln
		530				535					540				
Arg	Glu	Thr	Arg	Ala	Arg	Thr	Asn	Glu	Ala	Ala	Pro	Gly	Glu	Pro	Val
545					550					555					560
Ala	Val	Val	Ala	Met	Ala	Cys	Arg	Leu	Pro	Gly	Gly	Val	Ser	Thr	Pro
				565					570					575	
Glu	Glu	Phe	Trp	Glu	Leu	Leu	Ser	Glu	Gly	Arg	Asp	Ala	Val	Ala	Gly
			580					585					590		
Leu	Pro	Thr	Asp	Arg	Gly	Trp	Asp	Leu	Asp	Ser	Leu	Phe	His	Pro	Asp
		595					600					605			
Pro	Thr	Arg	Ser	Gly	Thr	Ala	His	Gln	Arg	Gly	Gly	Gly	Phe	Leu	Thr
		610				615						620			
Glu	Ala	Thr	Ala	Phe	Asp	Pro	Ala	Phe	Phe	Gly	Met	Ser	Pro	Arg	Glu
				625		630					635				640
Ala	Leu	Ala	Val	Asp	Pro	Gln	Gln	Arg	Leu	Met	Leu	Glu	Leu	Ser	Trp
				645					650					655	
Glu	Val	Leu	Glu	Arg	Ala	Gly	Ile	Pro	Pro	Thr	Ser	Leu	Gln	Ala	Ser
			660					665					670		
Pro	Thr	Gly	Val	Phe	Val	Gly	Leu	Ile	Pro	Gln	Glu	Tyr	Gly	Pro	Arg
		675					680					685			

-continued

Leu Ala Glu Gly Gly Glu Gly Val Glu Gly Tyr Leu Met Thr Gly Thr
 690 695 700
 Thr Thr Ser Val Ala Ser Gly Arg Ile Ala Tyr Thr Leu Gly Leu Glu
 705 710 715 720
 Gly Pro Ala Ile Ser Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala
 725 730 735
 Val His Leu Ala Cys Gln Ser Leu Arg Arg Gly Glu Ser Ser Leu Ala
 740 745 750
 Met Ala Gly Gly Val Thr Val Met Pro Thr Pro Gly Met Leu Val Asp
 755 760 765
 Phe Ser Arg Met Asn Ser Leu Ala Pro Asp Gly Arg Cys Lys Ala Phe
 770 775 780
 Ser Ala Gly Ala Asn Gly Phe Gly Met Ala Glu Gly Ala Gly Met Leu
 785 790 795 800
 Leu Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu
 805 810 815
 Ala Val Leu Arg Gly Thr Ala Val Asn Ser Asp Gly Ala Ser Asn Gly
 820 825 830
 Leu Ser Ala Pro Asn Gly Arg Ala Gln Val Arg Val Ile Gln Gln Ala
 835 840 845
 Leu Ala Glu Ser Gly Leu Gly Pro Ala Asp Ile Asp Ala Val Glu Ala
 850 855 860
 His Gly Thr Gly Thr Arg Leu Gly Asp Pro Ile Glu Ala Arg Ala Leu
 865 870 875 880
 Phe Glu Ala Tyr Gly Arg Asp Arg Glu Gln Pro Leu His Leu Gly Ser
 885 890 895
 Val Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly Val Ala Gly
 900 905 910
 Val Ile Lys Met Val Leu Ala Met Arg Ala Gly Thr Leu Pro Arg Thr
 915 920 925
 Leu His Ala Ser Glu Arg Ser Lys Glu Ile Asp Trp Ser Ser Gly Ala
 930 935 940
 Ile Ser Leu Leu Asp Glu Pro Glu Pro Trp Pro Ala Gly Ala Arg Pro
 945 950 955 960
 Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala His
 965 970 975
 Val Ile Val Glu Glu Ala Pro Glu Ser Ser Ala Asp Ala Val Ala Glu
 980 985 990
 Ser Gly Val Arg Val Pro Val Pro Val Val Pro Trp Val Val Ser Ala
 995 1000 1005
 Arg Ser Ala Glu Gly Leu Ala Ala Gln Ala Glu Arg Leu Ala Arg
 1010 1015 1020
 Phe Val Gly Glu Arg Ser Asp Gln Asp Pro Val Asp Ile Gly Phe
 1025 1030 1035
 Ser Leu Val Arg Ser Arg Ser Leu Leu Glu His Arg Ala Val Val
 1040 1045 1050
 Leu Gly Lys Gly Arg Asp Asp Leu Val Ala Gly Leu Ala Ser Leu
 1055 1060 1065
 Ala Ser Asp Gly Ser Ala Thr Gly Val Val Ser Gly Val Ala Arg
 1070 1075 1080
 Gly Arg Ala Arg Val Ala Phe Gly Phe Ser Gly Gln Gly Ala Gln
 1085 1090 1095

-continued

1475		1480		1485
Leu Val	Glu Ile Ala	Leu Arg	Ala Gly Asp	Glu Val Gly Cys Gly
1490		1495		1500
Arg Val	Glu Glu Leu Thr	Leu Glu Ile	Pro Leu	Val Val Pro Gln
1505		1510		1515
Glu Gly	Gly Val Thr Val	Gln Ile Arg	Val Gly	Ala Pro Asp Glu
1520		1525		1530
Ser Gly	Trp Arg Pro Met	Thr Val His	Ser Arg	Thr Asp Pro Glu
1535		1540		1545
Glu Glu	Trp Thr Arg His	Val Ser Gly	Val Leu	Ser Pro Asp Val
1550		1555		1560
Pro Thr	Glu Arg Tyr Asp	Leu Gly Ala	Trp Pro	Pro Ala Gly Ala
1565		1570		1575
Thr Pro	Val Glu Leu Asp	Gly Phe Tyr	Glu Ala	Tyr Ala Arg Leu
1580		1585		1590
Gly Tyr	Ala Tyr Gly Pro	Ser Phe Gln	Gly Leu	Arg Ala Ala Trp
1595		1600		1605
Arg Arg	Gly Asp Glu Val	Phe Ala Glu	Val Ser	Leu Pro Val Glu
1610		1615		1620
Glu Gln	Glu Thr Ala Gly	Arg Phe Thr	Leu His	Pro Ala Leu Leu
1625		1630		1635
Asp Ala	Ala Leu Gln Ser	Ala Gly Ala	Gly Ala	Phe Phe Asp Ser
1640		1645		1650
Gly Gly	Ser Met Arg Leu	Pro Phe Ala	Trp Ser	Gly Val Ser Val
1655		1660		1665
Phe Ala	Ala Gly Ala Ser	Thr Val Arg	Val Arg	Leu Ser Pro Ala
1670		1675		1680
Gly Pro	Asp Ala Val Thr	Val Ala Leu	Ala Asp	Pro Thr Gly Ala
1685		1690		1695
Pro Val	Ala Leu Val Glu	Arg Leu Leu	Ile Pro	Glu Met Ser Pro
1700		1705		1710
Glu Gln	Leu Glu Arg Val	Arg Gly Glu	Glu Lys	Glu Ala Pro Tyr
1715		1720		1725
Val Leu	Asp Trp Val Pro	Val Glu Val	Pro Ala	Asp Asp Leu Val
1730		1735		1740
Arg Pro	Glu Arg Trp Thr	Leu Leu Gly	Gly Ala	Asp Ala Gly Val
1745		1750		1755
Gly Leu	Asp Val Ala Gly	Ala Phe Ala	Ser Leu	Glu Pro Ser Asp
1760		1765		1770
Gly Ala	Pro Glu Phe Val	Val Leu Pro	Cys Val	Pro Pro Thr Ser
1775		1780		1785
Pro Thr	Arg Ala Ala Asp	Val Arg Gln	Ser Thr	Leu Gln Ala Leu
1790		1795		1800
Thr Val	Leu Gln Asn Trp	Val Thr Asp	Glu Arg	His Ala Asp Ser
1805		1810		1815
Arg Leu	Val Leu Val Thr	Arg Arg Ala	Val Gly	Val Gly Ala His
1820		1825		1830
Asp Asp	Val Pro Asp Leu	Thr His Ala	Ala Leu	Trp Gly Leu Val
1835		1840		1845
Arg Ser	Ala Gln Thr Glu	Asn Pro Gly	Arg Phe	Leu Leu Val Asp
1850		1855		1860

-continued

Leu	Asp	Glu	Gly	Ala	Glu	Leu	Ala	Glu	Val	Leu	Pro	Gly	Ala	Leu
1865						1870					1875			
Gly	Ser	Gly	Glu	Ser	Gln	Val	Ala	Val	Arg	Ala	Gly	Arg	Val	Leu
1880						1885					1890			
Ala	Ala	Arg	Leu	Ala	Arg	Ser	Gly	Ser	Gly	Gly	Ala	Glu	Leu	Val
1895						1900					1905			
Pro	Pro	Ala	Gly	Ala	Pro	Trp	Arg	Leu	Asp	Thr	Thr	Ser	Pro	Gly
1910						1915					1920			
Thr	Leu	Glu	Asn	Leu	Ala	Leu	Val	Pro	Ser	Ala	Glu	Glu	Pro	Leu
1925						1930					1935			
Gly	Pro	Leu	Asp	Val	Arg	Val	Ser	Val	Arg	Ala	Ala	Gly	Leu	Asn
1940						1945					1950			
Phe	Arg	Asp	Val	Leu	Ile	Ala	Leu	Gly	Met	Tyr	Pro	Gly	Asp	Ala
1955						1960					1965			
Arg	Met	Gly	Gly	Glu	Gly	Ala	Gly	Val	Val	Thr	Asp	Val	Gly	Ser
1970						1975					1980			
Glu	Val	Thr	Thr	Leu	Ala	Pro	Gly	Asp	Arg	Val	Met	Gly	Met	Leu
1985						1990					1995			
Ser	Ser	Ala	Phe	Gly	Pro	Thr	Ala	Val	Ser	Asp	His	Arg	Ala	Leu
2000						2005					2010			
Val	Arg	Val	Pro	Asp	Asp	Trp	Ser	Phe	Glu	Gln	Ala	Ala	Ser	Val
2015						2020					2025			
Pro	Thr	Val	Phe	Ala	Thr	Ala	Tyr	Tyr	Gly	Leu	Val	Asp	Leu	Ala
2030						2035					2040			
Glu	Leu	Arg	Ala	Gly	Gln	Ser	Val	Leu	Val	His	Ala	Ala	Ala	Gly
2045						2050					2055			
Gly	Val	Gly	Met	Ala	Ala	Val	Gln	Leu	Ala	Arg	His	Leu	Gly	Ala
2060						2065					2070			
Glu	Val	Phe	Gly	Thr	Ala	Ser	Thr	Gly	Lys	Trp	Asp	Ser	Leu	Arg
2075						2080					2085			
Ala	Gly	Gly	Leu	Asp	Ala	Glu	His	Ile	Ala	Ser	Ser	Arg	Thr	Val
2090						2095					2100			
Glu	Phe	Glu	Glu	Thr	Phe	Leu	Ala	Ala	Thr	Ala	Gly	Arg	Gly	Val
2105						2110					2115			
Asp	Val	Val	Leu	Asp	Ser	Leu	Ala	Gly	Glu	Phe	Val	Asp	Ala	Ser
2120						2125					2130			
Leu	Arg	Leu	Leu	Pro	Arg	Gly	Gly	Arg	Phe	Val	Glu	Met	Gly	Lys
2135						2140					2145			
Ala	Asp	Ile	Arg	Asp	Ala	Glu	Arg	Val	Ala	Ala	Asp	His	Pro	Gly
2150						2155					2160			
Val	Thr	Tyr	Arg	Ser	Phe	Asp	Leu	Leu	Glu	Ala	Gly	Leu	Asp	Arg
2165						2170					2175			
Phe	Gln	Glu	Ile	Leu	Thr	Glu	Val	Val	Arg	Leu	Phe	Glu	Arg	Gly
2180						2185					2190			
Val	Leu	Arg	His	Leu	Pro	Val	Thr	Ala	Trp	Asp	Val	Arg	Arg	Ala
2195						2200					2205			
Ala	Glu	Ala	Phe	Arg	Phe	Val	Ser	Gln	Ala	Arg	His	Val	Gly	Lys
2210						2215					2220			
Asn	Val	Leu	Val	Met	Pro	Arg	Val	Trp	Asp	Arg	Asp	Gly	Thr	Val
2225						2230					2235			
Leu	Ile	Thr	Gly	Gly	Thr	Gly	Ala	Leu	Gly	Ala	Leu	Val	Ala	Arg
2240						2245					2250			

-continued

His	Leu	Val	Ala	Glu	His	Gly	Met	Arg	Asn	Val	Leu	Leu	Ala	Gly
2255						2260					2265			
Arg	Arg	Gly	Val	Asp	Ala	Pro	Gly	Ala	Arg	Glu	Leu	Leu	Ala	Glu
2270						2275					2280			
Leu	Glu	Thr	Ala	Gly	Ala	Gln	Val	Ser	Val	Val	Ala	Cys	Asp	Val
2285						2290					2295			
Ala	Asp	Arg	Asp	Ala	Val	Ala	Glu	Leu	Ile	Ala	Lys	Val	Pro	Val
2300						2305					2310			
Glu	His	Pro	Leu	Thr	Ala	Val	Val	His	Thr	Ala	Gly	Val	Val	Ala
2315						2320					2325			
Asp	Ala	Thr	Leu	Thr	Ala	Leu	Asp	Ala	Glu	Arg	Val	Asp	Thr	Val
2330						2335					2340			
Leu	Arg	Ala	Lys	Val	Asp	Ala	Val	Leu	His	Leu	His	Glu	Ala	Thr
2345						2350					2355			
Arg	Gly	Leu	Asp	Leu	Ala	Gly	Phe	Val	Leu	Phe	Ser	Ser	Ala	Ser
2360						2365					2370			
Gly	Ile	Phe	Gly	Ser	Pro	Gly	Gln	Gly	Asn	Tyr	Ala	Ala	Ala	Asn
2375						2380					2385			
Ser	Phe	Ile	Asp	Ala	Phe	Ala	His	His	Arg	Arg	Ala	Gln	Gly	Leu
2390						2395					2400			
Pro	Ala	Leu	Ser	Leu	Ala	Trp	Gly	Leu	Trp	Ala	Arg	Thr	Ser	Gly
2405						2410					2415			
Met	Ala	Gly	Gln	Leu	Gly	His	Asp	Asp	Val	Ala	Arg	Ile	Ser	Arg
2420						2425					2430			
Thr	Gly	Leu	Ala	Pro	Ile	Thr	Asp	Asp	Gln	Gly	Met	Ala	Leu	Leu
2435						2440					2445			
Asp	Ala	Ala	Leu	Gly	Ala	Gly	Arg	Pro	Leu	Leu	Val	Pro	Val	Arg
2450						2455					2460			
Leu	Asp	Arg	Ala	Ala	Leu	Arg	Ser	Gln	Ala	Thr	Ala	Gly	Thr	Leu
2465						2470					2475			
Pro	Pro	Ile	Leu	Arg	Gly	Leu	Val	Arg	Ala	Thr	Val	Arg	Arg	Ala
2480						2485					2490			
Ala	Ser	Thr	Ala	Ala	Ala	Gln	Gly	Pro	Ser	Leu	Ala	Glu	Arg	Leu
2495						2500					2505			
Ala	Gly	Leu	Pro	Val	Thr	Glu	His	Glu	Arg	Ile	Val	Val	Glu	Leu
2510						2515					2520			
Val	Arg	Ala	Asp	Leu	Ala	Ala	Val	Leu	Gly	His	Ala	Ser	Ala	Glu
2525						2530					2535			
Arg	Val	Pro	Ala	Asp	Gln	Ala	Phe	Ala	Glu	Leu	Gly	Val	Asp	Ser
2540						2545					2550			
Leu	Thr	Ala	Val	Glu	Leu	Arg	Asn	Arg	Leu	Asn	Gly	Ala	Thr	Gly
2555						2560					2565			
Leu	Arg	Leu	Ala	Ala	Ser	Leu	Val	Phe	Asp	Tyr	Pro	Thr	Pro	Asn
2570						2575					2580			
Ala	Leu	Ala	Thr	His	Ile	Leu	Asp	Glu	Leu	Ala	Leu	Asp	Thr	Ala
2585						2590					2595			
Gly	Ala	Gly	Ala	Ala	Gly	Glu	Pro	Asp	Gly	Pro	Ala	Pro	Ala	Pro
2600						2605					2610			
Ala	Asp	Glu	Ala	Arg	Phe	Arg	Arg	Val	Ile	Asn	Ser	Ile	Pro	Leu
2615						2620					2625			
Asp	Arg	Ile	Arg	Arg	Ala	Gly	Leu	Leu	Asp	Ala	Leu	Leu	Gly	Leu

-continued

2630	2635	2640
Ala Gly Thr Ser Ala Asp Thr Ala Ala Ser Asp Asp Phe Asp Gln		
2645	2650	2655
Glu Glu Asp Gly Pro Ala Ile Ala Ser Met Asp Val Asp Asp Leu		
2660	2665	2670
Val Arg Ile Ala Leu Gly Glu Ser Asp Thr Thr Ala Asp Ile Thr		
2675	2680	2685
Glu Gly Thr Asp Arg Ser		
2690		

<210> SEQ ID NO 4

<211> LENGTH: 2227

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: KS domain from IdmP and AT-TE domains from CurM

<400> SEQUENCE: 4

Met Ser Ser Ala Ser Ser Glu Lys Ile Val Glu Ala Leu Arg Ala Ser		
1	5	10 15
Leu Thr Glu Asn Glu Arg Leu Arg Arg Leu Asn Gln Glu Leu Ala Ala		
	20	25 30
Ala Ala His Glu Pro Val Ala Ile Val Ser Met Ala Cys Arg Phe Pro		
	35	40 45
Gly Gly Val Glu Ser Pro Glu Asp Phe Trp Asp Leu Ile Ser Glu Gly		
50	55	60
Arg Asp Ala Val Ser Gly Leu Pro Asp Asn Arg Gly Trp Asp Leu Asp		
65	70	75 80
Ala Leu Tyr Asp Pro Asp Pro Glu Ala Gln Gly Lys Thr Tyr Val Arg		
	85	90 95
Glu Gly Ala Phe Leu Tyr Asp Ala Ala Glu Phe Asp Ala Glu Leu Phe		
	100	105 110
Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu		
115	120	125
Leu Met Glu Thr Ser Trp Glu Val Leu Glu Arg Ala Gly Ile Arg Pro		
130	135	140
Asp Ser Leu Arg Gly Lys Pro Val Gly Val Phe Thr Gly Gly Ile Thr		
145	150	155 160
Ser Asp Tyr Val Thr Arg His Tyr Ala Ser Gly Thr Ala Pro Gln Leu		
	165	170 175
Pro Ser Gly Val Glu Ser His Phe Met Thr Gly Ser Ala Gly Ser Val		
	180	185 190
Phe Ser Gly Arg Ile Ala Tyr Thr Tyr Gly Phe Glu Gly Pro Ala Val		
	195	200 205
Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Leu His Met Ala		
210	215	220
Ala Gln Ser Leu Arg Gln Gly Glu Cys Ser Leu Ala Phe Ala Gly Gly		
225	230	235 240
Val Ala Val Leu Pro Asn Pro Gly Thr Phe Val Gly Phe Ser Arg Gln		
	245	250 255
Arg Ala Leu Ser Pro Asp Gly Arg Cys Lys Ala Phe Ser Ala Asp Ala		
	260	265 270
Asp Gly Thr Gly Trp Gly Glu Gly Ala Gly Leu Val Leu Leu Glu Lys		
	275	280 285

-continued

Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu Ala Ile Leu Arg
 290 295 300

Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro
 305 310 315 320

Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ala Ala Leu Ala Asn Ala
 325 330 335

Arg Leu Ser Pro Asp Asp Val Asp Val Val Glu Ala His Gly Thr Gly
 340 345 350

Thr Pro Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Gln Ala Thr Tyr
 355 360 365

Gly Arg Ser Arg Ser Ala Glu Arg Pro Leu Trp Leu Gly Ser Val Lys
 370 375 380

Ser Asn Val Ala His Ala Gln Ala Ala Ala Gly Val Ala Ser Val Ile
 385 390 395 400

Lys Val Val Met Ala Leu Arg His Arg Leu Leu Pro Lys Thr Leu His
 405 410 415

Ala Asp Glu Arg Ser Pro His Ile Asp Trp His Ser Gly Ala Val Glu
 420 425 430

Leu Leu Thr Glu Ala Arg Glu Trp Ser Arg Thr Glu Gly Arg Ala Arg
 435 440 445

Arg Ala Gly Val Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His Val
 450 455 460

Ile Ile Glu Glu Ala Pro Glu Leu Ile Lys Gly Gln Lys Ala Lys Gly
 465 470 475 480

Lys Ser Glu Asn Asp Leu Glu Arg Pro Leu His Ile Leu Thr Leu Ser
 485 490 495

Thr Lys Thr Glu Lys Ala Leu Glu Glu Leu Val Ser Arg Tyr Gln Asn
 500 505 510

His Trp Glu Thr Tyr Pro Glu Leu Ala Ile Ser Asp Val Cys Tyr Thr
 515 520 525

Ala Asn Thr Gly Arg Ala Gln Phe Asn His Arg Leu Ala Val Ile Ala
 530 535 540

Ser Gly Ser Glu Glu Leu Thr Gln Lys Leu Arg Gln His Thr Ala Gly
 545 550 555 560

Glu Glu Val Val Gly Val Phe Ser Gly Lys Val Pro Asn Ser Gly Ser
 565 570 575

Glu Ser Lys Val Ala Phe Leu Phe Thr Gly Gln Gly Ser Gln Tyr Leu
 580 585 590

Asn Met Gly Arg Gln Leu Tyr Glu Thr Gln Pro Thr Phe Arg Gln Ala
 595 600 605

Leu Asp Thr Cys Asp His Ile Leu Arg Pro Tyr Leu Asp Asn Pro Leu
 610 615 620

Leu Glu Ile Leu Tyr Pro Gln Asp Ala Gln Lys Ser Asn Asp Ser Pro
 625 630 635 640

Leu Asp Gln Thr Gly Tyr Thr Gln Pro Ala Leu Phe Ser Ile Glu Tyr
 645 650 655

Ala Leu Leu Lys Leu Trp Glu Ser Trp Gly Ile Lys Pro Asn Val Val
 660 665 670

Met Gly His Ser Val Gly Glu Tyr Val Ala Ala Thr Val Ala Gly Val
 675 680 685

Phe Ser Leu Glu Asp Gly Leu Lys Leu Ile Ala Ala Arg Gly Arg Leu

-continued

690		695				700									
Met	Gln	Gly	Leu	Pro	Ala	Gly	Gly	Glu	Met	Val	Ser	Val	Met	Ala	Ser
705					710				715					720	
Glu	Ser	Lys	Val	Leu	Glu	Thr	Leu	Lys	Ala	Met	Ser	Leu	Glu	Asp	Lys
				725					730					735	
Val	Ala	Ile	Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Ile	Val	Ile	Ser	Gly
			740					745					750		
Glu	Ala	Glu	Ala	Ile	Arg	Ala	Met	Ala	Thr	His	Leu	Glu	Ser	Val	Gly
		755					760					765			
Ile	Lys	Thr	Lys	Gln	Leu	Gln	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu
	770					775					780				
Met	Glu	Pro	Met	Leu	Ala	Glu	Phe	Glu	Ala	Val	Ala	Asn	Gln	Ile	Thr
785					790					795					800
Tyr	His	Gln	Pro	Arg	Ile	Pro	Ile	Ile	Ser	Asn	Val	Thr	Gly	Thr	Lys
				805					810					815	
Ala	Asp	Lys	Ser	Ile	Ala	Thr	Ala	Gln	Tyr	Trp	Val	Asn	His	Val	Arg
			820					825					830		
Gln	Pro	Val	Arg	Phe	Ala	Gln	Gly	Met	Ala	Thr	Leu	His	Gln	Gln	Gly
		835					840					845			
Tyr	Glu	Thr	Phe	Leu	Glu	Ile	Gly	Ala	Lys	Pro	Ile	Leu	Leu	Gly	Met
	850					855					860				
Gly	Lys	Gln	Cys	Leu	Ser	Pro	Asp	Val	Gly	Val	Trp	Leu	Pro	Ser	Leu
865					870					875					880
Arg	His	Gly	Val	Asp	Glu	Trp	Gln	Gln	Ile	Leu	Ser	Ser	Leu	Gly	Gln
				885					890					895	
Leu	Tyr	Val	Gln	Gly	Ala	Lys	Val	Asp	Trp	Ser	Gly	Phe	Asp	Arg	Asp
		900						905					910		
Tyr	Ser	Arg	Glu	Lys	Val	Val	Leu	Pro	Thr	Tyr	Pro	Phe	Gln	Arg	Glu
		915					920					925			
Arg	Tyr	Trp	Val	Glu	Thr	Ser	Ile	Asn	Gln	Gln	Gln	Val	Val	Cys	Ser
	930						935				940				
Gly	Glu	Pro	Asn	Leu	Gln	Gly	Thr	Pro	Glu	Gly	Thr	Ser	Thr	Thr	Ile
945					950					955					960
Val	Lys	Leu	Leu	Ser	Gln	Gly	Asn	Thr	Lys	Glu	Leu	Ala	Glu	Lys	Val
				965					970					975	
Glu	Lys	Thr	Ser	Asp	Leu	Pro	Pro	Glu	Gln	Leu	Lys	Leu	Leu	Pro	Asp
			980					985					990		
Leu	Leu	Ala	Ser	Leu	Ser	Gln	Gln	His	Gln	Gln	Glu	Leu	Ala	Arg	Leu
		995					1000						1005		
Thr	Thr	Lys	Lys	Trp	Phe	Tyr	Lys	Val	Gln	Trp	Ile	Ser	Gln	Ala	
	1010					1015					1020				
Ile	Lys	Pro	Gln	Arg	Asn	Lys	Ser	Asn	Asn	Gln	Val	Cys	His	Trp	
	1025					1030					1035				
Leu	Ile	Leu	Thr	Asp	Ser	Lys	Gly	Leu	Gly	Lys	Ser	Leu	Ala	Thr	
	1040					1045					1050				
His	Leu	Gln	Gln	Leu	Gly	Asn	Glu	Cys	Ser	Val	Val	Tyr	Gln	Ala	
	1055					1060					1065				
Asp	Asn	Tyr	Gln	Asn	Tyr	Glu	Pro	Gly	Ile	Tyr	His	Ile	Asn	Pro	
	1070					1075					1080				
Ser	His	Pro	Gln	Glu	Phe	Glu	Gln	Val	Tyr	Gln	Thr	Ile	Phe	Glu	
	1085					1090					1095				

-continued

Asn	Gly	Lys	Leu	Pro	Leu	Gln	Lys	Val	Ile	His	Leu	Trp	Ser	Leu
1100						1105					1110			
Asp	Thr	Ala	Ser	Glu	Gln	Asp	Leu	Thr	Thr	Glu	Thr	Leu	Glu	Gln
1115						1120					1125			
Ala	Gln	Leu	Trp	Gly	Cys	Gly	Ser	Thr	Leu	His	Leu	Leu	Gln	Thr
1130						1135					1140			
Leu	Val	Lys	Asn	Pro	Asn	Ser	Thr	Pro	Pro	Lys	Leu	Trp	Met	Ile
1145						1150					1155			
Thr	Arg	Gly	Thr	Gln	Pro	Val	Leu	Ser	Pro	Thr	Glu	Lys	Leu	Thr
1160						1165					1170			
Val	Ala	Thr	Ser	Pro	Leu	Trp	Gly	Leu	Gly	Arg	Thr	Ile	Ala	Ser
1175						1180					1185			
Glu	His	Pro	Gln	Leu	Trp	Gly	Gly	Leu	Val	Asp	Leu	Asp	Pro	Gln
1190						1195					1200			
Gly	Ser	Glu	Asp	Glu	Val	Glu	Val	Leu	Leu	Gln	Gln	Ile	Ile	Asp
1205						1210					1215			
Ser	Gln	Lys	Glu	Asp	His	Leu	Ala	Val	Arg	Asn	Arg	Lys	Ile	Tyr
1220						1225					1230			
Val	Ala	Arg	Leu	Leu	Lys	His	Ile	Pro	Gln	Glu	Ser	Gln	Pro	Leu
1235						1240					1245			
Ser	Leu	Arg	Ser	Asp	Ala	Thr	Tyr	Leu	Ile	Thr	Gly	Gly	Leu	Gly
1250						1255					1260			
Ala	Leu	Gly	Leu	Lys	Thr	Ala	Ala	Trp	Met	Ala	Glu	Lys	Gly	Ala
1265						1270					1275			
Arg	Asn	Leu	Val	Leu	Ile	Ser	Arg	Arg	Gln	Pro	Ser	Glu	Gln	Ala
1280						1285					1290			
Gln	Gln	Thr	Ile	Gln	Ser	Leu	Glu	Glu	Leu	Gly	Thr	Gln	Val	Lys
1295						1300					1305			
Val	Leu	Ser	Ala	Asp	Ile	Ser	Val	Glu	Ser	Asp	Val	Ala	Asn	Ile
1310						1315					1320			
Leu	Glu	Gln	Ile	Gln	Thr	Ser	Leu	Pro	Pro	Leu	Leu	Gly	Val	Ile
1325						1330					1335			
His	Ala	Ala	Gly	Val	Leu	Asp	Asp	Gly	Leu	Leu	Gln	Gln	Thr	Asn
1340						1345					1350			
Trp	Glu	Arg	Phe	Thr	Lys	Val	Met	Ala	Pro	Lys	Val	Asn	Gly	Thr
1355						1360					1365			
Trp	Asn	Leu	His	Lys	Leu	Thr	Gln	His	Leu	Ser	Leu	Asp	Phe	Phe
1370						1375					1380			
Val	Cys	Phe	Ser	Ser	Met	Ser	Ser	Leu	Leu	Gly	Ser	Pro	Gly	Gln
1385						1390					1395			
Gly	Asn	Tyr	Ala	Ala	Ala	Asn	Ala	Phe	Met	Asp	Ala	Val	Val	His
1400						1405					1410			
Tyr	Arg	Arg	Glu	Met	Gly	Leu	Pro	Gly	Leu	Ser	Ile	Asn	Trp	Gly
1415						1420					1425			
Gly	Trp	Ser	Glu	Gly	Gly	Met	Ala	Thr	Arg	Leu	Ala	Ser	Gln	His
1430						1435					1440			
Gln	Asn	Arg	Met	Gln	Thr	Ala	Gly	Ile	Ser	Leu	Ile	Ser	Pro	Glu
1445						1450					1455			
Gln	Gly	Ile	Gln	Val	Leu	Glu	Glu	Leu	Val	Arg	Thr	Gln	Ser	Thr
1460						1465					1470			
Ala	Gln	Val	Gly	Val	Leu	Pro	Val	Asp	Trp	Ser	Val	Leu	Ala	Lys
1475						1480					1485			

-continued

Gln Phe Ser Ser Ala Asn Pro Ser Ser Leu Leu Leu Glu Leu Leu	1490	1495	1500
Gln Gln Glu Thr Ser Ser Glu Lys Thr Asp Glu Arg Ile Leu Glu	1505	1510	1515
Lys Leu Gln Ala Ala Pro Ile Thr Glu Arg Gln Asp Ile Leu Lys	1520	1525	1530
Asn Tyr Ile Gln Leu Val Val Ala Lys Thr Leu Gly Ile Asn Pro	1535	1540	1545
Ser Lys Ile Ser Thr Asp Asp Asn Phe Val Glu Leu Gly Met Asp	1550	1555	1560
Ser Leu Met Gly Met Glu Val Val Asn Lys Leu Ser Gly Asp Leu	1565	1570	1575
Asp Phe Ile Ile Tyr Pro Arg Glu Phe Tyr Glu Arg Pro Thr Ile	1580	1585	1590
Asp Ser Leu Thr Gln Tyr Leu Ser Ala Glu Leu Ser Glu Asp Asn	1595	1600	1605
Leu Ala Thr Gln Pro Ser Pro Thr Ser Leu Glu Ile Phe Ala Thr	1610	1615	1620
Lys Ser Ser Pro Ser Gly Asn Ser Ala Arg Pro Ala Ser Val Ser	1625	1630	1635
Ser Arg Leu Pro Gly Ile Ile Phe Ile Leu Ser Ser Pro Arg Ser	1640	1645	1650
Gly Ser Thr Leu Leu Arg Val Met Leu Ala Gly His Ser Ser Leu	1655	1660	1665
Phe Ser Pro Pro Glu Leu His Leu Leu Pro Phe Asn Thr Met Lys	1670	1675	1680
Glu Arg Gln Glu Gln Leu Asn Leu Ser Tyr Leu Gly Glu Gly Leu	1685	1690	1695
Gln Lys Thr Phe Met Glu Val Lys Asn Leu Asp Ala Thr Ala Ser	1700	1705	1710
Gln Ala Leu Ile Lys Asp Leu Glu Ser Gln Asn Leu Ser Ile Gln	1715	1720	1725
Gln Val Tyr Gly Met Leu Gln Glu Asn Ile Ala Pro Arg Leu Leu	1730	1735	1740
Val Asp Lys Ser Pro Thr Tyr Ala Met Glu Pro Thr Ile Leu Glu	1745	1750	1755
Arg Gly Glu Ala Leu Phe Ala Asn Ser Lys Tyr Ile Tyr Leu Val	1760	1765	1770
Arg His Pro Tyr Ser Val Ile Glu Ser Phe Val Arg Met Arg Met	1775	1780	1785
Gln Lys Leu Val Gly Leu Gly Glu Glu Asn Pro Tyr Arg Val Ala	1790	1795	1800
Glu Gln Val Trp Ala Lys Ser Asn Gln Asn Ile Leu Asn Phe Leu	1805	1810	1815
Ser Gln Leu Glu Pro Glu Arg Gln His Gln Ile Arg Tyr Glu Asp	1820	1825	1830
Leu Val Lys Lys Pro Gln Gln Val Leu Ser Gln Leu Cys Asp Phe	1835	1840	1845
Leu Asn Val Pro Phe Glu Pro Glu Leu Leu Gln Pro Tyr Gln Gly	1850	1855	1860
Asp Arg Met Thr Gly Gly Val His Gln Lys Ser Leu Ser Ile Ser			

-continued

1865	1870	1875
Asp Pro Asn Phe Leu Lys His Asn Thr Ile Asp Glu Ser Leu Ala 1880 1885 1890		
Asp Lys Trp Lys Thr Ile Gln Leu Pro Tyr Pro Leu Lys Ser Glu 1895 1900 1905		
Thr Gln Arg Ile Ala Ser Gln Leu Ser Tyr Glu Leu Pro Asn Leu 1910 1915 1920		
Val Thr Thr Pro Thr Asn Gln Gln Pro Gln Val Ser Thr Thr Pro 1925 1930 1935		
Ser Thr Glu Gln Pro Ile Met Glu Glu Lys Phe Leu Glu Phe Gly 1940 1945 1950		
Gly Asn Gln Ile Cys Leu Cys Ser Trp Gly Ser Pro Glu His Pro 1955 1960 1965		
Val Val Leu Cys Ile His Gly Ile Leu Glu Gln Gly Leu Ala Trp 1970 1975 1980		
Gln Glu Val Ala Leu Pro Leu Ala Ala Gln Gly Tyr Arg Val Val 1985 1990 1995		
Ala Pro Asp Leu Phe Gly His Gly Arg Ser Ser His Leu Glu Met 2000 2005 2010		
Val Thr Ser Tyr Ser Ser Leu Thr Phe Leu Ala Gln Ile Asp Arg 2015 2020 2025		
Val Ile Gln Glu Leu Pro Asp Gln Pro Leu Leu Leu Val Gly His 2030 2035 2040		
Ser Met Gly Ala Met Leu Ala Thr Ala Ile Ala Ser Val Arg Pro 2045 2050 2055		
Lys Lys Ile Lys Glu Leu Ile Leu Val Glu Leu Pro Leu Pro Ala 2060 2065 2070		
Glu Glu Ser Lys Lys Glu Ser Ala Val Asn Gln Leu Thr Thr Cys 2075 2080 2085		
Leu Asp Tyr Leu Ser Ser Thr Pro Gln His Pro Ile Phe Pro Asp 2090 2095 2100		
Val Ala Thr Ala Ala Ser Arg Leu Arg Gln Ala Ile Pro Ser Leu 2105 2110 2115		
Ser Glu Glu Phe Ser Tyr Ile Leu Ala Gln Arg Ile Thr Gln Pro 2120 2125 2130		
Asn Gln Gly Gly Val Arg Trp Ser Trp Asp Ala Ile Ile Arg Thr 2135 2140 2145		
Arg Ser Ile Leu Gly Leu Asn Asn Leu Pro Gly Gly Arg Ser Gln 2150 2155 2160		
Tyr Leu Glu Met Leu Lys Ser Ile Gln Val Pro Thr Thr Leu Val 2165 2170 2175		
Tyr Gly Asp Ser Ser Lys Leu Asn Arg Pro Glu Asp Leu Gln Gln 2180 2185 2190		
Gln Lys Met Thr Met Thr Gln Ala Lys Arg Val Phe Leu Ser Gly 2195 2200 2205		
Gly His Asn Leu His Ile Asp Ala Ala Ala Ala Leu Ala Ser Leu 2210 2215 2220		
Ile Leu Thr Ser 2225		

<210> SEQ ID NO 5

<211> LENGTH: 2740

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Hybrid polyketide synthase capable of producing
 butene

<400> SEQUENCE: 5

Met Ala Asp Leu Ser Lys Leu Ser Asp Ser Arg Thr Ala Gln Pro Gly
 1 5 10 15
 Arg Ile Val Arg Pro Trp Pro Leu Ser Gly Cys Asn Glu Ser Ala Leu
 20 25 30
 Arg Ala Arg Ala Arg Gln Leu Arg Ala His Leu Asp Arg Phe Pro Asp
 35 40 45
 Ala Gly Val Glu Gly Val Gly Ala Ala Leu Ala His Asp Glu Gln Ala
 50 55 60
 Asp Ala Gly Pro His Arg Ala Val Val Val Ala Ser Ser Thr Ser Glu
 65 70 75 80
 Leu Leu Asp Gly Leu Ala Ala Val Ala Asp Gly Arg Pro His Ala Ser
 85 90 95
 Val Val Arg Gly Val Ala Arg Pro Ser Ala Pro Val Val Phe Val Phe
 100 105 110
 Pro Gly Gln Gly Ala Gln Trp Ala Gly Met Ala Gly Glu Leu Leu Gly
 115 120 125
 Glu Ser Arg Val Phe Ala Ala Ala Met Asp Ala Cys Ala Arg Ala Phe
 130 135 140
 Glu Pro Val Thr Asp Trp Thr Leu Ala Gln Val Leu Asp Ser Pro Glu
 145 150 155 160
 Gln Ser Arg Arg Val Glu Val Val Gln Pro Ala Leu Phe Ala Val Gln
 165 170 175
 Thr Ser Leu Ala Ala Leu Trp Arg Ser Phe Gly Val Thr Pro Asp Ala
 180 185 190
 Val Val Gly His Ser Ile Gly Glu Leu Ala Ala Ala His Val Cys Gly
 195 200 205
 Ala Ala Gly Ala Ala Asp Ala Ala Arg Ala Ala Ala Leu Trp Ser Arg
 210 215 220
 Glu Met Ile Pro Leu Val Gly Asn Gly Asp Met Ala Ala Val Ala Leu
 225 230 235 240
 Ser Ala Asp Glu Ile Glu Pro Arg Ile Ala Arg Trp Asp Asp Asp Val
 245 250 255
 Val Leu Ala Gly Val Asn Gly Pro Arg Ser Val Leu Leu Thr Gly Ser
 260 265 270
 Pro Glu Pro Val Ala Arg Arg Val Gln Glu Leu Ser Ala Glu Gly Val
 275 280 285
 Arg Ala Gln Val Ile Asn Val Ser Met Ala Ala His Ser Ala Gln Val
 290 295 300
 Asp Asp Ile Ala Glu Gly Met Arg Ser Ala Leu Ala Trp Phe Ala Pro
 305 310 315 320
 Gly Gly Ser Glu Val Pro Phe Tyr Ala Ser Leu Thr Gly Gly Ala Val
 325 330 335
 Asp Thr Arg Glu Leu Val Ala Asp Tyr Trp Arg Arg Ser Phe Arg Leu
 340 345 350
 Pro Val Arg Phe Asp Glu Ala Ile Arg Ser Ala Leu Glu Val Gly Pro
 355 360 365

-continued

Gly	Thr	Phe	Val	Glu	Ala	Ser	Pro	His	Pro	Val	Leu	Ala	Ala	Ala	Leu
370						375					380				
Gln	Gln	Thr	Leu	Asp	Ala	Glu	Gly	Ser	Ser	Ala	Ala	Val	Val	Pro	Thr
385					390					395				400	
Leu	Gln	Arg	Gly	Gln	Gly	Gly	Met	Arg	Arg	Phe	Leu	Leu	Ala	Ala	Ala
			405					410						415	
Gln	Ala	Phe	Thr	Gly	Gly	Val	Ala	Val	Asp	Trp	Thr	Ala	Ala	Tyr	Asp
			420					425					430		
Asp	Val	Gly	Ala	Glu	Pro	Gly	Ser	Leu	Pro	Glu	Phe	Ala	Pro	Ala	Glu
		435					440					445			
Glu	Glu	Asp	Glu	Pro	Ala	Glu	Ser	Gly	Val	Asp	Trp	Asn	Ala	Pro	Pro
	450					455				460					
His	Val	Leu	Arg	Glu	Arg	Leu	Leu	Ala	Val	Val	Asn	Gly	Glu	Thr	Ala
465					470					475					480
Ala	Leu	Ala	Gly	Arg	Glu	Ala	Asp	Ala	Glu	Ala	Thr	Phe	Arg	Glu	Leu
			485						490					495	
Gly	Leu	Asp	Ser	Val	Leu	Ala	Ala	Gln	Leu	Arg	Ala	Lys	Val	Ser	Ala
			500					505						510	
Ala	Ile	Gly	Arg	Glu	Val	Asn	Ile	Ala	Leu	Leu	Tyr	Asp	His	Pro	Thr
		515					520					525			
Pro	Arg	Ala	Leu	Ala	Glu	Ala	Leu	Ser	Ser	Gly	Thr	Glu	Val	Ala	Gln
	530					535					540				
Arg	Glu	Thr	Arg	Ala	Arg	Thr	Asn	Glu	Ala	Ala	Pro	Gly	Glu	Pro	Ile
545					550					555					560
Ala	Val	Val	Ala	Met	Ala	Cys	Arg	Leu	Pro	Gly	Gly	Val	Ser	Thr	Pro
				565					570					575	
Glu	Glu	Phe	Trp	Glu	Leu	Leu	Ser	Glu	Gly	Arg	Asp	Ala	Val	Ala	Gly
			580					585					590		
Leu	Pro	Thr	Asp	Arg	Gly	Trp	Asp	Leu	Asp	Ser	Leu	Phe	His	Pro	Asp
		595					600					605			
Pro	Thr	Arg	Ser	Gly	Thr	Ala	His	Gln	Arg	Gly	Gly	Gly	Phe	Leu	Thr
	610					615					620				
Glu	Ala	Thr	Ala	Phe	Asp	Pro	Ala	Phe	Phe	Gly	Met	Ser	Pro	Arg	Glu
625					630					635					640
Ala	Leu	Ala	Val	Asp	Pro	Gln	Gln	Arg	Leu	Met	Leu	Glu	Leu	Ser	Trp
				645					650					655	
Glu	Val	Leu	Glu	Arg	Ala	Gly	Ile	Pro	Pro	Thr	Ser	Leu	Gln	Ala	Ser
			660					665					670		
Pro	Thr	Gly	Val	Phe	Val	Gly	Leu	Ile	Pro	Gln	Glu	Tyr	Gly	Pro	Arg
		675					680					685			
Leu	Ala	Glu	Gly	Gly	Glu	Gly	Val	Glu	Gly	Tyr	Leu	Met	Thr	Gly	Thr
	690					695					700				
Thr	Thr	Ser	Val	Ala	Ser	Gly	Arg	Ile	Ala	Tyr	Thr	Leu	Gly	Leu	Glu
705					710					715					720
Gly	Pro	Ala	Ile	Ser	Val	Asp	Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala
				725					730					735	
Val	His	Leu	Ala	Cys	Gln	Ser	Leu	Arg	Arg	Gly	Glu	Ser	Ser	Leu	Ala
			740					745					750		
Met	Ala	Gly	Gly	Val	Thr	Val	Met	Pro	Thr	Pro	Gly	Met	Leu	Val	Asp
		755					760					765			
Phe	Ser	Arg	Met	Asn	Ser	Leu	Ala	Pro	Asp	Gly	Arg	Cys	Lys	Ala	Phe
						775					780				

-continued

Ser Ala Gly Ala Asn Gly Phe Gly Met Ala Glu Gly Ala Gly Met Leu
 785 790 795 800
 Leu Leu Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu
 805 810 815
 Ala Val Leu Arg Gly Thr Ala Val Asn Ser Asp Gly Ala Ser Asn Gly
 820 825 830
 Leu Ser Ala Pro Asn Gly Arg Ala Gln Val Arg Val Ile Gln Gln Ala
 835 840 845
 Leu Ala Glu Ser Gly Leu Gly Pro Ala Asp Ile Asp Ala Val Glu Ala
 850 855 860
 His Gly Thr Gly Thr Arg Leu Gly Asp Pro Ile Glu Ala Arg Ala Leu
 865 870 875 880
 Phe Glu Ala Tyr Gly Arg Asp Arg Glu Gln Pro Leu His Leu Gly Ser
 885 890 895
 Val Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly Val Ala Gly
 900 905 910
 Val Ile Lys Met Val Leu Ala Met Arg Ala Gly Thr Leu Pro Arg Thr
 915 920 925
 Leu His Ala Ser Glu Arg Ser Lys Glu Ile Asp Trp Ser Ser Gly Ala
 930 935 940
 Ile Ser Leu Leu Asp Glu Pro Glu Pro Trp Pro Ala Gly Ala Arg Pro
 945 950 955 960
 Arg Arg Ala Gly Val Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His
 965 970 975
 Ala Ile Ile Glu Glu Ala Pro Glu Leu Ile Lys Gly Gln Lys Ala Lys
 980 985 990
 Gly Lys Ser Glu Asn Asp Leu Glu Arg Pro Leu His Ile Leu Thr Leu
 995 1000 1005
 Ser Thr Lys Thr Glu Lys Ala Leu Glu Glu Leu Val Ser Arg Tyr
 1010 1015 1020
 Gln Asn His Trp Glu Thr Tyr Pro Glu Leu Ala Ile Ser Asp Val
 1025 1030 1035
 Cys Tyr Thr Ala Asn Thr Gly Arg Ala Gln Phe Asn His Arg Leu
 1040 1045 1050
 Ala Val Ile Ala Ser Gly Ser Glu Glu Leu Thr Gln Lys Leu Arg
 1055 1060 1065
 Gln His Thr Ala Gly Glu Glu Val Val Gly Val Phe Ser Gly Lys
 1070 1075 1080
 Val Pro Asn Ser Gly Ser Glu Ser Lys Val Ala Phe Leu Phe Thr
 1085 1090 1095
 Gly Gln Gly Ser Gln Tyr Leu Asn Met Gly Arg Gln Leu Tyr Glu
 1100 1105 1110
 Thr Gln Pro Thr Phe Arg Gln Ala Leu Asp Thr Cys Asp His Ile
 1115 1120 1125
 Leu Arg Pro Tyr Leu Asp Asn Pro Leu Leu Glu Ile Leu Tyr Pro
 1130 1135 1140
 Gln Asp Ala Gln Lys Ser Asn Asp Ser Pro Leu Asp Gln Thr Gly
 1145 1150 1155
 Tyr Thr Gln Pro Ala Leu Phe Ser Ile Glu Tyr Ala Leu Leu Lys
 1160 1165 1170
 Leu Trp Glu Ser Trp Gly Ile Lys Pro Asn Val Val Met Gly His

-continued

1175						1180										1185
Ser	Val	Gly	Glu	Tyr	Val	Ala	Ala	Thr	Val	Ala	Gly	Val	Phe	Ser		
1190						1195					1200					
Leu	Glu	Asp	Gly	Leu	Lys	Leu	Ile	Ala	Ala	Arg	Gly	Arg	Leu	Met		
1205						1210					1215					
Gln	Gly	Leu	Pro	Ala	Gly	Gly	Glu	Met	Val	Ser	Val	Met	Ala	Ser		
1220						1225					1230					
Glu	Ser	Lys	Val	Leu	Glu	Thr	Leu	Lys	Ala	Met	Ser	Leu	Glu	Asp		
1235						1240					1245					
Lys	Val	Ala	Ile	Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Ile	Val	Ile		
1250						1255					1260					
Ser	Gly	Glu	Ala	Glu	Ala	Ile	Arg	Ala	Met	Ala	Thr	His	Leu	Glu		
1265						1270					1275					
Ser	Val	Gly	Ile	Lys	Thr	Lys	Gln	Leu	Gln	Val	Ser	His	Ala	Phe		
1280						1285					1290					
His	Ser	Pro	Leu	Met	Glu	Pro	Met	Leu	Ala	Glu	Phe	Glu	Ala	Val		
1295						1300					1305					
Ala	Asn	Gln	Ile	Thr	Tyr	His	Gln	Pro	Arg	Ile	Pro	Ile	Ile	Ser		
1310						1315					1320					
Asn	Val	Thr	Gly	Thr	Lys	Ala	Asp	Lys	Ser	Ile	Ala	Thr	Ala	Gln		
1325						1330					1335					
Tyr	Trp	Val	Asn	His	Val	Arg	Gln	Pro	Val	Arg	Phe	Ala	Gln	Gly		
1340						1345					1350					
Met	Ala	Thr	Leu	His	Gln	Gln	Gly	Tyr	Glu	Thr	Phe	Leu	Glu	Ile		
1355						1360					1365					
Gly	Ala	Lys	Pro	Ile	Leu	Leu	Gly	Met	Gly	Lys	Gln	Cys	Leu	Ser		
1370						1375					1380					
Pro	Asp	Val	Gly	Val	Trp	Leu	Pro	Ser	Leu	Arg	His	Gly	Val	Asp		
1385						1390					1395					
Glu	Trp	Gln	Gln	Ile	Leu	Ser	Ser	Leu	Gly	Gln	Leu	Tyr	Val	Gln		
1400						1405					1410					
Gly	Ala	Lys	Val	Asp	Trp	Ser	Gly	Phe	Asp	Arg	Asp	Tyr	Ser	Arg		
1415						1420					1425					
Glu	Lys	Val	Val	Leu	Pro	Thr	Tyr	Pro	Phe	Gln	Arg	Glu	Arg	Tyr		
1430						1435					1440					
Trp	Val	Glu	Thr	Ser	Ile	Asn	Gln	Gln	Gln	Val	Val	Cys	Ser	Gly		
1445						1450					1455					
Glu	Pro	Asn	Leu	Gln	Gly	Thr	Pro	Glu	Gly	Thr	Ser	Thr	Thr	Ile		
1460						1465					1470					
Val	Lys	Leu	Leu	Ser	Gln	Gly	Asn	Thr	Lys	Glu	Leu	Ala	Glu	Lys		
1475						1480					1485					
Val	Glu	Lys	Thr	Ser	Asp	Leu	Pro	Pro	Glu	Gln	Leu	Lys	Leu	Leu		
1490						1495					1500					
Pro	Asp	Leu	Leu	Ala	Ser	Leu	Ser	Gln	Gln	His	Gln	Gln	Glu	Leu		
1505						1510					1515					
Ala	Arg	Leu	Thr	Thr	Lys	Lys	Trp	Phe	Tyr	Lys	Val	Gln	Trp	Ile		
1520						1525					1530					
Ser	Gln	Ala	Ile	Lys	Pro	Gln	Arg	Asn	Lys	Ser	Asn	Asn	Gln	Val		
1535						1540					1545					
Cys	His	Trp	Leu	Ile	Leu	Thr	Asp	Ser	Lys	Gly	Leu	Gly	Lys	Ser		
1550						1555					1560					

-continued

Leu	Ala	Thr	His	Leu	Gln	Gln	Leu	Gly	Asn	Glu	Cys	Ser	Val	Val
1565						1570					1575			
Tyr	Gln	Ala	Asp	Asn	Tyr	Gln	Asn	Tyr	Glu	Pro	Gly	Ile	Tyr	His
1580						1585					1590			
Ile	Asn	Pro	Ser	His	Pro	Gln	Glu	Phe	Glu	Gln	Val	Tyr	Gln	Thr
1595						1600					1605			
Ile	Phe	Glu	Asn	Gly	Lys	Leu	Pro	Leu	Gln	Lys	Val	Ile	His	Leu
1610						1615					1620			
Trp	Ser	Leu	Asp	Thr	Ala	Ser	Glu	Gln	Asp	Leu	Thr	Thr	Glu	Thr
1625						1630					1635			
Leu	Glu	Gln	Ala	Gln	Leu	Trp	Gly	Cys	Gly	Ser	Thr	Leu	His	Leu
1640						1645					1650			
Leu	Gln	Thr	Leu	Val	Lys	Asn	Pro	Asn	Ser	Thr	Pro	Pro	Lys	Leu
1655						1660					1665			
Trp	Met	Ile	Thr	Arg	Gly	Thr	Gln	Pro	Val	Leu	Ser	Pro	Thr	Glu
1670						1675					1680			
Lys	Leu	Thr	Val	Ala	Thr	Ser	Pro	Leu	Trp	Gly	Leu	Gly	Arg	Thr
1685						1690					1695			
Ile	Ala	Ser	Glu	His	Pro	Gln	Leu	Trp	Gly	Gly	Leu	Val	Asp	Leu
1700						1705					1710			
Asp	Pro	Gln	Gly	Ser	Glu	Asp	Glu	Val	Glu	Val	Leu	Leu	Gln	Gln
1715						1720					1725			
Ile	Ile	Asp	Ser	Gln	Lys	Glu	Asp	His	Leu	Ala	Val	Arg	Asn	Arg
1730						1735					1740			
Lys	Ile	Tyr	Val	Ala	Arg	Leu	Leu	Lys	His	Ile	Pro	Gln	Glu	Ser
1745						1750					1755			
Gln	Pro	Leu	Ser	Leu	Arg	Ser	Asp	Ala	Thr	Tyr	Leu	Ile	Thr	Gly
1760						1765					1770			
Gly	Leu	Gly	Ala	Leu	Gly	Leu	Lys	Thr	Ala	Ala	Trp	Met	Ala	Glu
1775						1780					1785			
Lys	Gly	Ala	Arg	Asn	Leu	Val	Leu	Ile	Ser	Arg	Arg	Gln	Pro	Ser
1790						1795					1800			
Glu	Gln	Ala	Gln	Gln	Thr	Ile	Gln	Ser	Leu	Glu	Glu	Leu	Gly	Thr
1805						1810					1815			
Gln	Val	Lys	Val	Leu	Ser	Ala	Asp	Ile	Ser	Val	Glu	Ser	Asp	Val
1820						1825					1830			
Ala	Asn	Ile	Leu	Glu	Gln	Ile	Gln	Thr	Ser	Leu	Pro	Pro	Leu	Leu
1835						1840					1845			
Gly	Val	Ile	His	Ala	Ala	Gly	Val	Leu	Asp	Asp	Gly	Leu	Leu	Gln
1850						1855					1860			
Gln	Thr	Asn	Trp	Glu	Arg	Phe	Thr	Lys	Val	Met	Ala	Pro	Lys	Val
1865						1870					1875			
Asn	Gly	Thr	Trp	Asn	Leu	His	Lys	Leu	Thr	Gln	His	Leu	Ser	Leu
1880						1885					1890			
Asp	Phe	Phe	Val	Cys	Phe	Ser	Ser	Met	Ser	Ser	Leu	Leu	Gly	Ser
1895						1900					1905			
Pro	Gly	Gln	Gly	Asn	Tyr	Ala	Ala	Ala	Asn	Ala	Phe	Met	Asp	Ala
1910						1915					1920			
Val	Val	His	Tyr	Arg	Arg	Glu	Met	Gly	Leu	Pro	Gly	Leu	Ser	Ile
1925						1930					1935			
Asn	Trp	Gly	Gly	Trp	Ser	Glu	Gly	Gly	Met	Ala	Thr	Arg	Leu	Ala
1940						1945					1950			

-continued

Ser	Gln	His	Gln	Asn	Arg	Met	Gln	Thr	Ala	Gly	Ile	Ser	Leu	Ile
1955						1960					1965			
Ser	Pro	Glu	Gln	Gly	Ile	Gln	Val	Leu	Glu	Glu	Leu	Val	Arg	Thr
1970						1975					1980			
Gln	Ser	Thr	Ala	Gln	Val	Gly	Val	Leu	Pro	Val	Asp	Trp	Ser	Val
1985						1990					1995			
Leu	Ala	Lys	Gln	Phe	Ser	Ser	Ala	Asn	Pro	Ser	Ser	Leu	Leu	Leu
2000						2005					2010			
Glu	Leu	Leu	Gln	Gln	Glu	Thr	Ser	Ser	Glu	Lys	Thr	Asp	Glu	Arg
2015						2020					2025			
Ile	Leu	Glu	Lys	Leu	Gln	Ala	Ala	Pro	Ile	Thr	Glu	Arg	Gln	Asp
2030						2035					2040			
Ile	Leu	Lys	Asn	Tyr	Ile	Gln	Leu	Val	Val	Ala	Lys	Thr	Leu	Gly
2045						2050					2055			
Ile	Asn	Pro	Ser	Lys	Ile	Ser	Thr	Asp	Asp	Asn	Phe	Val	Glu	Leu
2060						2065					2070			
Gly	Met	Asp	Ser	Leu	Met	Gly	Met	Glu	Val	Val	Asn	Lys	Leu	Ser
2075						2080					2085			
Gly	Asp	Leu	Asp	Phe	Ile	Ile	Tyr	Pro	Arg	Glu	Phe	Tyr	Glu	Arg
2090						2095					2100			
Pro	Thr	Ile	Asp	Ser	Leu	Thr	Gln	Tyr	Leu	Ser	Ala	Glu	Leu	Ser
2105						2110					2115			
Glu	Asp	Asn	Leu	Ala	Thr	Gln	Pro	Ser	Pro	Thr	Ser	Leu	Glu	Ile
2120						2125					2130			
Phe	Ala	Thr	Lys	Ser	Ser	Pro	Ser	Gly	Asn	Ser	Ala	Arg	Pro	Ala
2135						2140					2145			
Ser	Val	Ser	Ser	Arg	Leu	Pro	Gly	Ile	Ile	Phe	Ile	Leu	Ser	Ser
2150						2155					2160			
Pro	Arg	Ser	Gly	Ser	Thr	Leu	Leu	Arg	Val	Met	Leu	Ala	Gly	His
2165						2170					2175			
Ser	Ser	Leu	Phe	Ser	Pro	Pro	Glu	Leu	His	Leu	Leu	Pro	Phe	Asn
2180						2185					2190			
Thr	Met	Lys	Glu	Arg	Gln	Glu	Gln	Leu	Asn	Leu	Ser	Tyr	Leu	Gly
2195						2200					2205			
Glu	Gly	Leu	Gln	Lys	Thr	Phe	Met	Glu	Val	Lys	Asn	Leu	Asp	Ala
2210						2215					2220			
Thr	Ala	Ser	Gln	Ala	Leu	Ile	Lys	Asp	Leu	Glu	Ser	Gln	Asn	Leu
2225						2230					2235			
Ser	Ile	Gln	Gln	Val	Tyr	Gly	Met	Leu	Gln	Glu	Asn	Ile	Ala	Pro
2240						2245					2250			
Arg	Leu	Leu	Val	Asp	Lys	Ser	Pro	Thr	Tyr	Ala	Met	Glu	Pro	Thr
2255						2260					2265			
Ile	Leu	Glu	Arg	Gly	Glu	Ala	Leu	Phe	Ala	Asn	Ser	Lys	Tyr	Ile
2270						2275					2280			
Tyr	Leu	Val	Arg	His	Pro	Tyr	Ser	Val	Ile	Glu	Ser	Phe	Val	Arg
2285						2290					2295			
Met	Arg	Met	Gln	Lys	Leu	Val	Gly	Leu	Gly	Glu	Glu	Asn	Pro	Tyr
2300						2305					2310			
Arg	Val	Ala	Glu	Gln	Val	Trp	Ala	Lys	Ser	Asn	Gln	Asn	Ile	Leu
2315						2320					2325			
Asn	Phe	Leu	Ser	Gln	Leu	Glu	Pro	Glu	Arg	Gln	His	Gln	Ile	Arg

-continued

Leu Ser Gly Gly His Asn Leu His Ile Asp Ala Ala Ala Ala Leu
2720 2725 2730

Ala Ser Leu Ile Leu Thr Ser
2735 2740

<210> SEQ ID NO 6

<211> LENGTH: 3191

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Hybrid polyketide synthase capable of producing propene

<400> SEQUENCE: 6

Met Ala Gly His Gly Asp Ala Thr Ala Gln Lys Ala Gln Asp Ala Glu
1 5 10 15

Lys Ser Glu Asp Gly Ser Asp Ala Ile Ala Val Ile Gly Met Ser Cys
20 25 30

Arg Phe Pro Gly Ala Pro Gly Thr Ala Glu Phe Trp Gln Leu Leu Ser
35 40 45

Ser Gly Ala Asp Ala Val Val Thr Ala Ala Asp Gly Arg Arg Arg Gly
50 55 60

Thr Ile Asp Ala Pro Ala Asp Phe Asp Ala Ala Phe Phe Gly Met Ser
65 70 75 80

Pro Arg Glu Ala Ala Ala Thr Asp Pro Gln Gln Arg Leu Val Leu Glu
85 90 95

Leu Gly Trp Glu Ala Leu Glu Asp Ala Gly Ile Val Pro Glu Ser Leu
100 105 110

Arg Gly Glu Ala Ala Ser Val Phe Val Gly Ala Met Asn Asp Asp Tyr
115 120 125

Ala Thr Leu Leu His Arg Ala Gly Ala Pro Thr Asp Thr Tyr Thr Ala
130 135 140

Thr Gly Leu Gln His Ser Met Ile Ala Asn Arg Leu Ser Tyr Phe Leu
145 150 155 160

Gly Leu Arg Gly Pro Ser Leu Val Val Asp Thr Gly Gln Ser Ser Ser
165 170 175

Leu Val Ala Val Ala Leu Ala Val Glu Ser Leu Arg Gly Gly Thr Ser
180 185 190

Gly Ile Ala Leu Ala Gly Gly Val Asn Leu Val Leu Ala Glu Glu Gly
195 200 205

Ser Ala Ala Met Glu Arg Val Gly Ala Leu Ser Pro Asp Gly Arg Cys
210 215 220

His Thr Phe Asp Ala Arg Ala Asn Gly Tyr Val Arg Gly Glu Gly Gly
225 230 235 240

Ala Ile Val Val Leu Lys Pro Leu Ala Asp Ala Leu Ala Asp Gly Asp
245 250 255

Arg Val Tyr Cys Val Val Arg Gly Val Ala Thr Gly Asn Asp Gly Gly
260 265 270

Gly Pro Gly Leu Thr Val Pro Asp Arg Ala Gly Gln Glu Ala Val Leu
275 280 285

Arg Ala Ala Cys Asp Gln Ala Gly Val Arg Pro Ala Asp Val Arg Phe
290 295 300

Val Glu Leu His Gly Thr Gly Thr Pro Ala Gly Asp Pro Val Glu Ala
305 310 315 320

-continued

Gly Ala Phe Arg Asp Thr Leu Asn Thr Leu Asn Tyr Gln Pro Pro Thr
 740 745 750
 Ile Pro Leu Ile Ser Asn Leu Thr Gly Gln Ile Ala Asp Pro Asn His
 755 760 765
 Leu Cys Thr Pro Asp Tyr Trp Ile Asp His Ala Arg His Thr Val Arg
 770 775 780
 Phe Ala Asp Ala Val Gln Thr Ala His His Gln Gly Thr Thr Thr Tyr
 785 790 795 800
 Leu Glu Ile Gly Pro His Pro Thr Leu Thr Thr Leu Leu His His Thr
 805 810 815
 Leu Asp Asn Pro Thr Thr Ile Pro Thr Leu His Arg Glu Arg Pro Glu
 820 825 830
 Pro Glu Thr Leu Thr Gln Ala Ile Ala Ala Val Gly Val Arg Thr Asp
 835 840 845
 Gly Ile Asp Trp Ala Val Leu Cys Gly Ala Ser Arg Pro Arg Arg Val
 850 855 860
 Glu Leu Pro Thr Tyr Ala Phe Gln Arg Arg Thr His Trp Ala Pro Gly
 865 870 875 880
 Leu Thr Pro Asn His Ala Pro Ala Asp Arg Pro Ala Ala Glu Pro Gln
 885 890 895
 Arg Ala Met Ala Val Gly Pro Val Ser Arg Glu Ala Leu Val Arg Leu
 900 905 910
 Val Gly Glu Thr Thr Ala Ser Val Leu Gly Leu Asp Gly Pro Asp Glu
 915 920 925
 Val Ala Leu Asp Arg Pro Phe Thr Ser Gln Gly Leu Asp Ser Met Thr
 930 935 940
 Ala Val Glu Leu Ala Gly Leu Leu Gly Thr Ala Ala Gly Val Ala Leu
 945 950 955 960
 Asp Pro Thr Leu Val Tyr Glu Leu Pro Thr Pro Arg Ala Val Ala Asp
 965 970 975
 His Leu Ala Lys Thr Leu Leu Gly Glu Ser Ala Ala Asp Ala Asp Gln
 980 985 990
 Glu Val Asn Gly Arg Thr Gly Glu Ala Glu Ala Lys Ala Gly Asp Pro
 995 1000 1005
 Ile Ala Val Ile Gly Ile Gly Cys Arg Phe Pro Gly Gly Val Ala
 1010 1015 1020
 Thr Pro Asp Asp Leu Trp Glu Leu Val Ala Ser Gly Thr Asp Ala
 1025 1030 1035
 Ile Ser Thr Phe Pro Thr Asp Arg Gly Trp Asp Leu Asp Gly Leu
 1040 1045 1050
 Tyr Asp Pro Asp Pro Ser Thr Pro Gly Lys Ser Tyr Val Arg His
 1055 1060 1065
 Gly Gly Phe Leu His Asp Ala Ala Gln Phe Asp Ala Glu Phe Phe
 1070 1075 1080
 Gly Ile Ser Pro Arg Glu Ala Thr Ala Met Asp Pro Gln Gln Arg
 1085 1090 1095
 Leu Leu Leu Glu Thr Ser Trp Glu Ala Leu Glu Arg Ala Gly Val
 1100 1105 1110
 Val Pro Glu Ser Leu Arg Gly Gly Arg Thr Gly Val Phe Val Gly
 1115 1120 1125
 Thr Thr Ala Pro Glu Tyr Gly Pro Arg Leu His Glu Gly Thr Asp

-continued

Arg	Gln	His	Thr	Ala	Gly	Glu	Glu	Val	Val	Gly	Val	Phe	Ser	Gly
1520						1525					1530			
Lys	Val	Pro	Asn	Ser	Gly	Ser	Glu	Ser	Lys	Val	Ala	Phe	Leu	Phe
1535						1540					1545			
Thr	Gly	Gln	Gly	Ser	Gln	Tyr	Leu	Asn	Met	Gly	Arg	Gln	Leu	Tyr
1550						1555					1560			
Glu	Thr	Gln	Pro	Thr	Phe	Arg	Gln	Ala	Leu	Asp	Thr	Cys	Asp	His
1565						1570					1575			
Ile	Leu	Arg	Pro	Tyr	Leu	Asp	Asn	Pro	Leu	Leu	Glu	Ile	Leu	Tyr
1580						1585					1590			
Pro	Gln	Asp	Ala	Gln	Lys	Ser	Asn	Asp	Ser	Pro	Leu	Asp	Gln	Thr
1595						1600					1605			
Gly	Tyr	Thr	Gln	Pro	Ala	Leu	Phe	Ser	Ile	Glu	Tyr	Ala	Leu	Leu
1610						1615					1620			
Lys	Leu	Trp	Glu	Ser	Trp	Gly	Ile	Lys	Pro	Asn	Val	Val	Met	Gly
1625						1630					1635			
His	Ser	Val	Gly	Glu	Tyr	Val	Ala	Ala	Thr	Val	Ala	Gly	Val	Phe
1640						1645					1650			
Ser	Leu	Glu	Asp	Gly	Leu	Lys	Leu	Ile	Ala	Ala	Arg	Gly	Arg	Leu
1655						1660					1665			
Met	Gln	Gly	Leu	Pro	Ala	Gly	Gly	Glu	Met	Val	Ser	Val	Met	Ala
1670						1675					1680			
Ser	Glu	Ser	Lys	Val	Leu	Glu	Thr	Leu	Lys	Ala	Met	Ser	Leu	Glu
1685						1690					1695			
Asp	Lys	Val	Ala	Ile	Ala	Ala	Ile	Asn	Gly	Pro	Glu	Ser	Ile	Val
1700						1705					1710			
Ile	Ser	Gly	Glu	Ala	Glu	Ala	Ile	Arg	Ala	Met	Ala	Thr	His	Leu
1715						1720					1725			
Glu	Ser	Val	Gly	Ile	Lys	Thr	Lys	Gln	Leu	Gln	Val	Ser	His	Ala
1730						1735					1740			
Phe	His	Ser	Pro	Leu	Met	Glu	Pro	Met	Leu	Ala	Glu	Phe	Glu	Ala
1745						1750					1755			
Val	Ala	Asn	Gln	Ile	Thr	Tyr	His	Gln	Pro	Arg	Ile	Pro	Ile	Ile
1760						1765					1770			
Ser	Asn	Val	Thr	Gly	Thr	Lys	Ala	Asp	Lys	Ser	Ile	Ala	Thr	Ala
1775						1780					1785			
Gln	Tyr	Trp	Val	Asn	His	Val	Arg	Gln	Pro	Val	Arg	Phe	Ala	Gln
1790						1795					1800			
Gly	Met	Ala	Thr	Leu	His	Gln	Gln	Gly	Tyr	Glu	Thr	Phe	Leu	Glu
1805						1810					1815			
Ile	Gly	Ala	Lys	Pro	Ile	Leu	Leu	Gly	Met	Gly	Lys	Gln	Cys	Leu
1820						1825					1830			
Ser	Pro	Asp	Val	Gly	Val	Trp	Leu	Pro	Ser	Leu	Arg	His	Gly	Val
1835						1840					1845			
Asp	Glu	Trp	Gln	Gln	Ile	Leu	Ser	Ser	Leu	Gly	Gln	Leu	Tyr	Val
1850						1855					1860			
Gln	Gly	Ala	Lys	Val	Asp	Trp	Ser	Gly	Phe	Asp	Arg	Asp	Tyr	Ser
1865						1870					1875			
Arg	Glu	Lys	Val	Val	Leu	Pro	Thr	Tyr	Pro	Phe	Gln	Arg	Glu	Arg
1880						1885					1890			
Tyr	Trp	Val	Glu	Thr	Ser	Ile	Asn	Gln	Gln	Gln	Val	Val	Cys	Ser
1895						1900					1905			

-continued

Gly	Glu	Pro	Asn	Leu	Gln	Gly	Thr	Pro	Glu	Gly	Thr	Ser	Thr	Thr
1910						1915					1920			
Ile	Val	Lys	Leu	Leu	Ser	Gln	Gly	Asn	Thr	Lys	Glu	Leu	Ala	Glu
1925						1930					1935			
Lys	Val	Glu	Lys	Thr	Ser	Asp	Leu	Pro	Pro	Glu	Gln	Leu	Lys	Leu
1940						1945					1950			
Leu	Pro	Asp	Leu	Leu	Ala	Ser	Leu	Ser	Gln	Gln	His	Gln	Gln	Glu
1955						1960					1965			
Leu	Ala	Arg	Leu	Thr	Thr	Lys	Lys	Trp	Phe	Tyr	Lys	Val	Gln	Trp
1970						1975					1980			
Ile	Ser	Gln	Ala	Ile	Lys	Pro	Gln	Arg	Asn	Lys	Ser	Asn	Asn	Gln
1985						1990					1995			
Val	Cys	His	Trp	Leu	Ile	Leu	Thr	Asp	Ser	Lys	Gly	Leu	Gly	Lys
2000						2005					2010			
Ser	Leu	Ala	Thr	His	Leu	Gln	Gln	Leu	Gly	Asn	Glu	Cys	Ser	Val
2015						2020					2025			
Val	Tyr	Gln	Ala	Asp	Asn	Tyr	Gln	Asn	Tyr	Glu	Pro	Gly	Ile	Tyr
2030						2035					2040			
His	Ile	Asn	Pro	Ser	His	Pro	Gln	Glu	Phe	Glu	Gln	Val	Tyr	Gln
2045						2050					2055			
Thr	Ile	Phe	Glu	Asn	Gly	Lys	Leu	Pro	Leu	Gln	Lys	Val	Ile	His
2060						2065					2070			
Leu	Trp	Ser	Leu	Asp	Thr	Ala	Ser	Glu	Gln	Asp	Leu	Thr	Thr	Glu
2075						2080					2085			
Thr	Leu	Glu	Gln	Ala	Gln	Leu	Trp	Gly	Cys	Gly	Ser	Thr	Leu	His
2090						2095					2100			
Leu	Leu	Gln	Thr	Leu	Val	Lys	Asn	Pro	Asn	Ser	Thr	Pro	Pro	Lys
2105						2110					2115			
Leu	Trp	Met	Ile	Thr	Arg	Gly	Thr	Gln	Pro	Val	Leu	Ser	Pro	Thr
2120						2125					2130			
Glu	Lys	Leu	Thr	Val	Ala	Thr	Ser	Pro	Leu	Trp	Gly	Leu	Gly	Arg
2135						2140					2145			
Thr	Ile	Ala	Ser	Glu	His	Pro	Gln	Leu	Trp	Gly	Gly	Leu	Val	Asp
2150						2155					2160			
Leu	Asp	Pro	Gln	Gly	Ser	Glu	Asp	Glu	Val	Glu	Val	Leu	Leu	Gln
2165						2170					2175			
Gln	Ile	Ile	Asp	Ser	Gln	Lys	Glu	Asp	His	Leu	Ala	Val	Arg	Asn
2180						2185					2190			
Arg	Lys	Ile	Tyr	Val	Ala	Arg	Leu	Leu	Lys	His	Ile	Pro	Gln	Glu
2195						2200					2205			
Ser	Gln	Pro	Leu	Ser	Leu	Arg	Ser	Asp	Ala	Thr	Tyr	Leu	Ile	Thr
2210						2215					2220			
Gly	Gly	Leu	Gly	Ala	Leu	Gly	Leu	Lys	Thr	Ala	Ala	Trp	Met	Ala
2225						2230					2235			
Glu	Lys	Gly	Ala	Arg	Asn	Leu	Val	Leu	Ile	Ser	Arg	Arg	Gln	Pro
2240						2245					2250			
Ser	Glu	Gln	Ala	Gln	Gln	Thr	Ile	Gln	Ser	Leu	Glu	Glu	Leu	Gly
2255						2260					2265			
Thr	Gln	Val	Lys	Val	Leu	Ser	Ala	Asp	Ile	Ser	Val	Glu	Ser	Asp
2270						2275					2280			
Val	Ala	Asn	Ile	Leu	Glu	Gln	Ile	Gln	Thr	Ser	Leu	Pro	Pro	Leu

-continued

Ile Phe Pro Asp Val Ala Thr Ala Ala Ser Arg Leu Arg Gln Ala
 3065 3070 3075

Ile Pro Ser Leu Ser Glu Glu Phe Ser Tyr Ile Leu Ala Gln Arg
 3080 3085 3090

Ile Thr Gln Pro Asn Gln Gly Gly Val Arg Trp Ser Trp Asp Ala
 3095 3100 3105

Ile Ile Arg Thr Arg Ser Ile Leu Gly Leu Asn Asn Leu Pro Gly
 3110 3115 3120

Gly Arg Ser Gln Tyr Leu Glu Met Leu Lys Ser Ile Gln Val Pro
 3125 3130 3135

Thr Thr Leu Val Tyr Gly Asp Ser Ser Lys Leu Asn Arg Pro Glu
 3140 3145 3150

Asp Leu Gln Gln Gln Lys Met Thr Met Thr Gln Ala Lys Arg Val
 3155 3160 3165

Phe Leu Ser Gly Gly His Asn Leu His Ile Asp Ala Ala Ala Ala
 3170 3175 3180

Leu Ala Ser Leu Ile Leu Thr Ser
 3185 3190

<210> SEQ ID NO 7
 <211> LENGTH: 2688
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Hybrid polyketide synthase capable of producing
 styrene

<400> SEQUENCE: 7

Met Thr Lys Glu Tyr Thr Arg Pro Gln Ser Ala Pro Leu Thr Glu Gly
 1 5 10 15

Asp Leu Leu Thr Leu Ile Val Ala His Leu Ala Glu Arg Leu Arg Met
 20 25 30

Asp Ala Arg Phe Ile Asp Val His Glu Pro Phe Ser Arg His Gly Leu
 35 40 45

Asp Ser Arg Gly Ala Val Asp Leu Val Val Asp Leu Arg Thr Ala Leu
 50 55 60

Gly Arg Pro Leu Ser Pro Val Val Val Trp Gln His Pro Thr Pro Asp
 65 70 75 80

Ala Leu Ala Arg His Leu Ala Gly Gly Ala Asp Ala Arg Glu Gly Gln
 85 90 95

Ala Arg Ala Asp Ser Ala Tyr Glu Arg Pro Gly Ala Pro Asn Glu Pro
 100 105 110

Ile Ala Ile Val Gly Met Ala Cys Arg Phe Pro Gly Ala Pro Asp Val
 115 120 125

Asp Ser Tyr Trp Arg Leu Leu Ser Gly Gly Val Asp Ala Val Thr Glu
 130 135 140

Val Pro Ala Gly Arg Trp Asp Met Asp Ala Phe Tyr Asp Arg Asp Pro
 145 150 155 160

Arg Ser Leu Gly Asp Val Ser Thr Leu Arg Gly Gly Phe Ile Asp Asp
 165 170 175

Val Asp Arg Phe Asp Ala Met Phe Phe Gly Ile Ser Pro Arg Glu Ala
 180 185 190

Val Ser Met Asp Pro Gln Gln Arg Leu Met Leu Glu Leu Ala Trp Glu
 195 200 205

-continued

Ala Leu Glu Asp Ala Gly Ile Val Ala Glu Arg Leu Lys Glu Ser Leu
210 215 220

Thr Gly Val Phe Phe Gly Cys Ile Trp Asp Asp Tyr Val Thr Leu Ile
225 230 235 240

His Gln Arg Gly Arg Gly Ala Ile Ala Gln His Thr Val Thr Gly Asn
245 250 255

His Arg Ser Ile Ile Ala Asn Arg Val Ser Tyr Thr Leu Asp Leu Arg
260 265 270

Gly Pro Ser Met Thr Val Asp Ser Ala Cys Ser Ser Ala Leu Val Thr
275 280 285

Ile His Met Ala Cys Glu Ser Leu Arg Ser Gly Glu Ser Thr Leu Ala
290 295 300

Leu Ala Gly Gly Val Asn Leu Asn Ile Ala Pro Glu Ser Thr Ile Gly
305 310 315 320

Val His Lys Phe Gly Gly Leu Ser Pro Asp Gly Arg Cys Phe Thr Phe
325 330 335

Asp Ala Arg Ala Asn Gly Tyr Val Arg Gly Glu Gly Gly Val Val
340 345 350

Val Leu Lys Arg Leu Ser Ser Ala Ile Ala Asp Gly Asp Pro Ile Ile
355 360 365

Cys Val Ile Arg Gly Ser Ala Val Asn Asn Asp Gly Ala Ser Asn Gly
370 375 380

Leu Thr Gly Pro Asn Pro Leu Ala Gln Glu Ala Val Leu Arg Thr Ala
385 390 395 400

Tyr Glu Arg Ala Gly Val Asn Pro Ala Asp Val Gln Tyr Val Glu Leu
405 410 415

His Gly Thr Gly Thr Gln Leu Gly Asp Pro Val Glu Ala Ser Ala Leu
420 425 430

Gly Ala Val Leu Gly Lys Arg Arg Pro Ala Glu Arg Pro Leu Leu Val
435 440 445

Gly Ser Ala Lys Thr Asn Val Gly His Leu Glu Gly Ala Ala Gly Ile
450 455 460

Val Gly Leu Leu Lys Ala Ala Leu Cys Leu Lys His Lys Gln Leu Ala
465 470 475 480

Pro Asn Leu Asn Phe Glu Thr Pro Asn Pro His Ile Pro Phe Ala Glu
485 490 495

Leu Asn Leu Lys Val Gln Gly Ala Leu Gly Pro Trp Pro Asp Met Asp
500 505 510

Arg Pro Leu Val Cys Gly Val Ser Ser Phe Gly Leu Gly Gly Thr Asn
515 520 525

Ala His Val Val Leu Ser Glu Trp Ala Ser Leu Glu Ala Glu Leu His
530 535 540

Pro Leu Ala Ala Glu Ser Pro Glu Ala Leu Arg Glu Glu Val Gln Arg
545 550 555 560

Arg Leu Leu Thr Met Thr Ser Leu Val Gly Arg Ala Pro Leu Ser Phe
565 570 575

Leu Cys Gly Arg Ser Ala Ala Gln Arg Ser Ala Lys Glu His Arg Leu
580 585 590

Ala Val Thr Ala Arg Ser Phe Glu Glu Leu Lys Gln Arg Leu Leu Gly
595 600 605

Phe Leu Glu His Glu Lys His Val Ser Val Ser Ala Gly Arg Val Asp

-continued

610			615			620									
Leu	Gly	Ala	Ala	Pro	Lys	Val	Val	Phe	Val	Phe	Ala	Gly	Gln	Gly	Ala
625					630					635					640
Gln	Trp	Phe	Gly	Met	Gly	Arg	Ala	Leu	Leu	Gln	Arg	Glu	Pro	Val	Phe
			645						650						655
Arg	Thr	Thr	Ile	Glu	Gln	Cys	Ser	Ser	Phe	Ile	Gln	Gln	Asn	Leu	Gly
			660					665					670		
Trp	Ser	Leu	Leu	Asp	Glu	Leu	Met	Thr	Asp	Arg	Glu	Ser	Ser	Arg	Leu
		675					680					685			
Asp	Glu	Ile	Asp	Val	Ser	Leu	Pro	Ala	Ile	Ile	Ser	Ile	Glu	Ile	Ala
690						695					700				
Leu	Ala	Ala	Gln	Trp	Arg	Ala	Trp	Gly	Val	Glu	Pro	Ala	Phe	Val	Val
705					710					715					720
Gly	His	Ser	Thr	Gly	Glu	Ile	Ala	Ala	Ala	His	Val	Ala	Gly	Val	Leu
				725					730					735	
Ser	Ile	Glu	Asp	Ala	Met	Arg	Thr	Ile	Cys	Ala	Tyr	Gly	Arg	Ile	Ile
			740					745					750		
Arg	Lys	Leu	Arg	Gly	Lys	Gly	Gly	Met	Gly	Leu	Val	Ala	Leu	Ser	Trp
		755					760					765			
Glu	Asp	Ala	Gly	Lys	Glu	Leu	Thr	Gly	Tyr	Glu	Gly	Arg	Leu	Phe	Arg
770						775					780				
Ala	Ile	Glu	His	Ser	Ala	Asp	Ser	Thr	Val	Leu	Ala	Gly	Glu	Pro	Asp
785					790					795					800
Ala	Leu	Asp	Ala	Leu	Leu	Gln	Ala	Leu	Glu	Arg	Lys	Asn	Val	Phe	Cys
			805						810					815	
Arg	Arg	Val	Ala	Met	Asp	Val	Ala	Pro	His	Cys	Pro	Gln	Val	Asp	Cys
			820					825					830		
Leu	Arg	Asp	Glu	Leu	Phe	Asp	Ala	Leu	Arg	Glu	Val	Arg	Pro	Asn	Lys
		835					840					845			
Ala	Gln	Ile	Pro	Ile	Val	Ser	Glu	Val	Thr	Gly	Thr	Ala	Leu	Asp	Gly
		850					855				860				
Glu	Arg	Phe	Asp	Ala	Ser	His	Trp	Val	Arg	Asn	Phe	Gly	Asp	Pro	Ala
865					870					875				880	
Leu	Phe	Ser	Thr	Ala	Ile	Asp	His	Leu	Leu	Gln	Glu	Gly	Phe	Asp	Ile
			885						890					895	
Phe	Leu	Glu	Leu	Thr	Pro	His	Pro	Leu	Ala	Leu	Pro	Ala	Ile	Glu	Ser
			900					905					910		
Asn	Leu	Arg	Arg	Ser	Gly	Arg	Arg	Gly	Val	Val	Leu	Pro	Ser	Leu	Arg
		915					920					925			
Arg	Asn	Glu	Asp	Glu	Arg	Gly	Val	Met	Leu	Asp	Thr	Leu	Gly	Val	Leu
930					935						940				
Tyr	Val	Arg	Gly	Ala	Pro	Val	Arg	Trp	Asp	Asn	Val	Tyr	Pro	Ala	Ala
945					950					955					960
Phe	Glu	Ser	Met	Pro	Leu	Pro	Ser	Thr	Ala	Gly	Gly	Gly	Lys	Pro	Leu
			965						970					975	
Pro	Pro	Met	Pro	Leu	Leu	Ile	Ser	Ala	Arg	Thr	Asp	Ala	Ala	Leu	Ala
			980					985					990		
Ala	Gln	Ala	Ala	Arg	Leu	Arg	Ala	His	Leu	Asp	Ser	His	Leu	Asp	Leu
		995					1000					1005			
Glu	Leu	Val	Asp	Val	Ala	Tyr	Ser	Leu	Ala	Ala	Thr	Arg	Thr	His	
1010						1015					1020				

-continued

Phe	Glu	Arg	Arg	Ala	Val	Val	Val	Ala	Arg	Asp	Arg	Ala	Gly	Ile
1025						1030					1035			
Leu	Asp	Gly	Leu	Asp	Ala	Leu	Ala	His	Gly	Gly	Ser	Ala	Ala	Leu
1040						1045					1050			
Leu	Gly	Arg	Ser	Ala	Ala	His	Gly	Lys	Leu	Ala	Ile	Leu	Phe	Thr
1055						1060					1065			
Gly	Gln	Gly	Ser	Gln	Arg	Pro	Thr	Met	Gly	Arg	Ala	Leu	Tyr	Asp
1070						1075					1080			
Ala	Phe	Pro	Val	Phe	Arg	Gly	Ala	Leu	Asp	Ala	Ala	Ala	Ala	His
1085						1090					1095			
Leu	Asp	Arg	Asp	Leu	Asp	Arg	Pro	Leu	Arg	Asp	Val	Leu	Phe	Ala
1100						1105					1110			
Pro	Asp	Gly	Ser	Glu	Gln	Ala	Ala	Arg	Leu	Asp	Gln	Thr	Ala	Phe
1115						1120					1125			
Thr	Gln	Pro	Ala	Leu	Phe	Ala	Leu	Glu	Val	Ala	Leu	Phe	Glu	Leu
1130						1135					1140			
Leu	Gln	Ser	Phe	Gly	Leu	Lys	Pro	Ala	Leu	Leu	Leu	Gly	His	Ser
1145						1150					1155			
Ile	Gly	Glu	Leu	Val	Ala	Ala	His	Val	Ala	Gly	Val	Leu	Ser	Leu
1160						1165					1170			
Gln	Asp	Ala	Cys	Thr	Leu	Val	Ala	Ala	Arg	Ala	Lys	Leu	Met	Gln
1175						1180					1185			
Ala	Leu	Pro	Gln	Gly	Gly	Ala	Met	Val	Thr	Leu	Gln	Ala	Ser	Glu
1190						1195					1200			
Gln	Glu	Ala	Arg	Asp	Leu	Leu	Gln	Ala	Ala	Glu	Gly	Arg	Val	Ser
1205						1210					1215			
Leu	Ala	Ala	Val	Asn	Gly	His	Leu	Ser	Thr	Val	Val	Ala	Gly	Asp
1220						1225					1230			
Glu	Asp	Ala	Val	Leu	Lys	Ile	Ala	Arg	Gln	Val	Glu	Ala	Leu	Gly
1235						1240					1245			
Arg	Lys	Ala	Thr	Arg	Leu	Arg	Val	Ser	His	Ala	Phe	His	Ser	Pro
1250						1255					1260			
His	Met	Asp	Gly	Met	Leu	Asp	Asp	Phe	Arg	Arg	Val	Ala	Gln	Gly
1265						1270					1275			
Leu	Thr	Phe	His	Pro	Ala	Arg	Ile	Pro	Ile	Ile	Ser	Asn	Val	Thr
1280						1285					1290			
Gly	Ala	Arg	Ala	Thr	Asp	Gln	Glu	Leu	Ala	Ser	Pro	Glu	Thr	Trp
1295						1300					1305			
Val	Arg	His	Val	Arg	Asp	Thr	Val	Arg	Phe	Leu	Asp	Gly	Val	Arg
1310						1315					1320			
Thr	Leu	His	Ala	Glu	Gly	Ala	Arg	Ala	Phe	Leu	Glu	Leu	Gly	Pro
1325						1330					1335			
His	Pro	Val	Leu	Ser	Ala	Leu	Ala	Gln	Asp	Ala	Leu	Gly	His	Asp
1340						1345					1350			
Glu	Gly	Pro	Ser	Pro	Cys	Ala	Phe	Leu	Pro	Thr	Leu	Arg	Lys	Gly
1355						1360					1365			
Arg	Asp	Asp	Ala	Glu	Ala	Phe	Thr	Ala	Ala	Leu	Gly	Ala	Leu	His
1370						1375					1380			
Ala	Ala	Gly	Leu	Thr	Pro	Asp	Trp	Asn	Ala	Phe	Phe	Ala	Pro	Phe
1385						1390					1395			
Ala	Pro	Cys	Lys	Val	Pro	Leu	Pro	Thr	Tyr	Thr	Phe	Gln	Arg	Glu
1400						1405					1410			

-continued

1790						1795								1800
Ile	Gly	Asp	Met	Thr	Pro	Glu	Arg	Ile	Glu	Arg	Val	Leu	Ala	Pro
1805						1810					1815			
Lys	Leu	Asp	Ser	Ala	Leu	His	Leu	His	Glu	Leu	Thr	Lys	Asn	Ser
1820						1825					1830			
Ala	Leu	Asp	Ala	Phe	Val	Leu	Tyr	Ala	Ser	Leu	Ser	Gly	Val	Leu
1835						1840					1845			
Gly	Asn	Pro	Gly	Gln	Ala	Asn	Tyr	Ala	Ala	Ala	Asn	Ala	Phe	Leu
1850						1855					1860			
Asp	Ala	Leu	Ala	Glu	His	Arg	Arg	Ser	Leu	Gly	Leu	Thr	Ala	Thr
1865						1870					1875			
Ser	Val	Ala	Trp	Gly	Gly	Trp	Gly	Gly	Gly	Gly	Met	Ala	Thr	Glu
1880						1885					1890			
Arg	Val	Ala	Ala	Gln	Leu	Gln	Gln	Arg	Gly	Leu	Leu	Gln	Met	Ala
1895						1900					1905			
Pro	Ser	Leu	Ala	Leu	Ala	Ala	Leu	Ala	Gln	Ala	Leu	Gln	Gln	Asp
1910						1915					1920			
Glu	Thr	Thr	Ile	Thr	Val	Ala	Asp	Ile	Asp	Trp	Ser	Arg	Phe	Ala
1925						1930					1935			
Pro	Ala	Phe	Ser	Val	Ala	Arg	Gln	Arg	Pro	Leu	Leu	Arg	Asp	Leu
1940						1945					1950			
Pro	Glu	Ala	Gln	Arg	Ala	Leu	Gln	Ala	Ser	Glu	Gly	Ala	Ser	Ser
1955						1960					1965			
Glu	His	Gly	Pro	Ala	Thr	Gly	Leu	Leu	Asp	Glu	Leu	Arg	Ser	Arg
1970						1975					1980			
Ser	Glu	Ser	Glu	Gln	Leu	Asp	Leu	Leu	Ala	Thr	Leu	Val	Arg	Gly
1985						1990					1995			
Glu	Thr	Ala	Thr	Val	Leu	Gly	His	Ala	Glu	Ala	Ser	His	Val	Asp
2000						2005					2010			
Pro	Asp	Lys	Gly	Phe	Met	Asp	Leu	Gly	Leu	Asp	Ser	Leu	Met	Thr
2015						2020					2025			
Val	Glu	Leu	Arg	Arg	Arg	Leu	Gln	Lys	Ala	Thr	Gly	Val	Lys	Leu
2030						2035					2040			
Pro	Pro	Thr	Leu	Ala	Phe	Asp	His	Pro	Ser	Pro	His	Arg	Val	Ala
2045						2050					2055			
Phe	Phe	Leu	Arg	Asp	Ser	Leu	Ser	Glu	Asp	Asn	Leu	Ala	Thr	Gln
2060						2065					2070			
Pro	Ser	Pro	Thr	Ser	Leu	Glu	Ile	Phe	Ala	Thr	Lys	Ser	Ser	Pro
2075						2080					2085			
Ser	Gly	Asn	Ser	Ala	Arg	Pro	Ala	Ser	Val	Ser	Ser	Arg	Leu	Pro
2090						2095					2100			
Gly	Ile	Ile	Phe	Ile	Leu	Ser	Ser	Pro	Arg	Ser	Gly	Ser	Thr	Leu
2105						2110					2115			
Leu	Arg	Val	Met	Leu	Ala	Gly	His	Ser	Ser	Leu	Phe	Ser	Pro	Pro
2120						2125					2130			
Glu	Leu	His	Leu	Leu	Pro	Phe	Asn	Thr	Met	Lys	Glu	Arg	Gln	Glu
2135						2140					2145			
Gln	Leu	Asn	Leu	Ser	Tyr	Leu	Gly	Glu	Gly	Leu	Gln	Lys	Thr	Phe
2150						2155					2160			
Met	Glu	Val	Lys	Asn	Leu	Asp	Ala	Thr	Ala	Ser	Gln	Ala	Leu	Ile
2165						2170					2175			

-continued

Lys	Asp	Leu	Glu	Ser	Gln	Asn	Leu	Ser	Ile	Gln	Gln	Val	Tyr	Gly
2180						2185					2190			
Met	Leu	Gln	Glu	Asn	Ile	Ala	Pro	Arg	Leu	Leu	Val	Asp	Lys	Ser
2195						2200					2205			
Pro	Thr	Tyr	Ala	Met	Glu	Pro	Thr	Ile	Leu	Glu	Arg	Gly	Glu	Ala
2210						2215					2220			
Leu	Phe	Ala	Asn	Ser	Lys	Tyr	Ile	Tyr	Leu	Val	Arg	His	Pro	Tyr
2225						2230					2235			
Ser	Val	Ile	Glu	Ser	Phe	Val	Arg	Met	Arg	Met	Gln	Lys	Leu	Val
2240						2245					2250			
Gly	Leu	Gly	Glu	Glu	Asn	Pro	Tyr	Arg	Val	Ala	Glu	Gln	Val	Trp
2255						2260					2265			
Ala	Lys	Ser	Asn	Gln	Asn	Ile	Leu	Asn	Phe	Leu	Ser	Gln	Leu	Glu
2270						2275					2280			
Pro	Glu	Arg	Gln	His	Gln	Ile	Arg	Tyr	Glu	Asp	Leu	Val	Lys	Lys
2285						2290					2295			
Pro	Gln	Gln	Val	Leu	Ser	Gln	Leu	Cys	Asp	Phe	Leu	Asn	Val	Pro
2300						2305					2310			
Phe	Glu	Pro	Glu	Leu	Leu	Gln	Pro	Tyr	Gln	Gly	Asp	Arg	Met	Thr
2315						2320					2325			
Gly	Gly	Val	His	Gln	Lys	Ser	Leu	Ser	Ile	Ser	Asp	Pro	Asn	Phe
2330						2335					2340			
Leu	Lys	His	Asn	Thr	Ile	Asp	Glu	Ser	Leu	Ala	Asp	Lys	Trp	Lys
2345						2350					2355			
Thr	Ile	Gln	Leu	Pro	Tyr	Pro	Leu	Lys	Ser	Glu	Thr	Gln	Arg	Ile
2360						2365					2370			
Ala	Ser	Gln	Leu	Ser	Tyr	Glu	Leu	Pro	Asn	Leu	Val	Thr	Thr	Pro
2375						2380					2385			
Thr	Asn	Gln	Gln	Pro	Gln	Val	Ser	Thr	Thr	Pro	Ser	Thr	Glu	Gln
2390						2395					2400			
Pro	Ile	Met	Glu	Glu	Lys	Phe	Leu	Glu	Phe	Gly	Gly	Asn	Gln	Ile
2405						2410					2415			
Cys	Leu	Cys	Ser	Trp	Gly	Ser	Pro	Glu	His	Pro	Val	Val	Leu	Cys
2420						2425					2430			
Ile	His	Gly	Ile	Leu	Glu	Gln	Gly	Leu	Ala	Trp	Gln	Glu	Val	Ala
2435						2440					2445			
Leu	Pro	Leu	Ala	Ala	Gln	Gly	Tyr	Arg	Val	Val	Ala	Pro	Asp	Leu
2450						2455					2460			
Phe	Gly	His	Gly	Arg	Ser	Ser	His	Leu	Glu	Met	Val	Thr	Ser	Tyr
2465						2470					2475			
Ser	Ser	Leu	Thr	Phe	Leu	Ala	Gln	Ile	Asp	Arg	Val	Ile	Gln	Glu
2480						2485					2490			
Leu	Pro	Asp	Gln	Pro	Leu	Leu	Leu	Val	Gly	His	Ser	Met	Gly	Ala
2495						2500					2505			
Met	Leu	Ala	Thr	Ala	Ile	Ala	Ser	Val	Arg	Pro	Lys	Lys	Ile	Lys
2510						2515					2520			
Glu	Leu	Ile	Leu	Val	Glu	Leu	Pro	Leu	Pro	Ala	Glu	Glu	Ser	Lys
2525						2530					2535			
Lys	Glu	Ser	Ala	Val	Asn	Gln	Leu	Thr	Thr	Cys	Leu	Asp	Tyr	Leu
2540						2545					2550			
Ser	Ser	Thr	Pro	Gln	His	Pro	Ile	Phe	Pro	Asp	Val	Ala	Thr	Ala
2555						2560					2565			

-continued

Ala Ser Arg Leu Arg Gln Ala Ile Pro Ser Leu Ser Glu Glu Phe
 2570 2575 2580

Ser Tyr Ile Leu Ala Gln Arg Ile Thr Gln Pro Asn Gln Gly Gly
 2585 2590 2595

Val Arg Trp Ser Trp Asp Ala Ile Ile Arg Thr Arg Ser Ile Leu
 2600 2605 2610

Gly Leu Asn Asn Leu Pro Gly Gly Arg Ser Gln Tyr Leu Glu Met
 2615 2620 2625

Leu Lys Ser Ile Gln Val Pro Thr Thr Leu Val Tyr Gly Asp Ser
 2630 2635 2640

Ser Lys Leu Asn Arg Pro Glu Asp Leu Gln Gln Gln Lys Met Thr
 2645 2650 2655

Met Thr Gln Ala Lys Arg Val Phe Leu Ser Gly Gly His Asn Leu
 2660 2665 2670

His Ile Asp Ala Ala Ala Ala Leu Ala Ser Leu Ile Leu Thr Ser
 2675 2680 2685

<210> SEQ ID NO 8

<211> LENGTH: 3177

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Hybrid polyketide synthase capable of producing pentene

<400> SEQUENCE: 8

Met Arg Ala Pro Tyr Gly Asn Arg Gln Val Asn Arg Arg Phe Leu Arg
 1 5 10 15

Glu Phe Arg Ala Lys Arg Pro His Cys Val Ser Pro Leu His Phe Leu
 20 25 30

Ala Glu Phe Ser Glu Ser Arg Gln Thr Thr Gly Ser Ala Gly Val Thr
 35 40 45

Ala Pro Ile Asp Arg Pro Gly Val Ser Met Ala Pro Lys Ser Gly Ala
 50 55 60

Gln Arg Ser Ser Asp Ile Ala Val Val Gly Met Ser Cys Arg Leu Pro
 65 70 75 80

Gly Ala Pro Gly Ile Asp Glu Phe Trp His Leu Leu Thr Thr Gly Gly
 85 90 95

Ser Ala Ile Glu Arg Arg Ala Asp Gly Thr Trp Arg Gly Ser Leu Asp
 100 105 110

Gly Ala Ala Asp Phe Asp Ala Ala Phe Phe Asp Met Thr Pro Arg Gln
 115 120 125

Ala Ala Ala Ala Asp Pro Gln Gln Arg Leu Met Leu Glu Leu Gly Trp
 130 135 140

Thr Ala Leu Glu Asn Ala Gly Ile Val Pro Gly Ser Leu Ala Gly Thr
 145 150 155 160

Asp Thr Gly Val Phe Val Gly Ile Ala Ala Asp Asp Tyr Ala Ala Leu
 165 170 175

Leu His Arg Ser Ala Thr Pro Val Ser Gly His Thr Ala Thr Gly Leu
 180 185 190

Ser Arg Gly Met Ala Ala Asn Arg Leu Ser Tyr Leu Leu Gly Leu Arg
 195 200 205

Gly Pro Ser Leu Ala Val Asp Ser Ala Gln Ser Ser Ser Leu Val Ala
 210 215 220

-continued

Val His Leu Ala Cys Glu Ser Leu Arg Arg Gly Glu Ser Asp Leu Ala
 225 230 235 240
 Ile Val Gly Gly Val Ser Leu Ile Leu Ala Glu Asp Ser Thr Ala Gly
 245 250 255
 Met Glu Leu Met Gly Ala Leu Ser Pro Asp Gly Arg Cys His Thr Phe
 260 265 270
 Asp Ala Arg Ala Asn Gly Tyr Val Arg Gly Glu Gly Gly Ala Cys Val
 275 280 285
 Val Leu Lys Pro Leu Glu Arg Ala Leu Ala Asp Gly Asp Arg Val His
 290 295 300
 Cys Val Val Arg Gly Ser Ala Val Asn Asn Asp Gly Gly Gly Ser Thr
 305 310 315 320
 Leu Thr Thr Pro His Arg Glu Ala Gln Ala Ala Val Leu Arg Ala Ala
 325 330 335
 Tyr Glu Arg Ala Gly Val Gly Pro Asp Gln Val Ser Tyr Val Glu Leu
 340 345 350
 His Gly Thr Gly Thr Pro Val Gly Asp Pro Val Glu Ala Ala Ala Leu
 355 360 365
 Gly Ala Val Leu Gly Thr Ala His Gly Arg Asn Ala Pro Leu Ser Val
 370 375 380
 Gly Ser Val Lys Thr Asn Val Gly His Leu Glu Ala Ala Ala Gly Leu
 385 390 395 400
 Val Gly Phe Val Lys Ala Ala Leu Cys Val Arg Glu Gly Val Val Pro
 405 410 415
 Pro Ser Leu Asn His Ala Thr Pro Asn Pro Ala Ile Pro Met Asp Arg
 420 425 430
 Leu Asn Leu Arg Val Pro Thr Arg Leu Glu Pro Trp Pro His Pro Asp
 435 440 445
 Asp Arg Ala Thr Gly Arg Leu Arg Leu Ala Gly Val Ser Ser Phe Gly
 450 455 460
 Met Gly Gly Thr Asn Ala His Val Val Val Glu Glu Ala Pro Leu Pro
 465 470 475 480
 Glu Ala Gly Glu Pro Val Gly Ala Gly Val Pro Leu Ala Val Val Pro
 485 490 495
 Val Val Val Ser Gly Arg Ser Ala Gly Ala Val Ala Glu Leu Ala Ser
 500 505 510
 Arg Leu Asn Glu Ser Val Arg Ser Asp Arg Leu Val Asp Val Gly Leu
 515 520 525
 Ser Ser Val Val Ser Arg Ser Val Phe Glu His Arg Ser Val Val Leu
 530 535 540
 Ala Gly Asp Ser Ala Glu Leu Ser Ala Gly Leu Asp Ala Leu Ala Ala
 545 550 555 560
 Asp Gly Val Ser Pro Val Leu Val Ser Gly Val Ala Ser Val Gly Gly
 565 570 575
 Gly Arg Ser Val Phe Val Phe Pro Gly Ala Gly Val Lys Trp Ala Gly
 580 585 590
 Met Ala Leu Gly Leu Trp Ala Glu Ser Ala Val Phe Ala Glu Ser Met
 595 600 605
 Ala Arg Cys Glu Ala Ala Phe Ala Gly Leu Val Glu Trp Arg Leu Ala
 610 615 620
 Asp Val Leu Gly Asp Gly Ala Ala Leu Glu Arg Glu Asp Val Val Gln

-continued

625	630	635	640
Pro Ala Ser Phe	Ala Val Met Val Ser	Leu Ala Ala Leu Trp	Arg Ser
	645	650	655
Leu Gly Val Val	Pro Asp Ala Val Val	Gly His Ser Gln Gly	Glu Ile
	660	665	670
Ala Ala Ala Val Val	Ala Gly Gly Leu Ser	Leu Glu Asp Gly	Ala Arg
	675	680	685
Val Val Val Leu Arg	Ala Arg Val Ala	Glu Glu Val Leu	Ser Gly Gly
	690	695	700
Gly Ile Ala Ser Val	Arg Leu Ser Arg	Ala Glu Val Glu	Glu Arg Leu
	710	715	720
Ala Gly Gly Gly Gly	Gly Gly Leu Ser Val	Ala Val Val Asn	Ala Pro Ser
	725	730	735
Ser Thr Val Val Ala	Gly Glu Leu Gly	Asp Leu Asp Arg	Phe Val Ala
	740	745	750
Ala Cys Glu Ala Glu	Gly Val Arg Ala	Arg Arg Leu Glu	Phe Gly Tyr
	755	760	765
Ala Ser His Ser Arg	Phe Val Glu Pro	Val Arg Glu Arg	Leu Leu Glu
	770	775	780
Gly Leu Ala Asp Val	Arg Pro Val Arg	Gly Arg Ile Pro	Phe Tyr Ser
	785	790	800
Thr Val Glu Ala Ala	Glu Phe Asp Thr	Ala Gly Leu Asp	Ala Glu Tyr
	805	810	815
Trp Phe Gly Asn Leu	Arg Arg Pro Val	Arg Phe Gln Glu	Thr Val Glu
	820	825	830
Arg Leu Leu Ala Asp	Gly Phe Arg Val	Phe Val Glu Cys	Gly Ala His
	835	840	845
Pro Val Leu Thr Gly	Ala Val Gln Glu	Thr Ala Glu Thr	Ala Gly Arg
	850	855	860
Glu Ile Cys Ser Val	Gly Ser Leu Arg	Arg Asp Glu Gly	Gly Leu Arg
	865	870	875
Arg Phe Leu Thr Ser	Ala Ala Glu Ala	Phe Val Gln Gly	Val Glu Val
	885	890	895
Ser Trp Pro Val Leu	Phe Asp Gly Thr	Gly Ala Arg Thr	Val Asp Leu
	900	905	910
Pro Thr Tyr Pro Phe	Gln Arg Arg His	His Trp Ala Pro	Asp Gly Ser
	915	920	925
Ala Ser Ala Ala Pro	Thr Arg Asp Ile	Arg Pro Asp Glu	Thr Ala Ala
	930	935	940
Val Pro Ala Asp Thr	Met Asp Leu Ala	Gly Gln Leu Arg	Ala Asp Val
	945	950	955
Ala Ser Leu Pro Thr	Thr Glu Gln Ile	Ala Arg Leu Leu	Asp Gln Val
	965	970	975
Arg Asp Gly Val Ala	Thr Val Leu Gly	Leu Asp Ala Arg	Asp Glu Val
	980	985	990
Arg Ala Glu Ala Thr	Phe Lys Glu Leu	Gly Val Glu Ser	Leu Thr Gly
	995	1000	1005
Val Glu Leu Lys Asn	His Leu Arg Ala	Arg Thr Gly Leu	His Val
	1010	1015	1020
Pro Thr Ser Leu Ile	Tyr Asp Cys Pro	Thr Pro Leu Ala	Ala Ala Ala
	1025	1030	1035

-continued

His	Tyr	Leu	Arg	Asp	Glu	Leu	Leu	Gly	Arg	Pro	Ala	Glu	Gln	Ala
1040						1045					1050			
Val	Val	Pro	Ala	Gly	Ile	Pro	Val	Asp	Glu	Pro	Ile	Ala	Ile	Val
1055						1060					1065			
Gly	Met	Gly	Cys	Arg	Leu	Pro	Gly	Gly	Val	Ser	Ser	Pro	Glu	Gly
1070						1075					1080			
Leu	Trp	Asp	Leu	Val	Ala	Ser	Gly	Val	Asp	Ala	Val	Ser	Pro	Phe
1085						1090					1095			
Pro	Thr	Asp	Arg	Gly	Trp	Asp	Val	Gly	Gly	Leu	Phe	Asp	Pro	Glu
1100						1105					1110			
Pro	Gly	Val	Pro	Gly	Arg	Ser	Tyr	Val	Arg	Glu	Gly	Gly	Phe	Leu
1115						1120					1125			
His	Glu	Ala	Gly	Glu	Phe	Asp	Ala	Gly	Phe	Phe	Gly	Ile	Ser	Pro
1130						1135					1140			
Arg	Glu	Ala	Leu	Ala	Met	Asp	Pro	Gln	Gln	Arg	Leu	Leu	Leu	Glu
1145						1150					1155			
Thr	Ser	Trp	Glu	Ala	Leu	Glu	Arg	Ala	Gly	Ile	Asp	Pro	His	Thr
1160						1165					1170			
Leu	Arg	Gly	Ser	Arg	Thr	Gly	Val	Tyr	Ala	Gly	Val	Met	Ala	Gln
1175						1180					1185			
Glu	Tyr	Gly	Pro	Arg	Leu	His	Glu	Gly	Ala	Asp	Gly	Tyr	Glu	Gly
1190						1195					1200			
Tyr	Leu	Leu	Thr	Gly	Ser	Ser	Ser	Ser	Val	Ala	Ser	Gly	Arg	Ile
1205						1210					1215			
Ser	Tyr	Val	Leu	Gly	Leu	Glu	Gly	Pro	Ala	Val	Thr	Val	Asp	Thr
1220						1225					1230			
Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Val	Arg	Ala
1235						1240					1245			
Leu	Arg	Ser	Gly	Glu	Cys	Asp	Leu	Ala	Leu	Ala	Gly	Gly	Ala	Thr
1250						1255					1260			
Val	Met	Ala	Glu	Pro	Gly	Met	Phe	Val	Glu	Phe	Ser	Arg	Gln	Arg
1265						1270					1275			
Gly	Leu	Ser	Ala	His	Gly	Arg	Cys	Lys	Ala	Tyr	Ser	Asp	Ser	Ala
1280						1285					1290			
Asp	Gly	Thr	Gly	Trp	Ala	Glu	Gly	Ala	Gly	Val	Leu	Leu	Val	Glu
1295						1300					1305			
Arg	Leu	Ser	Asp	Ala	Val	Arg	His	Gly	Arg	Arg	Val	Leu	Ala	Val
1310						1315					1320			
Val	Arg	Gly	Ser	Ala	Val	Asn	Gln	Asp	Gly	Ala	Ser	Asn	Gly	Leu
1325						1330					1335			
Thr	Ala	Pro	Asn	Gly	Arg	Ser	Gln	Ser	Arg	Leu	Ile	Arg	Gln	Ala
1340						1345					1350			
Leu	Ala	Asp	Ala	Arg	Leu	Gly	Val	Ala	Asp	Val	Asp	Val	Val	Glu
1355						1360					1365			
Gly	His	Gly	Thr	Gly	Thr	Arg	Leu	Gly	Asp	Pro	Ile	Glu	Ala	Gln
1370						1375					1380			
Ala	Leu	Leu	Ala	Thr	Tyr	Gly	Gln	Arg	Asp	Ala	Gly	Arg	Pro	Leu
1385						1390					1395			
Arg	Leu	Gly	Ser	Leu	Lys	Ser	Asn	Val	Gly	His	Thr	Gln	Ala	Ala
1400						1405					1410			
Ala	Gly	Val	Ala	Gly	Val	Ile	Lys	Met	Val	Met	Ala	Met	Arg	His
1415						1420					1425			

-continued

Gly Val	Leu Pro Lys Thr	Leu His Val Asp Glu	Pro Thr Ala Glu	
1430		1435	1440	
Val Asp	Trp Ser Ala Gly	Ala Val Ser Leu Leu	Arg Glu Gln Glu	
1445		1450	1455	
Ala Trp	Pro Arg Gly Glu	Arg Val Arg Arg Ala	Gly Val Ser Ser	
1460		1465	1470	
Phe Gly	Val Ser Gly Thr	Asn Ala His Val Ile	Leu Glu Gln Pro	
1475		1480	1485	
Pro Gly	Val Pro Ser Gln	Ser Ala Gly Pro Gly	Ser Gly Ser Val	
1490		1495	1500	
Val Asp	Val Pro Val Val	Pro Trp Met Val Ser	Gly Lys Thr Pro	
1505		1510	1515	
Glu Ala	Leu Ser Ala Gln	Ala Thr Ala Leu Met	Thr Tyr Leu Asp	
1520		1525	1530	
Glu Arg	Pro Asp Val Ser	Ser Leu Asp Val Gly	Tyr Ser Leu Ala	
1535		1540	1545	
Leu Thr	Arg Ser Ala Leu	Asp Glu Arg Ala Val	Val Leu Gly Ser	
1550		1555	1560	
Asp Arg	Glu Thr Leu Leu	Cys Gly Val Lys Ala	Leu Ser Ala Gly	
1565		1570	1575	
His Glu	Ala Ser Gly Leu	Val Thr Gly Ser Val	Gly Ala Gly Gly	
1580		1585	1590	
Arg Ile	Gly Phe Val Phe	Ser Gly Gln Gly Gly	Gln Trp Leu Gly	
1595		1600	1605	
Met Gly	Arg Gly Leu Tyr	Arg Ala Phe Pro Val	Phe Ala Ala Ala	
1610		1615	1620	
Phe Asp	Glu Ala Cys Ala	Glu Leu Asp Ala His	Leu Gly Gln Glu	
1625		1630	1635	
Ile Gly	Val Arg Glu Val	Val Ser Gly Ser Asp	Ala Gln Leu Leu	
1640		1645	1650	
Asp Arg	Thr Leu Trp Ala	Gln Ser Gly Leu Phe	Ala Leu Gln Val	
1655		1660	1665	
Gly Leu	Leu Lys Leu Leu	Asp Ser Trp Gly Val	Arg Pro Ser Val	
1670		1675	1680	
Val Leu	Gly His Ser Val	Gly Glu Leu Ala Ala	Ala Phe Ala Ala	
1685		1690	1695	
Gly Val	Val Ser Leu Ser	Gly Ala Ala Arg Leu	Val Ala Gly Arg	
1700		1705	1710	
Ala Arg	Leu Met Gln Ala	Leu Pro Ser Gly Gly	Gly Met Leu Ala	
1715		1720	1725	
Val Pro	Ala Gly Glu Glu	Leu Leu Trp Ser Leu	Leu Ala Asp Gln	
1730		1735	1740	
Gly Asp	Arg Val Gly Ile	Ala Ala Val Asn Ala	Ala Gly Ser Val	
1745		1750	1755	
Val Leu	Ser Gly Asp Arg	Asp Val Leu Asp Asp	Leu Ala Gly Arg	
1760		1765	1770	
Leu Asp	Gly Gln Gly Ile	Arg Ser Arg Trp Leu	Arg Val Ser His	
1775		1780	1785	
Ala Phe	His Ser Tyr Arg	Met Asp Pro Met Leu	Ala Glu Phe Ala	
1790		1795	1800	
Glu Leu	Ala Arg Thr Val	Asp Tyr Arg Arg Cys	Glu Val Pro Ile	

-continued

1805						1810									1815
Val	Ser	Thr	Leu	Thr	Gly	Asp	Leu	Asp	Asp	Ala	Gly	Arg	Met	Ser	
1820						1825					1830				
Gly	Pro	Asp	Tyr	Trp	Val	Arg	Gln	Val	Arg	Glu	Pro	Val	Arg	Phe	
1835						1840					1845				
Ala	Asp	Gly	Val	Gln	Ala	Leu	Val	Glu	His	Asp	Val	Ala	Thr	Val	
1850						1855					1860				
Val	Glu	Leu	Gly	Pro	Asp	Gly	Ala	Leu	Ser	Ala	Leu	Ile	Gln	Glu	
1865						1870					1875				
Cys	Val	Ala	Ala	Ser	Asp	His	Ala	Gly	Arg	Leu	Ser	Ala	Val	Pro	
1880						1885					1890				
Ala	Met	Arg	Arg	Asn	Gln	Asp	Glu	Ala	Gln	Lys	Val	Met	Thr	Ala	
1895						1900					1905				
Leu	Ala	His	Val	His	Val	Arg	Gly	Gly	Ala	Val	Asp	Trp	Arg	Ser	
1910						1915					1920				
Phe	Phe	Ala	Gly	Thr	Gly	Ala	Lys	Gln	Ile	Glu	Leu	Pro	Thr	Tyr	
1925						1930					1935				
Ala	Phe	Gln	Arg	Gln	Arg	Tyr	Trp	Leu	Val	Pro	Ser	Asp	Ser	Gly	
1940						1945					1950				
Asp	Val	Thr	Gly	Ala	Gly	Leu	Ala	Gly	Ala	Glu	His	Pro	Leu	Leu	
1955						1960					1965				
Gly	Ala	Val	Val	Pro	Val	Ala	Gly	Gly	Asp	Glu	Val	Leu	Leu	Thr	
1970						1975					1980				
Gly	Arg	Ile	Ser	Val	Arg	Thr	His	Pro	Trp	Leu	Ala	Glu	His	Arg	
1985						1990					1995				
Val	Leu	Gly	Glu	Val	Ile	Val	Ala	Gly	Thr	Ala	Leu	Leu	Glu	Ile	
2000						2005					2010				
Ala	Leu	His	Ala	Gly	Glu	Arg	Leu	Gly	Cys	Glu	Arg	Val	Glu	Glu	
2015						2020					2025				
Leu	Thr	Leu	Glu	Ala	Pro	Leu	Val	Leu	Pro	Glu	Arg	Gly	Ala	Ile	
2030						2035					2040				
Gln	Val	Gln	Leu	Arg	Val	Gly	Ala	Pro	Glu	Asn	Ser	Gly	Arg	Arg	
2045						2050					2055				
Pro	Met	Ala	Leu	Tyr	Ser	Arg	Pro	Glu	Gly	Ala	Ala	Glu	His	Asp	
2060						2065					2070				
Trp	Thr	Arg	His	Ala	Thr	Gly	Arg	Leu	Ala	Pro	Gly	Arg	Gly	Glu	
2075						2080					2085				
Ala	Ala	Gly	Asp	Leu	Ala	Asp	Trp	Pro	Ala	Pro	Gly	Ala	Leu	Pro	
2090						2095					2100				
Val	Asp	Leu	Asp	Glu	Phe	Tyr	Arg	Asp	Leu	Ala	Glu	Leu	Gly	Leu	
2105						2110					2115				
Glu	Tyr	Gly	Pro	Ile	Phe	Gln	Gly	Leu	Lys	Ala	Ala	Trp	Arg	Gln	
2120						2125					2130				
Gly	Asp	Glu	Val	Tyr	Ala	Glu	Ala	Ala	Leu	Pro	Gly	Thr	Glu	Asp	
2135						2140					2145				
Ser	Gly	Phe	Gly	Val	His	Pro	Ala	Leu	Leu	Asp	Ala	Ala	Leu	His	
2150						2155					2160				
Ala	Thr	Ala	Val	Arg	Asp	Met	Asp	Asp	Ala	Arg	Leu	Pro	Phe	Gln	
2165						2170					2175				
Trp	Glu	Gly	Val	Ser	Leu	His	Ala	Lys	Ala	Ala	Pro	Ala	Leu	Arg	
2180						2185					2190				

-continued

Val	Arg	Val	Val	Pro	Ala	Gly	Asp	Asp	Ala	Lys	Ser	Leu	Leu	Val
2195						2200					2205			
Cys	Asp	Gly	Thr	Gly	Arg	Pro	Val	Ile	Ser	Val	Asp	Arg	Leu	Val
2210						2215					2220			
Leu	Arg	Ser	Ala	Ala	Ala	Arg	Arg	Thr	Gly	Ala	Arg	Arg	Gln	Ala
2225						2230					2235			
His	Gln	Ala	Arg	Leu	Tyr	Arg	Leu	Ser	Trp	Pro	Thr	Val	Gln	Leu
2240						2245					2250			
Pro	Thr	Ser	Ala	Gln	Pro	Pro	Ser	Cys	Val	Leu	Leu	Gly	Thr	Ser
2255						2260					2265			
Glu	Val	Ser	Ala	Asp	Ile	Gln	Val	Tyr	Pro	Asp	Leu	Arg	Ser	Leu
2270						2275					2280			
Thr	Ala	Ala	Leu	Asp	Ala	Gly	Ala	Glu	Pro	Pro	Gly	Val	Val	Ile
2285						2290					2295			
Ala	Pro	Thr	Pro	Pro	Gly	Gly	Gly	Arg	Thr	Ala	Asp	Val	Arg	Glu
2300						2305					2310			
Thr	Thr	Arg	His	Ala	Leu	Asp	Leu	Val	Gln	Gly	Trp	Leu	Ser	Asp
2315						2320					2325			
Gln	Arg	Leu	Asn	Glu	Ser	Arg	Leu	Leu	Leu	Val	Thr	Gln	Gly	Ala
2330						2335					2340			
Val	Ala	Val	Glu	Pro	Gly	Glu	Pro	Val	Thr	Asp	Leu	Ala	Gln	Ala
2345						2350					2355			
Ala	Leu	Trp	Gly	Leu	Leu	Arg	Ser	Thr	Gln	Thr	Glu	His	Pro	Asp
2360						2365					2370			
Arg	Phe	Val	Leu	Val	Asp	Val	Pro	Glu	Pro	Ala	Gln	Leu	Leu	Pro
2375						2380					2385			
Ala	Leu	Pro	Gly	Val	Leu	Ala	Cys	Gly	Glu	Pro	Gln	Leu	Ala	Leu
2390						2395					2400			
Arg	Arg	Gly	Gly	Ala	His	Ala	Pro	Arg	Leu	Ala	Gly	Leu	Gly	Ser
2405						2410					2415			
Asp	Asp	Val	Leu	Pro	Val	Pro	Asp	Gly	Thr	Gly	Trp	Arg	Leu	Glu
2420						2425					2430			
Ala	Thr	Arg	Pro	Gly	Ser	Leu	Asp	Gly	Leu	Ala	Leu	Val	Asp	Glu
2435						2440					2445			
Pro	Thr	Ala	Thr	Ala	Pro	Leu	Gly	Asp	Gly	Glu	Val	Arg	Ile	Ala
2450						2455					2460			
Met	Arg	Ala	Ala	Gly	Val	Asn	Phe	Arg	Asp	Ala	Leu	Ile	Ala	Leu
2465						2470					2475			
Gly	Met	Tyr	Pro	Gly	Val	Ala	Ser	Leu	Gly	Ser	Glu	Gly	Ala	Gly
2480						2485					2490			
Val	Val	Val	Glu	Thr	Gly	Pro	Gly	Val	Thr	Gly	Leu	Ala	Pro	Gly
2495						2500					2505			
Asp	Arg	Val	Met	Gly	Met	Ile	Pro	Lys	Ala	Phe	Gly	Pro	Leu	Ala
2510						2515					2520			
Val	Ala	Asp	His	Arg	Met	Val	Thr	Arg	Ile	Pro	Ala	Gly	Trp	Ser
2525						2530					2535			
Phe	Ala	Arg	Ala	Ala	Ser	Val	Pro	Ile	Val	Phe	Leu	Thr	Ala	Tyr
2540						2545					2550			
Tyr	Ala	Leu	Val	Asp	Leu	Ala	Gly	Leu	Arg	Pro	Gly	Glu	Ser	Leu
2555						2560					2565			
Leu	Val	His	Ser	Ala	Ala	Gly	Gly	Val	Gly	Met	Ala	Ala	Ile	Gln
2570						2575					2580			

-continued

Leu	Ala	Arg	His	Leu	Gly	Ala	Glu	Val	Tyr	Ala	Thr	Ala	Ser	Glu
2585						2590					2595			
Asp	Lys	Trp	Gln	Ala	Val	Glu	Leu	Ser	Arg	Glu	His	Leu	Ala	Ser
2600						2605					2610			
Ser	Arg	Thr	Cys	Asp	Phe	Glu	Gln	Gln	Phe	Leu	Gly	Ala	Thr	Gly
2615						2620					2625			
Gly	Arg	Gly	Val	Asp	Val	Val	Leu	Asn	Ser	Leu	Ala	Gly	Glu	Phe
2630						2635					2640			
Ala	Asp	Ala	Ser	Leu	Arg	Met	Leu	Pro	Arg	Gly	Gly	Arg	Phe	Leu
2645						2650					2655			
Glu	Leu	Gly	Lys	Thr	Asp	Val	Arg	Asp	Pro	Val	Glu	Val	Ala	Asp
2660						2665					2670			
Ala	His	Pro	Gly	Val	Ser	Tyr	Gln	Ala	Phe	Asp	Thr	Val	Glu	Ala
2675						2680					2685			
Gly	Pro	Gln	Arg	Ile	Gly	Glu	Met	Leu	His	Glu	Leu	Val	Glu	Leu
2690						2695					2700			
Phe	Glu	Gly	Arg	Val	Leu	Glu	Pro	Leu	Pro	Val	Thr	Ala	Trp	Asp
2705						2710					2715			
Val	Arg	Gln	Ala	Pro	Glu	Ala	Leu	Arg	His	Leu	Ser	Gln	Ala	Arg
2720						2725					2730			
His	Val	Gly	Lys	Leu	Val	Leu	Thr	Met	Pro	Pro	Val	Trp	Asp	Ala
2735						2740					2745			
Ala	Gly	Thr	Val	Leu	Val	Thr	Gly	Gly	Thr	Gly	Ala	Leu	Gly	Ala
2750						2755					2760			
Glu	Val	Ala	Arg	His	Leu	Val	Ile	Glu	Arg	Gly	Val	Arg	Asn	Leu
2765						2770					2775			
Val	Leu	Val	Ser	Arg	Arg	Gly	Pro	Ala	Ala	Ser	Gly	Ala	Ala	Glu
2780						2785					2790			
Leu	Val	Ala	Gln	Leu	Thr	Ala	Tyr	Gly	Ala	Glu	Val	Ser	Leu	Gln
2795						2800					2805			
Ala	Cys	Asp	Val	Ala	Asp	Arg	Glu	Thr	Leu	Ala	Lys	Val	Leu	Ala
2810						2815					2820			
Ser	Ile	Pro	Asp	Glu	His	Pro	Leu	Thr	Ala	Val	Val	His	Ala	Ala
2825						2830					2835			
Gly	Val	Leu	Asp	Asp	Gly	Val	Ser	Glu	Ser	Leu	Thr	Val	Glu	Arg
2840						2845					2850			
Leu	Asp	Gln	Val	Leu	Arg	Pro	Lys	Val	Asp	Gly	Ala	Arg	Asn	Leu
2855						2860					2865			
Leu	Glu	Leu	Ile	Asp	Pro	Asp	Val	Ala	Leu	Val	Leu	Phe	Ser	Ser
2870						2875					2880			
Val	Ser	Gly	Val	Leu	Gly	Ser	Gly	Gly	Gln	Gly	Asn	Tyr	Ala	Ala
2885						2890					2895			
Ala	Asn	Ser	Phe	Leu	Asp	Ala	Leu	Ala	Gln	Gln	Arg	Gln	Ser	Arg
2900						2905					2910			
Gly	Leu	Pro	Thr	Arg	Ser	Leu	Ala	Trp	Gly	Pro	Trp	Ala	Glu	His
2915						2920					2925			
Gly	Met	Ala	Ser	Thr	Leu	Arg	Glu	Ala	Glu	Gln	Asp	Arg	Leu	Ala
2930						2935					2940			
Arg	Ser	Gly	Leu	Leu	Pro	Ile	Ser	Thr	Glu	Glu	Gly	Leu	Ser	Gln
2945						2950					2955			
Phe	Asp	Ala	Ala	Cys	Gly	Gly	Ala	His	Thr	Val	Val	Ala	Pro	Val

-continued

2960	2965	2970
Arg Phe Ser Arg Leu Ser Asp Gly Asn Ala Ile Lys Phe Ser Val		
2975	2980	2985
Leu Gln Gly Leu Val Gly Pro His Arg Val Asn Lys Ala Ala Thr		
2990	2995	3000
Ala Asp Asp Ala Glu Ser Leu Arg Lys Arg Leu Gly Arg Leu Pro		
3005	3010	3015
Asp Ala Glu Gln His Arg Ile Leu Leu Asp Leu Val Arg Met His		
3020	3025	3030
Val Ala Ala Val Leu Gly Phe Ala Gly Ser Gln Glu Ile Thr Ala		
3035	3040	3045
Asp Gly Thr Phe Lys Val Leu Gly Phe Asp Ser Leu Thr Val Val		
3050	3055	3060
Glu Leu Arg Asn Arg Ile Asn Gly Ala Thr Gly Leu Arg Leu Pro		
3065	3070	3075
Ala Thr Leu Val Phe Asn Tyr Pro Thr Pro Asp Ala Leu Ala Ala		
3080	3085	3090
His Leu Val Thr Ala Leu Ser Ala Asp Arg Leu Ala Gly Thr Phe		
3095	3100	3105
Glu Glu Leu Asp Arg Trp Ala Ala Asn Leu Pro Thr Leu Ala Arg		
3110	3115	3120
Asp Glu Ala Thr Arg Ala Gln Ile Thr Thr Arg Leu Gln Ala Ile		
3125	3130	3135
Leu Gln Ser Leu Ala Asp Val Ser Gly Gly Thr Gly Gly Gly Ser		
3140	3145	3150
Val Pro Asp Arg Leu Arg Ser Ala Thr Asp Asp Glu Leu Phe Gln		
3155	3160	3165
Leu Leu Asp Asn Asp Leu Glu Leu Pro		
3170	3175	

<210> SEQ ID NO 9

<211> LENGTH: 2081

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Hybrid polyketide synthase capable of producing pentene

<400> SEQUENCE: 9

Met Ser Asn Glu Glu Lys Leu Arg Glu Tyr Leu Arg Arg Ala Leu Val			
1	5	10	15
Asp Leu His Gln Ala Arg Glu Arg Leu His Glu Ala Glu Ser Gly Glu			
	20	25	30
Arg Glu Pro Ile Ala Ile Val Ala Met Gly Cys Arg Tyr Pro Gly Gly			
	35	40	45
Val Gln Asp Pro Glu Gly Leu Trp Lys Leu Val Ala Ser Gly Gly Asp			
	50	55	60
Ala Ile Gly Glu Phe Pro Ala Asp Arg Gly Trp His Leu Asp Glu Leu			
	65	70	75
Tyr Asp Pro Asp Pro Asp Gln Pro Gly Thr Cys Tyr Thr Arg His Gly			
	85	90	95
Gly Phe Leu His Asp Ala Gly Glu Phe Asp Ala Gly Phe Phe Asp Ile			
	100	105	110
Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Leu			

-continued

115			120			125									
Glu	Ile	Ser	Trp	Glu	Thr	Val	Glu	Ser	Ala	Gly	Met	Asp	Pro	Arg	Ser
130						135					140				
Leu	Arg	Gly	Ser	Arg	Thr	Gly	Val	Phe	Ala	Gly	Leu	Met	Tyr	Glu	Gly
145					150					155					160
Tyr	Asp	Thr	Gly	Ala	His	Arg	Ala	Gly	Glu	Gly	Val	Glu	Gly	Tyr	Leu
				165					170					175	
Gly	Thr	Gly	Asn	Ala	Gly	Ser	Val	Ala	Ser	Gly	Arg	Val	Ala	Tyr	Ala
			180					185					190		
Phe	Gly	Phe	Glu	Gly	Pro	Ala	Val	Thr	Val	Asp	Thr	Ala	Cys	Ser	Ser
		195					200					205			
Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Cys	Gln	Ser	Leu	Arg	Gln	Gly	Glu
	210					215					220				
Cys	Asp	Leu	Ala	Leu	Ala	Gly	Gly	Val	Thr	Val	Met	Ser	Thr	Pro	Glu
225					230					235					240
Arg	Phe	Val	Glu	Phe	Ser	Arg	Gln	Arg	Gly	Leu	Ala	Pro	Asp	Gly	Arg
				245					250					255	
Cys	Lys	Ser	Phe	Ala	Ala	Ala	Ala	Asp	Gly	Thr	Gly	Trp	Gly	Glu	Gly
			260					265					270		
Ala	Gly	Leu	Val	Leu	Leu	Glu	Arg	Leu	Ser	Asp	Ala	Arg	Arg	Asn	Gly
		275					280					285			
His	Arg	Val	Leu	Ala	Val	Val	Arg	Gly	Ser	Ala	Val	Asn	Gln	Asp	Gly
	290					295					300				
Ala	Ser	Asn	Gly	Leu	Thr	Ala	Pro	Asn	Gly	Leu	Ala	Gln	Glu	Arg	Val
305					310					315					320
Ile	Gln	Gln	Val	Leu	Thr	Ser	Ala	Gly	Leu	Ser	Ala	Ser	Asp	Val	Asp
				325					330					335	
Ala	Val	Glu	Ala	His	Gly	Thr	Gly	Thr	Arg	Leu	Gly	Asp	Pro	Ile	Glu
			340					345					350		
Ala	Gln	Ala	Leu	Ile	Ala	Ala	Tyr	Gly	Gln	Asp	Arg	Asp	Arg	Asp	Arg
		355					360					365			
Pro	Leu	Trp	Leu	Gly	Ser	Val	Lys	Ser	Asn	Ile	Gly	His	Thr	Gln	Ala
	370					375					380				
Ala	Ala	Gly	Val	Ala	Gly	Val	Ile	Lys	Met	Val	Met	Ala	Met	Arg	His
385					390					395					400
Gly	Glu	Leu	Pro	Arg	Thr	Leu	His	Val	Asp	Glu	Pro	Asn	Ser	His	Val
				405					410					415	
Asp	Trp	Ser	Ala	Gly	Ala	Val	Arg	Leu	Leu	Thr	Glu	Asn	Ile	Arg	Trp
			420					425					430		
Pro	Gly	Thr	Gly	Thr	Arg	Arg	Ala	Gly	Val	Ser	Ser	Phe	Gly	Val	Ser
		435					440					445			
Gly	Thr	Asn	Ala	His	Val	Ile	Val	Gly	Asp	Tyr	Ala	Gln	Gln	Lys	Ser
	450					455					460				
Pro	Leu	Ala	Pro	Pro	Ala	Thr	Gln	Asp	Arg	Pro	Trp	His	Leu	Leu	Thr
465					470					475					480
Leu	Ser	Ala	Lys	Asn	Ala	Gln	Ala	Leu	Asn	Ala	Leu	Gln	Lys	Ser	Tyr
				485					490					495	
Gly	Asp	Tyr	Leu	Ala	Gln	His	Pro	Ser	Val	Asp	Pro	Arg	Asp	Leu	Cys
			500					505					510		
Leu	Ser	Ala	Asn	Thr	Gly	Arg	Ser	Pro	Leu	Lys	Glu	Arg	Arg	Phe	Phe
		515					520						525		

-continued

Val	Phe	Lys	Gln	Val	Ala	Asp	Leu	Gln	Gln	Thr	Leu	Asn	Gln	Asp	Phe
	530					535						540			
Leu	Ala	Gln	Pro	Arg	Leu	Ser	Ser	Pro	Ala	Lys	Ile	Ala	Phe	Leu	Phe
545					550					555					560
Thr	Gly	Gln	Gly	Ser	Gln	Tyr	Tyr	Gly	Met	Gly	Gln	Gln	Leu	Tyr	Gln
				565					570					575	
Thr	Ser	Pro	Val	Phe	Arg	Gln	Val	Leu	Asp	Glu	Cys	Asp	Arg	Leu	Trp
			580					585					590		
Gln	Thr	Tyr	Ser	Pro	Glu	Ala	Pro	Ala	Leu	Thr	Asp	Leu	Leu	Tyr	Gly
		595					600					605			
Asn	His	Asn	Pro	Asp	Leu	Val	His	Glu	Thr	Val	Tyr	Thr	Gln	Pro	Leu
610					615						620				
Leu	Phe	Ala	Val	Glu	Tyr	Ala	Ile	Ala	Gln	Leu	Trp	Leu	Ser	Trp	Gly
625				630						635					640
Val	Thr	Pro	Asp	Phe	Cys	Met	Gly	His	Ser	Val	Gly	Glu	Tyr	Val	Ala
				645					650					655	
Ala	Cys	Leu	Ala	Gly	Val	Phe	Ser	Leu	Ala	Asp	Gly	Met	Lys	Leu	Ile
			660					665					670		
Thr	Ala	Arg	Gly	Lys	Leu	Met	His	Ala	Leu	Pro	Ser	Asn	Gly	Ser	Met
		675					680						685		
Ala	Ala	Val	Phe	Ala	Asp	Lys	Thr	Val	Ile	Lys	Pro	Tyr	Leu	Ser	Glu
	690					695					700				
His	Leu	Thr	Val	Gly	Ala	Glu	Asn	Gly	Ser	His	Leu	Val	Leu	Ser	Gly
705				710						715					720
Lys	Thr	Pro	Cys	Leu	Glu	Ala	Ser	Ile	His	Lys	Leu	Gln	Ser	Gln	Gly
				725					730					735	
Ile	Lys	Thr	Lys	Pro	Leu	Lys	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu
			740					745					750		
Met	Ala	Pro	Met	Leu	Ala	Glu	Phe	Arg	Glu	Ile	Ala	Glu	Gln	Ile	Thr
		755					760					765			
Phe	His	Pro	Pro	Arg	Ile	Pro	Leu	Ile	Ser	Asn	Val	Thr	Gly	Gly	Gln
	770					775					780				
Ile	Glu	Ala	Glu	Ile	Ala	Gln	Ala	Asp	Tyr	Trp	Val	Lys	His	Val	Ser
785					790					795					800
Gln	Pro	Val	Lys	Phe	Val	Gln	Ser	Ile	Gln	Thr	Leu	Ala	Gln	Ala	Gly
				805					810					815	
Val	Asn	Val	Tyr	Leu	Glu	Ile	Gly	Val	Lys	Pro	Val	Leu	Leu	Ser	Met
			820					825					830		
Gly	Arg	His	Cys	Leu	Ala	Glu	Gln	Glu	Ala	Val	Trp	Leu	Pro	Ser	Leu
		835					840					845			
Arg	Pro	His	Ser	Glu	Pro	Trp	Pro	Glu	Ile	Leu	Thr	Ser	Leu	Gly	Lys
		850				855						860			
Leu	Tyr	Glu	Gln	Gly	Leu	Asn	Ile	Asp	Trp	Gln	Thr	Val	Glu	Ala	Gly
865					870					875					880
Asp	Arg	Arg	Arg	Lys	Leu	Ile	Leu	Pro	Thr	Tyr	Pro	Phe	Gln	Arg	Gln
				885					890					895	
Arg	Tyr	Trp	Phe	Asn	Gln	Gly	Ser	Trp	Gln	Thr	Val	Glu	Thr	Glu	Ser
			900					905					910		
Val	Asn	Pro	Gly	Pro	Asp	Asp	Leu	Asn	Asp	Trp	Leu	Tyr	Gln	Val	Ala
		915					920					925			
Trp	Thr	Pro	Leu	Asp	Thr	Leu	Pro	Pro	Ala	Pro	Glu	Pro	Ser	Ala	Lys
						935					940				

-continued

Leu Trp Leu Ile Leu Gly Asp Arg His Asp His Gln Pro Ile Glu Ala
 945 950 955 960

Gln Phe Lys Asn Ala Gln Arg Val Tyr Leu Gly Gln Ser Asn His Phe
 965 970 975

Pro Thr Asn Ala Pro Trp Glu Val Ser Ala Asp Ala Leu Asp Asn Leu
 980 985 990

Phe Thr His Val Gly Ser Gln Asn Leu Ala Gly Ile Leu Tyr Leu Cys
 995 1000 1005

Pro Pro Gly Glu Asp Pro Glu Asp Leu Asp Glu Ile Gln Lys Gln
 1010 1015 1020

Thr Ser Gly Phe Ala Leu Gln Leu Ile Gln Thr Leu Tyr Gln Gln
 1025 1030 1035

Lys Ile Ala Val Pro Cys Trp Phe Val Thr His Gln Ser Gln Arg
 1040 1045 1050

Val Leu Glu Thr Asp Ala Val Thr Gly Phe Ala Gln Gly Gly Leu
 1055 1060 1065

Trp Gly Leu Ala Gln Ala Ile Ala Leu Glu His Pro Glu Leu Trp
 1070 1075 1080

Gly Gly Ile Ile Asp Val Asp Asp Ser Leu Pro Asn Phe Ala Gln
 1085 1090 1095

Ile Cys Gln Gln Arg Gln Val Gln Gln Leu Ala Val Arg His Gln
 1100 1105 1110

Lys Leu Tyr Gly Ala Gln Leu Lys Lys Gln Pro Ser Leu Pro Gln
 1115 1120 1125

Lys Asn Leu Gln Ile Gln Pro Gln Gln Thr Tyr Leu Val Thr Gly
 1130 1135 1140

Gly Leu Gly Ala Ile Gly Arg Lys Ile Ala Gln Trp Leu Ala Ala
 1145 1150 1155

Ala Gly Ala Glu Lys Val Ile Leu Val Ser Arg Arg Ala Pro Ala
 1160 1165 1170

Ala Asp Gln Gln Thr Leu Pro Thr Asn Ala Val Val Tyr Pro Cys
 1175 1180 1185

Asp Leu Ala Asp Ala Ala Gln Val Ala Lys Leu Phe Gln Thr Tyr
 1190 1195 1200

Pro His Ile Lys Gly Ile Phe His Ala Ala Gly Thr Leu Ala Asp
 1205 1210 1215

Gly Leu Leu Gln Gln Gln Thr Trp Gln Lys Phe Gln Thr Val Ala
 1220 1225 1230

Ala Ala Lys Met Lys Gly Thr Trp His Leu His Arg His Ser Gln
 1235 1240 1245

Lys Leu Asp Leu Asp Phe Phe Val Leu Phe Ser Ser Val Ala Gly
 1250 1255 1260

Val Leu Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Arg
 1265 1270 1275

Gly Met Ala Ala Ile Ala Gln Tyr Arg Gln Ala Gln Gly Leu Pro
 1280 1285 1290

Ala Leu Ala Ile His Trp Gly Pro Trp Ala Glu Gly Gly Met Ala
 1295 1300 1305

Asn Ser Leu Ser Asn Gln Asn Leu Ala Trp Leu Pro Pro Pro Gln
 1310 1315 1320

Gly Leu Thr Ile Leu Glu Lys Val Leu Gly Ala Gln Gly Glu Met

-continued

Asp 1715	Glu	Ala	Leu	Leu	Asn	Pro 1720	Tyr	Ser	Gly	Asp	Arg 1725	Leu	Thr	Asp
Gly 1730	Leu	His	Gln	Gln	Ser	Met 1735	Gly	Val	Gly	Asp	Pro 1740	Asn	Phe	Leu
Gln 1745	His	Lys	Thr	Ile	Asp	Pro 1750	Ala	Leu	Ala	Asp	Lys 1755	Trp	Arg	Ser
Ile 1760	Thr	Leu	Pro	Ala	Ala	Leu 1765	Gln	Leu	Asp	Thr	Ile 1770	Gln	Leu	Ala
Glu 1775	Thr	Phe	Ala	Tyr	Asp	Leu 1780	Pro	Gln	Glu	Pro	Gln 1785	Leu	Thr	Pro
Gln 1790	Thr	Gln	Ser	Leu	Pro	Ser 1795	Met	Val	Glu	Arg	Phe 1800	Val	Thr	Val
Arg 1805	Gly	Leu	Glu	Thr	Cys	Leu 1810	Cys	Glu	Trp	Gly	Asp 1815	Arg	His	Gln
Pro 1820	Leu	Val	Leu	Leu	Leu	His 1825	Gly	Ile	Leu	Glu	Gln 1830	Gly	Ala	Ser
Trp 1835	Gln	Leu	Ile	Ala	Pro	Gln 1840	Leu	Ala	Ala	Gln	Gly 1845	Tyr	Trp	Val
Val 1850	Ala	Pro	Asp	Leu	Arg	Gly 1855	His	Gly	Lys	Ser	Ala 1860	His	Ala	Gln
Ser 1865	Tyr	Ser	Met	Leu	Asp	Phe 1870	Leu	Ala	Asp	Val	Asp 1875	Ala	Leu	Ala
Lys 1880	Gln	Leu	Gly	Asp	Arg	Pro 1885	Phe	Thr	Leu	Val	Gly 1890	His	Ser	Met
Gly 1895	Ser	Ile	Ile	Gly	Ala	Met 1900	Tyr	Ala	Gly	Ile	Arg 1905	Gln	Thr	Gln
Val 1910	Glu	Lys	Leu	Ile	Leu	Val 1915	Glu	Thr	Ile	Val	Pro 1920	Asn	Asp	Ile
Asp 1925	Asp	Ala	Glu	Thr	Gly	Asn 1930	His	Leu	Thr	Thr	His 1935	Leu	Asp	Tyr
Leu 1940	Ala	Ala	Pro	Pro	Gln	His 1945	Pro	Ile	Phe	Pro	Ser 1950	Leu	Glu	Val
Ala 1955	Ala	Arg	Arg	Leu	Arg	Gln 1960	Ala	Thr	Pro	Gln	Leu 1965	Pro	Lys	Asp
Leu 1970	Ser	Ala	Phe	Leu	Thr	Gln 1975	Arg	Ser	Thr	Lys	Ser 1980	Val	Glu	Lys
Gly 1985	Val	Gln	Trp	Arg	Trp	Asp 1990	Ala	Phe	Leu	Arg	Thr 1995	Arg	Ala	Gly
Ile 2000	Glu	Phe	Asn	Gly	Ile	Ser 2005	Arg	Arg	Arg	Tyr	Leu 2010	Ala	Leu	Leu
Lys 2015	Asp	Ile	Gln	Ala	Pro	Ile 2020	Thr	Leu	Ile	Tyr	Gly 2025	Asp	Gln	Ser
Glu 2030	Phe	Asn	Arg	Pro	Ala	Asp 2035	Leu	Gln	Ala	Ile	Gln 2040	Ala	Ala	Leu
Pro 2045	Gln	Ala	Gln	Arg	Leu	Thr 2050	Val	Ala	Gly	Gly	His 2055	Asn	Leu	His
Phe 2060	Glu	Asn	Pro	Gln	Ala	Ile 2065	Ala	Gln	Ile	Val	Tyr 2070	Gln	Gln	Leu
Gln 2075	Thr	Pro	Val	Pro	Lys	Thr 2080	Gln							

-continued

<211> LENGTH: 582
 <212> TYPE: PRT
 <213> ORGANISM: *Lyngbya majuscula*
 <400> SEQUENCE: 10

Phe Ile Leu Ser Ser Pro Arg Ser Gly Ser Thr Leu Leu Arg Val Met
 1 5 10 15
 Leu Ala Gly His Ser Ser Leu Phe Ser Pro Pro Glu Leu His Leu Leu
 20 25 30
 Pro Phe Asn Thr Met Lys Glu Arg Gln Glu Gln Leu Asn Leu Ser Tyr
 35 40 45
 Leu Gly Glu Gly Leu Gln Lys Thr Phe Met Glu Val Lys Asn Leu Asp
 50 55 60
 Ala Thr Ala Ser Gln Ala Leu Ile Lys Asp Leu Glu Ser Gln Asn Leu
 65 70 75 80
 Ser Ile Gln Gln Val Tyr Gly Met Leu Gln Glu Asn Ile Ala Pro Arg
 85 90 95
 Leu Leu Val Asp Lys Ser Pro Thr Tyr Ala Met Glu Pro Thr Ile Leu
 100 105 110
 Glu Arg Gly Glu Ala Leu Phe Ala Asn Ser Lys Tyr Ile Tyr Leu Val
 115 120 125
 Arg His Pro Tyr Ser Val Ile Glu Ser Phe Val Arg Met Arg Met Gln
 130 135 140
 Lys Leu Val Gly Leu Gly Glu Glu Asn Pro Tyr Arg Val Ala Glu Gln
 145 150 155 160
 Val Trp Ala Lys Ser Asn Gln Asn Ile Leu Asn Phe Leu Ser Gln Leu
 165 170 175
 Glu Pro Glu Arg Gln His Gln Ile Arg Tyr Glu Asp Leu Val Lys Lys
 180 185 190
 Pro Gln Gln Val Leu Ser Gln Leu Cys Asp Phe Leu Asn Val Pro Phe
 195 200 205
 Glu Pro Glu Leu Leu Gln Pro Tyr Gln Gly Asp Arg Met Thr Gly Gly
 210 215 220
 Val His Gln Lys Ser Leu Ser Ile Ser Asp Pro Asn Phe Leu Lys His
 225 230 235 240
 Asn Thr Ile Asp Glu Ser Leu Ala Asp Lys Trp Lys Thr Ile Gln Leu
 245 250 255
 Pro Tyr Pro Leu Lys Ser Glu Thr Gln Arg Ile Ala Ser Gln Leu Ser
 260 265 270
 Tyr Glu Leu Pro Asn Leu Val Thr Thr Pro Thr Asn Gln Gln Pro Gln
 275 280 285
 Val Ser Thr Thr Pro Ser Thr Glu Gln Pro Ile Met Glu Glu Lys Phe
 290 295 300
 Leu Glu Phe Gly Gly Asn Gln Ile Cys Leu Cys Ser Trp Gly Ser Pro
 305 310 315 320
 Glu His Pro Val Val Leu Cys Ile His Gly Ile Leu Glu Gln Gly Leu
 325 330 335
 Ala Trp Gln Glu Val Ala Leu Pro Leu Ala Ala Gln Gly Tyr Arg Val
 340 345 350
 Val Ala Pro Asp Leu Phe Gly His Gly Arg Ser Ser His Leu Glu Met
 355 360 365
 Val Thr Ser Tyr Ser Ser Leu Thr Phe Leu Ala Gln Ile Asp Arg Val
 370 375 380

-continued

```

Ile Gln Glu Leu Pro Asp Gln Pro Leu Leu Leu Val Gly His Ser Met
385                               390                               395                               400

Gly Ala Met Leu Ala Thr Ala Ile Ala Ser Val Arg Pro Lys Lys Ile
                               405                               410                               415

Lys Glu Leu Ile Leu Val Glu Leu Pro Leu Pro Ala Glu Glu Ser Lys
                               420                               425                               430

Lys Glu Ser Ala Val Asn Gln Leu Thr Thr Cys Leu Asp Tyr Leu Ser
                               435                               440                               445

Ser Thr Pro Gln His Pro Ile Phe Pro Asp Val Ala Thr Ala Ala Ser
                               450                               455                               460

Arg Leu Arg Gln Ala Ile Pro Ser Leu Ser Glu Glu Phe Ser Tyr Ile
465                               470                               475                               480

Leu Ala Gln Arg Ile Thr Gln Pro Asn Gln Gly Gly Val Arg Trp Ser
                               485                               490                               495

Trp Asp Ala Ile Ile Arg Thr Arg Ser Ile Leu Gly Leu Asn Asn Leu
                               500                               505                               510

Pro Gly Gly Arg Ser Gln Tyr Leu Glu Met Leu Lys Ser Ile Gln Val
                               515                               520                               525

Pro Thr Thr Leu Val Tyr Gly Asp Ser Ser Lys Leu Asn Arg Pro Glu
                               530                               535                               540

Asp Leu Gln Gln Gln Lys Met Thr Met Thr Gln Ala Lys Arg Val Phe
545                               550                               555                               560

Leu Ser Gly Gly His Asn Leu His Ile Asp Ala Ala Ala Ala Leu Ala
                               565                               570                               575

Ser Leu Ile Leu Thr Ser
                               580

```

```

<210> SEQ ID NO 11
<211> LENGTH: 261
<212> TYPE: PRT
<213> ORGANISM: Lyngbya majuscula

```

```

<400> SEQUENCE: 11

```

```

Phe Ile Leu Ser Ser Pro Arg Ser Gly Ser Thr Leu Leu Arg Val Met
1                               5                               10                               15

Leu Ala Gly His Ser Ser Leu Phe Ser Pro Pro Glu Leu His Leu Leu
                               20                               25                               30

Pro Phe Asn Thr Met Lys Glu Arg Gln Glu Gln Leu Asn Leu Ser Tyr
                               35                               40                               45

Leu Gly Glu Gly Leu Gln Lys Thr Phe Met Glu Val Lys Asn Leu Asp
50                               55                               60

Ala Thr Ala Ser Gln Ala Leu Ile Lys Asp Leu Glu Ser Gln Asn Leu
65                               70                               75                               80

Ser Ile Gln Gln Val Tyr Gly Met Leu Gln Glu Asn Ile Ala Pro Arg
                               85                               90                               95

Leu Leu Val Asp Lys Ser Pro Thr Tyr Ala Met Glu Pro Thr Ile Leu
                               100                              105                              110

Glu Arg Gly Glu Ala Leu Phe Ala Asn Ser Lys Tyr Ile Tyr Leu Val
                               115                              120                              125

Arg His Pro Tyr Ser Val Ile Glu Ser Phe Val Arg Met Arg Met Gln
                               130                              135                              140

Lys Leu Val Gly Leu Gly Glu Glu Asn Pro Tyr Arg Val Ala Glu Gln
145                               150                               155                               160

```


-continued

Val Trp Ala Lys Ser Asn Gln Asn Ile Leu Asn Phe Leu Ser Gln Leu
165 170 175

Glu Pro Glu Arg Gln His Gln Ile Arg Tyr Glu Asp Leu Val Lys Lys
180 185 190

Pro Gln Gln Val Leu Ser Gln Leu Cys Asp Phe Leu Asn Val Pro Phe
195 200 205

Glu Pro Glu Leu Leu Gln Pro Tyr Gln Gly Asp Arg Met Thr Gly Gly
210 215 220

Val His Gln Lys Ser Leu Ser Ile Ser Asp Pro Asn Phe Leu Lys His
225 230 235 240

Asn Thr Ile Asp Glu Ser Leu Ala Asp Lys Trp Lys Thr Ile Gln Leu
245 250 255

Pro Tyr Pro Leu Lys
260

<210> SEQ ID NO 12
<211> LENGTH: 281
<212> TYPE: PRT
<213> ORGANISM: Lyngbya majuscula

<400> SEQUENCE: 12

Glu Lys Phe Leu Glu Phe Gly Gly Asn Gln Ile Cys Leu Cys Ser Trp
1 5 10 15

Gly Ser Pro Glu His Pro Val Val Leu Cys Ile His Gly Ile Leu Glu
20 25 30

Gln Gly Leu Ala Trp Gln Glu Val Ala Leu Pro Leu Ala Ala Gln Gly
35 40 45

Tyr Arg Val Val Ala Pro Asp Leu Phe Gly His Gly Arg Ser Ser His
50 55 60

Leu Glu Met Val Thr Ser Tyr Ser Ser Leu Thr Phe Leu Ala Gln Ile
65 70 75 80

Asp Arg Val Ile Gln Glu Leu Pro Asp Gln Pro Leu Leu Leu Val Gly
85 90 95

His Ser Met Gly Ala Met Leu Ala Thr Ala Ile Ala Ser Val Arg Pro
100 105 110

Lys Lys Ile Lys Glu Leu Ile Leu Val Glu Leu Pro Leu Pro Ala Glu
115 120 125

Glu Ser Lys Lys Glu Ser Ala Val Asn Gln Leu Thr Thr Cys Leu Asp
130 135 140

Tyr Leu Ser Ser Thr Pro Gln His Pro Ile Phe Pro Asp Val Ala Thr
145 150 155 160

Ala Ala Ser Arg Leu Arg Gln Ala Ile Pro Ser Leu Ser Glu Glu Phe
165 170 175

Ser Tyr Ile Leu Ala Gln Arg Ile Thr Gln Pro Asn Gln Gly Gly Val
180 185 190

Arg Trp Ser Trp Asp Ala Ile Ile Arg Thr Arg Ser Ile Leu Gly Leu
195 200 205

Asn Asn Leu Pro Gly Gly Arg Ser Gln Tyr Leu Glu Met Leu Lys Ser
210 215 220

Ile Gln Val Pro Thr Thr Leu Val Tyr Gly Asp Ser Ser Lys Leu Asn
225 230 235 240

Arg Pro Glu Asp Leu Gln Gln Gln Lys Met Thr Met Thr Gln Ala Lys
245 250 255

-continued

Arg Val Phe Leu Ser Gly Gly His Asn Leu His Ile Asp Ala Ala Ala
 260 265 270

Ala Leu Ala Ser Leu Ile Leu Thr Ser
 275 280

<210> SEQ ID NO 13

<211> LENGTH: 626

<212> TYPE: PRT

<213> ORGANISM: Salmonella typhimurium

<400> SEQUENCE: 13

Met Ser Phe Ser Glu Phe Tyr Gln Arg Ser Ile Asn Glu Pro Glu Ala
 1 5 10 15

Phe Trp Ala Glu Gln Ala Arg Arg Ile Asp Trp Arg Gln Pro Phe Thr
 20 25 30

Gln Thr Leu Asp His Ser Arg Pro Pro Phe Ala Arg Trp Phe Cys Gly
 35 40 45

Gly Thr Thr Asn Leu Cys His Asn Ala Val Asp Arg Trp Arg Asp Lys
 50 55 60

Gln Pro Glu Ala Leu Ala Leu Ile Ala Val Ser Ser Glu Thr Asp Glu
 65 70 75 80

Glu Arg Thr Phe Thr Phe Ser Gln Leu His Asp Glu Val Asn Ile Val
 85 90 95

Ala Ala Met Leu Leu Ser Leu Gly Val Gln Arg Gly Asp Arg Val Leu
 100 105 110

Val Tyr Met Pro Met Ile Ala Glu Ala Gln Ile Thr Leu Leu Ala Cys
 115 120 125

Ala Arg Ile Gly Ala Ile His Ser Val Val Phe Gly Gly Phe Ala Ser
 130 135 140

His Ser Val Ala Ala Arg Ile Asp Asp Ala Arg Pro Ala Leu Ile Val
 145 150 155 160

Ser Ala Asp Ala Gly Ala Arg Gly Gly Lys Ile Leu Pro Tyr Lys Lys
 165 170 175

Leu Leu Asp Asp Ala Ile Ala Gln Ala Gln His Gln Pro Lys His Val
 180 185 190

Leu Leu Val Asp Arg Gly Leu Ala Lys Met Ala Trp Val Asp Gly Arg
 195 200 205

Asp Leu Asp Phe Ala Thr Leu Arg Gln Gln His Leu Gly Ala Ser Val
 210 215 220

Pro Val Ala Trp Leu Glu Ser Asn Glu Thr Ser Cys Ile Leu Tyr Thr
 225 230 235 240

Ser Gly Thr Thr Gly Lys Pro Lys Gly Val Gln Arg Asp Val Gly Gly
 245 250 255

Tyr Ala Val Ala Leu Ala Thr Ser Met Asp Thr Ile Phe Gly Gly Lys
 260 265 270

Ala Gly Gly Val Phe Phe Cys Ala Ser Asp Ile Gly Trp Val Val Gly
 275 280 285

His Ser Tyr Ile Val Tyr Ala Pro Leu Leu Ala Gly Met Ala Thr Ile
 290 295 300

Val Tyr Glu Gly Leu Pro Thr Tyr Pro Asp Cys Gly Val Trp Trp Lys
 305 310 315 320

Ile Val Glu Lys Tyr Gln Val Asn Arg Met Phe Ser Ala Pro Thr Ala
 325 330 335

-continued

Ile Arg Val Leu Lys Lys Phe Pro Thr Ala Gln Ile Arg Asn His Asp
 340 345 350

Leu Ser Ser Leu Glu Ala Leu Tyr Leu Ala Gly Glu Pro Leu Asp Glu
 355 360 365

Pro Thr Ala Ser Trp Val Thr Glu Thr Leu Gly Val Pro Val Ile Asp
 370 375 380

Asn Tyr Trp Gln Thr Glu Ser Gly Trp Pro Ile Met Ala Leu Ala Arg
 385 390 395 400

Ala Leu Asp Asp Arg Pro Ser Arg Leu Gly Ser Pro Gly Val Pro Met
 405 410 415

Tyr Gly Tyr Asn Val Gln Leu Leu Asn Glu Val Thr Gly Glu Pro Cys
 420 425 430

Gly Ile Asn Glu Lys Gly Met Leu Val Ile Glu Gly Pro Leu Pro Pro
 435 440 445

Gly Cys Ile Gln Thr Ile Trp Gly Asp Asp Ala Arg Phe Val Lys Thr
 450 455 460

Tyr Trp Ser Leu Phe Asn Arg Gln Val Tyr Ala Thr Phe Asp Trp Gly
 465 470 475 480

Ile Arg Asp Ala Glu Gly Tyr Tyr Phe Ile Leu Gly Arg Thr Asp Asp
 485 490 495

Val Ile Asn Ile Ala Gly His Arg Leu Gly Thr Arg Glu Ile Glu Glu
 500 505 510

Ser Ile Ser Ser Tyr Pro Asn Val Ala Glu Val Ala Val Val Gly Ile
 515 520 525

Lys Asp Ala Leu Lys Gly Gln Val Ala Val Ala Phe Val Ile Pro Lys
 530 535 540

Gln Ser Asp Thr Leu Ala Asp Arg Glu Ala Ala Arg Asp Glu Glu Asn
 545 550 555 560

Ala Ile Met Ala Leu Val Asp Asn Gln Ile Gly His Phe Gly Arg Pro
 565 570 575

Ala His Val Trp Phe Val Ser Gln Leu Pro Lys Thr Arg Ser Gly Lys
 580 585 590

Met Leu Arg Arg Thr Ile Gln Ala Glu Gly Arg Asp Pro Gly Asp Leu
 595 600 605

Thr Thr Ile Asp Asp Pro Ala Ser Leu Gln Gln Ile Arg Gln Ala Ile
 610 615 620

Glu Glu
 625

<210> SEQ ID NO 14
 <211> LENGTH: 410
 <212> TYPE: PRT
 <213> ORGANISM: Mus musculus

<400> SEQUENCE: 14

Met Ala Ala Ala Leu Leu Ala Arg Ala Arg Gly Pro Leu Arg Arg Ala
 1 5 10 15

Leu Gly Val Arg Asp Trp Arg Arg Leu His Thr Val Tyr Gln Ser Val
 20 25 30

Glu Leu Pro Glu Thr His Gln Met Leu Arg Gln Thr Cys Arg Asp Phe
 35 40 45

Ala Glu Lys Glu Leu Val Pro Ile Ala Ala Gln Leu Asp Arg Glu His
 50 55 60

-continued

Leu Phe Pro Thr Ala Gln Val Lys Lys Met Gly Glu Leu Gly Leu Leu
 65 70 75 80
 Ala Met Asp Val Pro Glu Glu Leu Ser Gly Ala Gly Leu Gly Tyr Leu
 85 90 95
 Ala Tyr Ser Ile Ala Leu Glu Glu Ile Ser Arg Ala Cys Ala Ser Thr
 100 105 110
 Gly Val Ile Met Ser Val Asn Asn Ser Leu Tyr Leu Gly Pro Ile Leu
 115 120 125
 Lys Phe Gly Ser Ala Gln Gln Lys Gln Gln Trp Ile Thr Pro Phe Thr
 130 135 140
 Asn Gly Asp Lys Ile Gly Cys Phe Ala Leu Ser Glu Pro Gly Asn Gly
 145 150 155 160
 Ser Asp Ala Gly Ala Ala Ser Thr Thr Ala Arg Glu Glu Gly Asp Ser
 165 170 175
 Trp Val Leu Asn Gly Thr Lys Ala Trp Ile Thr Asn Ser Trp Glu Ala
 180 185 190
 Ser Ala Thr Val Val Phe Ala Ser Thr Asp Arg Ser Arg Gln Asn Lys
 195 200 205
 Gly Ile Ser Ala Phe Leu Val Pro Met Pro Thr Pro Gly Leu Thr Leu
 210 215 220
 Gly Lys Lys Glu Asp Lys Leu Gly Ile Arg Ala Ser Ser Thr Ala Asn
 225 230 235 240
 Leu Ile Phe Glu Asp Cys Arg Ile Pro Lys Glu Asn Leu Leu Gly Glu
 245 250 255
 Pro Gly Met Gly Phe Lys Ile Ala Met Gln Thr Leu Asp Met Gly Arg
 260 265 270
 Ile Gly Ile Ala Ser Gln Ala Leu Gly Ile Ala Gln Ala Ser Leu Asp
 275 280 285
 Cys Ala Val Lys Tyr Ala Glu Asn Arg Asn Ala Phe Gly Ala Pro Leu
 290 295 300
 Thr Lys Leu Gln Asn Ile Gln Phe Lys Leu Ala Asp Met Ala Leu Ala
 305 310 315 320
 Leu Glu Ser Ala Arg Leu Leu Thr Trp Arg Ala Ala Met Leu Lys Asp
 325 330 335
 Asn Lys Lys Pro Phe Thr Lys Glu Ser Ala Met Arg Lys Leu Ala Ala
 340 345 350
 Ser Glu Ala Ala Thr Ala Ile Ser Ala Ile Gln Ile Leu Gly Ser Met
 355 360 365
 Gly Tyr Val Thr Glu Met Pro Ala Glu Arg Tyr Tyr Arg Asp Ala Arg
 370 375 380
 Ile Thr Glu Ile Tyr Glu Gly Thr Ser Glu Ile Gln Arg Leu Val Ile
 385 390 395 400
 Ala Gly His Leu Leu Arg Ser Tyr Arg Ser
 405 410

<210> SEQ ID NO 15
 <211> LENGTH: 292
 <212> TYPE: PRT
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 15

Thr Ala Lys Thr Ala Asn Gly Cys Glu Ala Val Cys Ile Phe Val Asn
 1 5 10 15

-continued

Asp Asp Gly Ser Arg Pro Val Leu Glu Glu Leu Lys Lys His Gly Val
 20 25 30
 Lys Tyr Ile Ala Leu Arg Cys Ala Gly Phe Asn Asn Val Asp Leu Asp
 35 40 45
 Ala Ala Lys Glu Leu Gly Leu Lys Val Val Arg Val Pro Ala Tyr Asp
 50 55 60
 Pro Glu Ala Val Ala Glu His Ala Ile Gly Met Met Met Thr Leu Asn
 65 70 75 80
 Arg Arg Ile His Arg Ala Tyr Gln Arg Thr Arg Asp Ala Asn Phe Ser
 85 90 95
 Leu Glu Gly Leu Thr Gly Phe Thr Met Tyr Gly Lys Thr Ala Gly Val
 100 105 110
 Ile Gly Thr Gly Lys Ile Gly Val Ala Met Leu Arg Ile Leu Lys Gly
 115 120 125
 Phe Gly Met Arg Leu Leu Ala Phe Asp Pro Tyr Pro Ser Ala Ala Ala
 130 135 140
 Leu Glu Leu Gly Val Glu Tyr Val Asp Leu Pro Thr Leu Phe Ser Glu
 145 150 155 160
 Ser Asp Val Ile Ser Leu His Cys Pro Leu Thr Pro Glu Asn Tyr His
 165 170 175
 Leu Leu Asn Glu Ala Ala Phe Asp Gln Met Lys Asn Gly Val Met Ile
 180 185 190
 Val Asn Thr Ser Arg Gly Ala Leu Ile Asp Ser Gln Ala Ala Ile Glu
 195 200 205
 Ala Leu Lys Asn Gln Lys Ile Gly Ser Leu Gly Met Asp Val Tyr Glu
 210 215 220
 Asn Glu Arg Asp Leu Phe Phe Glu Asp Lys Ser Asn Asp Val Ile Gln
 225 230 235 240
 Asp Asp Val Phe Arg Arg Leu Ser Ala Cys His Asn Val Leu Phe Thr
 245 250 255
 Gly His Gln Ala Phe Leu Thr Ala Glu Ala Leu Thr Ser Ile Ser Gln
 260 265 270
 Thr Thr Leu Gln Asn Leu Ser Asn Leu Glu Lys Gly Glu Thr Cys Pro
 275 280 285
 Asn Glu Leu Val
 290

<210> SEQ ID NO 16
 <211> LENGTH: 522
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium proponicum
 <400> SEQUENCE: 16

Met Arg Lys Val Pro Ile Ile Thr Ala Asp Glu Ala Ala Lys Leu Ile
 1 5 10 15
 Lys Asp Gly Asp Thr Val Thr Thr Ser Gly Phe Val Gly Asn Ala Ile
 20 25 30
 Pro Glu Ala Leu Asp Arg Ala Val Glu Lys Arg Phe Leu Glu Thr Gly
 35 40 45
 Glu Pro Lys Asn Ile Thr Tyr Val Tyr Cys Gly Ser Gln Gly Asn Arg
 50 55 60
 Asp Gly Arg Gly Ala Glu His Phe Ala His Glu Gly Leu Leu Lys Arg
 65 70 75 80

-continued

Tyr Ile Ala Gly His Trp Ala Thr Val Pro Ala Leu Gly Lys Met Ala
 85 90 95

Met Glu Asn Lys Met Glu Ala Tyr Asn Val Ser Gln Gly Ala Leu Cys
 100 105 110

His Leu Phe Arg Asp Ile Ala Ser His Lys Pro Gly Val Phe Thr Lys
 115 120 125

Val Gly Ile Gly Thr Phe Ile Asp Pro Arg Asn Gly Gly Gly Lys Val
 130 135 140

Asn Asp Ile Thr Lys Glu Asp Ile Val Glu Leu Val Glu Ile Lys Gly
 145 150 155 160

Gln Glu Tyr Leu Phe Tyr Pro Ala Phe Pro Ile His Val Ala Leu Ile
 165 170 175

Arg Gly Thr Tyr Ala Asp Glu Ser Gly Asn Ile Thr Phe Glu Lys Glu
 180 185 190

Val Ala Pro Leu Glu Gly Thr Ser Val Cys Gln Ala Val Lys Asn Ser
 195 200 205

Gly Gly Ile Val Val Val Gln Val Glu Arg Val Val Lys Ala Gly Thr
 210 215 220

Leu Asp Pro Arg His Val Lys Val Pro Gly Ile Tyr Val Asp Tyr Val
 225 230 235 240

Val Val Ala Asp Pro Glu Asp His Gln Gln Ser Leu Asp Cys Glu Tyr
 245 250 255

Asp Pro Ala Leu Ser Gly Glu His Arg Arg Pro Glu Val Val Gly Glu
 260 265 270

Pro Leu Pro Leu Ser Ala Lys Lys Val Ile Gly Arg Arg Gly Ala Ile
 275 280 285

Glu Leu Glu Lys Asp Val Ala Val Asn Leu Gly Val Gly Ala Pro Glu
 290 295 300

Tyr Val Ala Ser Val Ala Asp Glu Glu Gly Ile Val Asp Phe Met Thr
 305 310 315 320

Leu Thr Ala Glu Ser Gly Ala Ile Gly Gly Val Pro Ala Gly Gly Val
 325 330 335

Arg Phe Gly Ala Ser Tyr Asn Ala Asp Ala Leu Ile Asp Gln Gly Tyr
 340 345 350

Gln Phe Asp Tyr Tyr Asp Gly Gly Gly Leu Asp Leu Cys Tyr Leu Gly
 355 360 365

Leu Ala Glu Cys Asp Glu Lys Gly Asn Ile Asn Val Ser Arg Phe Gly
 370 375 380

Pro Arg Ile Ala Gly Cys Gly Gly Phe Ile Asn Ile Thr Gln Asn Thr
 385 390 395 400

Pro Lys Val Phe Phe Cys Gly Thr Phe Thr Ala Gly Gly Leu Lys Val
 405 410 415

Lys Ile Glu Asp Gly Lys Val Ile Ile Val Gln Glu Gly Lys Gln Lys
 420 425 430

-continued

Lys Phe Leu Lys Ala Val Glu Gln Ile Thr Phe Asn Gly Asp Val Ala
 435 440 445

Leu Ala Asn Lys Gln Gln Val Thr Tyr Ile Thr Glu Arg Cys Val Phe
 450 455 460

Leu Leu Lys Glu Asp Gly Leu His Leu Ser Glu Ile Ala Pro Gly Ile
 465 470 475 480

Gln Thr Gln Ile Leu Asp Val Met Asp Phe Ala Pro Ile Ile Asp Arg
 485 490 495

Asp Ala Asn Gly Gln Ile Lys Leu Met Asp Ala Ala Leu Phe Ala Glu
 500 505 510

Gly Leu Met Gly Leu Lys Glu Met Lys Ser
 515 520

<210> SEQ ID NO 17
 <211> LENGTH: 124
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium proponicum

<400> SEQUENCE: 17

Glu Phe Lys Ile Ala Ile Val Asp Asp Asp Leu Ala Gln Glu Ser Arg
 1 5 10 15

Gln Ile Arg Val Asp Val Leu Asp Gly Glu Gly Gly Pro Leu Tyr Arg
 20 25 30

Met Ala Lys Ala Trp Gln Gln Met Tyr Gly Cys Ser Leu Ala Thr Asp
 35 40 45

Thr Lys Lys Gly Arg Gly Arg Met Leu Ile Asn Lys Thr Ile Gln Thr
 50 55 60

Gly Ala Asp Ala Ile Val Val Ala Met Met Lys Phe Cys Asp Pro Glu
 65 70 75 80

Glu Trp Asp Tyr Pro Val Met Tyr Arg Glu Phe Glu Glu Lys Gly Val
 85 90 95

Lys Ser Leu Met Ile Glu Val Asp Gln Glu Val Ser Ser Phe Glu Gln
 100 105 110

Ile Lys Thr Arg Leu Gln Ser Phe Val Glu Met Leu
 115 120

<210> SEQ ID NO 18
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces antibioticus

<400> SEQUENCE: 18

Ser Ser Ser Ala Gly Ile Asp Pro Gly Arg Ala Phe Gln Asp Met Gly
 1 5 10 15

Ile

<210> SEQ ID NO 19
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Saccharopolyspora erythraea

<400> SEQUENCE: 19

Ala Ser Ala Glu Arg Val Pro Ala Asp Gln Ala Phe Ala Glu Leu Gly
 1 5 10 15

Val

prises one or more nucleic acids encoding propionyl-CoA ligase (synthetase) (EC 6.2.1.17) and acyl-CoA dehydrogenase (mammalian) (EC 1.3.99.3), or functional variants thereof, wherein when cultured and optionally provided with propionate the PKS is capable of synthesizing acrylyl-CoA and producing butadiene.

23. The host cell of claim **21**, wherein the host cell comprises a PKS which produces butadiene comprising a loading module comprising an acrylyl-ACP starter, and further comprises one or more nucleic acids encoding lactate dehydrogenase (EC 6.2.1.17), lactate CoA transferase (EC 2.8.3.1), propionyl-CoA ligase (synthetase) (EC 6.2.1.17), and lactoyl-CoA dehydratase (EC 4.2.164), or functional variants thereof, wherein when cultured and optionally provided with propionate and glucose the PKS is capable of synthesizing acrylyl-CoA and producing butadiene.

24. The host cell of claim **21**, wherein the host cell comprises a PKS which produces butadiene comprising a loading module comprising an acrylyl-ACP starter, and further comprises one or more nucleic acids encoding acetyl-CoA carboxylase (EC 6.4.1.2), malonyl-CoA reductase (EC 1.2.1.-), 3-hydroxypropionate:CoA ligase, and 3-hydroxypropionyl-CoA hydratase (EC 4.2.1.17), or functional variants thereof, wherein when cultured the PKS is capable of synthesizing acrylyl-CoA and producing butadiene.

25. The host cell of claim **21**, wherein the host cell comprises a PKS which produces butadiene comprising a loading module comprising an acrylyl-ACP starter, and further comprises one or more nucleic acids encoding propionyl-CoA

ligase (synthetase) (EC 6.2.1.17), the AccA/PccB gene products and lactoyl-CoA dehydratase (EC 4.2.164), and lactate dehydrogenase (EC 6.2.1.17), lactate CoA transferase (EC 2.8.3.1), propionyl-CoA ligase (synthetase) (EC 6.2.1.17), and lactoyl-CoA dehydratase (EC 4.2.164), or acyl-CoA dehydrogenase, or functional variants thereof, wherein when cultured and optionally provided with propionate the PKS is capable of synthesizing acrylyl-CoA and producing butadiene.

26. A method of producing an α -olefin, comprising: providing a host cell of claim **21**, and culturing said host cell in a suitable culture medium such that the α -olefin is produced.

27. The method of claim **26**, further comprising isolating the isolating the α -olefin.

28. The method of claim **27**, further comprising polymerizing the α -olefin to produce a polymer.

29. The method of claim **26**, wherein the α -olefin is a polyolefin.

30. The method of claim **29**, wherein the polyolefin is butadiene, isoprene, or (E)-deca-1,5-diene.

31. A composition comprising an α -olefin isolated from the host cell of claim **21**, and trace residues and/or contaminants of the host cell.

32. The composition of claim **31**, wherein the α -olefin is polyolefin.

33. The composition of claim **32**, wherein the polyolefin is butadiene, isoprene, or (E)-deca-1,5-diene.

* * * * *